20. Literaturverzeichnis – Maligne Ovarialtumoren

1. Robert Koch-Institut und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V., Krebs in Deutschland für 2017/2018, 13. Ausgabe, 2021., https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/krebs_in_deutschland_inhalt.html

2. Menon, U, Gentry-Maharaj, A, Burnell, M, Singh, N, Ryan, A, Karpinskyj, C, et.al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial., Lancet, 2021. 397 (10290)(10290): p. 2182-2193., https://pubmed.ncbi.nlm.nih.gov/33991479/

3. Scottish Intercollegiate Guidelines Network, SIGN #75: Epithelial ovarian cancer. A national clinical guideline.Scottish Intercollegiate Guidelines Network,, 2003., https://www.sign.ac.uk/media/1073/sign135_oct2018.pdf

4. The Australian Cancer Network and National Breast Cancer Centre, Clinical practice guidelines for the management of women with epithelial ovarian cancerNational Breast Cancer Centre, Camperdown, NSW, 2004., https://www.canceraustralia.gov.au/publications-and-resources/cancer-australia-publications/clinical-practice-guidelines-management-women-epithelial-ovarian-cancer

5. Menon, U., Gentry-Maharaj, A., Hallett, R., Ryan, A., Burnell, M., Sharma, A., et.al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), Lancet Oncol, 2009. 10(4): p. 327-40., https://pubmed.ncbi.nlm.nih.gov/19282241/

6. Kobayashi, H., Yamada, Y., Sado, T., Sakata, M., Yoshida, S., Kawaguchi, R., et.al. A randomized study of screening for ovarian cancer: a multicenter study in Japan, Int J Gynecol Cancer, 2008. 18(3): p. 414-20., https://pubmed.ncbi.nlm.nih.gov/17645503/

7. Buys, S. S., Partridge, E., Black, A., Johnson, C. C., Lamerato, L., Isaacs, C., et.al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial, JAMA, 2011. 305(22): p. 2295-303., https://pubmed.ncbi.nlm.nih.gov/21642681/

8. Fung, M. F., Bryson, P., Johnston, M., Chambers, A., Screening postmenopausal women for ovarian cancer: a systematic review, J Obstet Gynaecol Can, 2004. 26(8): p. 717-28., https://pubmed.ncbi.nlm.nih.gov/15307976/

9. van Nagell, J. R., Jr., Miller, R. W., DeSimone, C. P., Ueland, F. R., Podzielinski, I., Goodrich, S. T., et.al. Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening, Obstet Gynecol, 2011. 118(6): p. 1212-21., https://pubmed.ncbi.nlm.nih.gov/22105249/

10. Timmerman, D., Testa, A. C., Bourne, T., Ameye, L., Jurkovic, D., Van Holsbeke, C., et.al. Simple ultrasound-based rules for the diagnosis of ovarian cancer, Ultrasound Obstet Gynecol, 2008. 31(6): p. 681-90., https://pubmed.ncbi.nlm.nih.gov/18504770/

11. Timmerman, D., Valentin, L., Bourne, T. H., Collins, W. P., Verrelst, H., Vergote, I., Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group, Ultrasound Obstet Gynecol, 2000. 16(5): p. 500-5., https://pubmed.ncbi.nlm.nih.gov/11169340/

12. Jacobs, I. J., Menon, U., Ryan, A., Gentry-Maharaj, A., Burnell, M., Kalsi, J. K., et.al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial, Lancet, 2016. 387(10022): p. 945-56., https://pubmed.ncbi.nlm.nih.gov/26707054/

13. Menon, U., Ryan, A., Kalsi, J., Gentry-Maharaj, A., Dawnay, A., Habib, M., et.al. Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening, J Clin Oncol, 2015. 33(18): p. 2062-71., https://pubmed.ncbi.nlm.nih.gov/25964255/

14. Karlan, B. Y., Baldwin, R. L., Lopez-Luevanos, E., Raffel, L. J., Barbuto, D., Narod, S., et.al. Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening, Am J Obstet Gynecol, 1999. 180(4): p. 917-28., https://pubmed.ncbi.nlm.nih.gov/10203660/

15. Moller, P., Borg, A., Heimdal, K., Apold, J., Vallon-Christersson, J., Hovig, E., et.al. The BRCA1 syndrome and other inherited breast or breast-ovarian cancers in a Norwegian prospective series, Eur J Cancer, 2001. 37(8): p. 1027-32., https://pubmed.ncbi.nlm.nih.gov/11334729/

16. Taylor, L., Schwarz, H., Identification of a soluble OX40 isoform: development of a specific and quantitative immunoassay, J Immunol Methods, 2001. 255(1-2): p. 67-72., https://pubmed.ncbi.nlm.nih.gov/11470287/

17. van der Velde, N. M., Mourits, M. J., Arts, H. J., de Vries, J., Leegte, B. K., Dijkhuis, G., et.al. Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?, Int J Cancer, 2009. 124(4): p. 919-23., https://pubmed.ncbi.nlm.nih.gov/19035463/

18. Taylor, L., Schwarz, H., Identification of a soluble OX40 isoform: development of a specific and quantitative immunoassay, J Immunol Methods, 2001. 255(1-2): p. 67-72., https://pubmed.ncbi.nlm.nih.gov/11470287/

19. Daniels, M. S., Babb, S. A., King, R. H., Urbauer, D. L., Batte, B. A., Brandt, A. C., et.al. Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study, J Clin Oncol, 2014. 32(12): p. 1249-55., https://pubmed.ncbi.nlm.nih.gov/24638001/

20. Booth, S. J., Turnbull, L. W., Poole, D. R., Richmond, I., The accurate staging of ovarian cancer using 3T magnetic resonance imaging--a realistic option, BJOG, 2008. 115(7): p. 894-901., https://pubmed.ncbi.nlm.nih.gov/18485169/

21. Bristow, R. E., del Carmen, M. G., Pannu, H. K., Cohade, C., Zahurak, M. L., Fishman, E. K., et.al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT, Gynecol Oncol, 2003. 90(3): p. 519-28., https://pubmed.ncbi.nlm.nih.gov/13678719/

22. Buy, J. N., Ghossain, M. A., Sciot, C., Bazot, M., Guinet, C., Prevot, S., et.al. Epithelial tumors of the ovary: CT findings and correlation with US, Radiology, 1991. 178(3): p. 811-8., https://pubmed.ncbi.nlm.nih.gov/1994423/

23. Forstner, R., Hricak, H., Occhipinti, K. A., Powell, C. B., Frankel, S. D., Stern, J. L., Ovarian cancer: staging with CT and MR imaging, Radiology, 1995. 197(3): p. 619-26., https://pubmed.ncbi.nlm.nih.gov/7480729/

24. Forstner, R., Sala, E., Kinkel, K., Spencer, J. A., ESUR guidelines: ovarian cancer staging and follow-up, Eur Radiol, 2010. 20(12): p. 2773-80., https://pubmed.ncbi.nlm.nih.gov/20839002/

25. Gu, P., Pan, L. L., Wu, S. Q., Sun, L., Huang, G., CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis, Eur J Radiol, 2009. 71(1): p. 164-74., https://pubmed.ncbi.nlm.nih.gov/18378417/

26. Hricak, H., Chen, M., Coakley, F. V., Kinkel, K., Yu, K. K., Sica, G., et.al. Complex adnexal masses: detection and characterization with MR imaging--multivariate analysis, Radiology, 2000. 214(1): p. 39-46., https://pubmed.ncbi.nlm.nih.gov/10644099/

27. Kinkel, K., Lu, Y., Mehdizade, A., Pelte, M. F., Hricak, H., Indeterminate ovarian mass at US: incremental value of second imaging test for characterization--meta-analysis and Bayesian analysis, Radiology, 2005. 236(1): p. 85-94., https://pubmed.ncbi.nlm.nih.gov/15955864/

28. Meyer, J. I., Kennedy, A. W., Friedman, R., Ayoub, A., Zepp, R. C., Ovarian carcinoma: value of CT in predicting success of debulking surgery, AJR Am J Roentgenol, 1995. 165(4): p. 875-8., https://pubmed.ncbi.nlm.nih.gov/7676985/

29. Nam, E. J., Yun, M. J., Oh, Y. T., Kim, J. W., Kim, J. H., Kim, S., et.al. Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI, Gynecol Oncol, 2010. 116(3): p. 389-94., https://pubmed.ncbi.nlm.nih.gov/19926121/

30. Peng, N. J., Liou, W. S., Liu, R. S., Hu, C., Tsay, D. G., Liu, C. B., Early detection of recurrent ovarian cancer in patients with low-level increases in serum CA-125 levels by 2-[F-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography, Cancer Biother Radiopharm, 2011. 26(2): p. 175-81., https://pubmed.ncbi.nlm.nih.gov/21510748/

31. Risum, S., Hogdall, C., Markova, E., Berthelsen, A. K., Loft, A., Jensen, F., et.al. Influence of 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery, Int J Gynecol Cancer, 2009. 19(4): p. 600-4., https://pubmed.ncbi.nlm.nih.gov/19509556/

32. Salani, R., Axtell, A., Gerardi, M., Holschneider, C., Bristow, R. E., Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer, Gynecol Oncol, 2008. 108(2): p. 271-5., https://pubmed.ncbi.nlm.nih.gov/18164380/

33. Takekuma, M., Maeda, M., Ozawa, T., Yasumi, K., Torizuka, T., Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer, Int J Clin Oncol, 2005. 10(3): p. 177-81., https://pubmed.ncbi.nlm.nih.gov/15990965/

34. Torizuka, T., Nobezawa, S., Kanno, T., Futatsubashi, M., Yoshikawa, E., Okada, H., et.al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose, Eur J Nucl Med Mol Imaging, 2002. 29(6): p. 797-803., https://pubmed.ncbi.nlm.nih.gov/12029554/

35. Yuan, Y., Gu, Z. X., Tao, X. F., Liu, S. Y., Computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with ovarian cancer: a meta-analysis, Eur J Radiol, 2012. 81(5): p. 1002-6., https://pubmed.ncbi.nlm.nih.gov/21349672/

36. Bankhead, C. R., Kehoe, S. T., Austoker, J., Symptoms associated with diagnosis of ovarian cancer: a systematic review, BJOG, 2005. 112(7): p. 857-65., https://pubmed.ncbi.nlm.nih.gov/15957984/

37. IQWIG, Positronenemissionstomographie (PET) und PET/CT bei Ovarialkarzinom, 2011., https://www.iqwig.de/download/d06-01i_vorbericht_pet_bei_ovarialkarzinom.pdf?rev=186471

38. Zhao, S. H., Qiang, J. W., Zhang, G. F., Ma, F. H., Cai, S. Q., Li, H. M., et.al. Diffusion-weighted MR imaging for differentiating borderline from malignant epithelial tumours of the ovary: pathological correlation, Eur Radiol, 2014. 24(9): p. 2292-9., https://pubmed.ncbi.nlm.nih.gov/24871335/

39. Michielsen, K., Vergote, I., Op de Beeck, K., Amant, F., Leunen, K., Moerman, P., et.al. Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT, Eur Radiol, 2014. 24(4): p. 889-901., https://pubmed.ncbi.nlm.nih.gov/24322510/

40. Dauwen, H., Van Calster, B., Deroose, C. M., Op de Beeck, K., Amant, F., Neven, P., et.al. PET/CT in the staging of patients with a pelvic mass suspicious for ovarian cancer, Gynecol Oncol, 2013. 131(3): p. 694-700., https://pubmed.ncbi.nlm.nih.gov/23988417/

41. IQWIG, Positronenemissionstomographie (PET) und PET/CT bei Ovarialkarzinom, 2012. 123:, https://www.iqwig.de/download/d06-01i_abschlussbericht_pet_und_pet-ct_bei_ovarialkarzinom.pdf?rev=186472

42. Roze, J.F.et al., Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer, 2018., https://pubmed.ncbi.nlm.nih.gov/30298516/

43. Borrelli, G.M. et al., Role of Imaging Tools for the Diagnosis of Borderline Ovarian Tumors: A Systematic Review and Meta-Analysis, 2017., https://pubmed.ncbi.nlm.nih.gov/28027973/

44. Kasper, S.M. et al., Imaging diagnostics in ovarian cancer: magnetic resonance imaging and a scoring system guiding choice of primary treatment, 2017., https://pubmed.ncbi.nlm.nih.gov/27984747/

45. Xu, B., et al., Diagnostic value of positron emission tomography (PET) and PET/computed tomography in recurrent/metastatic ovarian cancer: A meta-analysis, 2017., https://pubmed.ncbi.nlm.nih.gov/28150407/

46. Rutten, M.J. et al., Laparoscopy to Predict the Result of Primary Cytoreductive Surgery in Patients With Advanced Ovarian Cancer: A Randomized Controlled Trial., 2017., https://pubmed.ncbi.nlm.nih.gov/28029317/

47. Force, U.S.P.S.T., et al., Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement, 2018., https://pubmed.ncbi.nlm.nih.gov/29450531/

48. Henderson, J.T., et al., Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force, 2018., https://pubmed.ncbi.nlm.nih.gov/29450530/

49. Temkin, S.M., et al.,, Outcomes from ovarian cancer screening in the PLCO trial: Histologic heterogeneity impacts detection, overdiagnosis and survival, 2017., https://pubmed.ncbi.nlm.nih.gov/29156299/

50. Expert Panel on Women's, I., et al., ACR Appropriateness Criteria((R)) Ovarian Cancer Screening, 2017., https://pubmed.ncbi.nlm.nih.gov/29101987/

51. Buhling, K.J., et al., The role of transvaginal ultrasonography for detecting ovarian cancer in an asymptomatic screening population: a systematic review, 2017., https://pubmed.ncbi.nlm.nih.gov/28357559/

52. Espada, M., Garcia-Flores, J. R., Jimenez, M., Alvarez-Moreno, E., De Haro, M., Gonzalez-Cortijo, L., et.al. Diffusion-weighted magnetic resonance imaging evaluation of intra-abdominal sites of implants to predict likelihood of suboptimal cytoreductive surgery in patients with ovarian carcinoma, Eur Radiol, 2013. 23(9): p. 2636-42., https://pubmed.ncbi.nlm.nih.gov/23604800/

53. Axtell, A. E., Lee, M. H., Bristow, R. E., Dowdy, S. C., Cliby, W. A., Raman, S., et.al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer, J Clin Oncol, 2007. 25(4): p. 384-9., https://pubmed.ncbi.nlm.nih.gov/17264334/

54. Rustin, G. J., van der Burg, M. E., Griffin, C. L., Guthrie, D., Lamont, A., Jayson, G. C., et.al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial, Lancet, 2010. 376(9747): p. 1155-63., https://pubmed.ncbi.nlm.nih.gov/20888993/

55. ESMO, ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of ovarian cancer, Ann Oncol, 2001. 12(9): p. 1205-7., https://pubmed.ncbi.nlm.nih.gov/11697825/

56. Gu, P., Pan, L. L., Wu, S. Q., Sun, L., Huang, G., CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis, Eur J Radiol, 2009. 71(1): p. 164-74., https://pubmed.ncbi.nlm.nih.gov/18378417/

57. Jacobs, I., Bast, R. C., Jr., The CA 125 tumour-associated antigen: a review of the literature, Hum Reprod, 1989. 4(1): p. 1-12., https://pubmed.ncbi.nlm.nih.gov/2651469/

58. Partridge, E. E., Barnes, M. N., Epithelial ovarian cancer: prevention, diagnosis, and treatment, CA Cancer J Clin, 1999. 49(5): p. 297-320., https://pubmed.ncbi.nlm.nih.gov/11198956/

59. Takekuma, M., Maeda, M., Ozawa, T., Yasumi, K., Torizuka, T., Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer, Int J Clin Oncol, 2005. 10(3): p. 177-81., https://pubmed.ncbi.nlm.nih.gov/15990965/

60. Bristow, R. E., Lagasse, L. D., Karlan, B. Y., Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Patient selection and review of the literature, Cancer, 1996. 78(10): p. 2049-62., https://pubmed.ncbi.nlm.nih.gov/8918397/

61. Gysels, M., Higginson, I. J., Interactive technologies and videotapes for patient education in cancer care: systematic review and meta-analysis of randomised trials, Support Care Cancer, 2007. 15(1): p. 7-20., https://pubmed.ncbi.nlm.nih.gov/17024500/

62. Wofford, J. L., Smith, E. D., Miller, D. P., The multimedia computer for office-based patient education: a systematic review, Patient Educ Couns, 2005. 59(2): p. 148-57., https://pubmed.ncbi.nlm.nih.gov/16257619/

63. NHS, Effective Health Care: Informing, communicating and sharing decision with people who have cancer, NHS Centre for Reviews and Dissemination. Plymouth: Latimer Trend & Company Ltd, 2000., https://www.york.ac.uk/media/crd/ehc66.pdf

64. Wright, E. B., Holcombe, C., Salmon, P., Doctors' communication of trust, care, and respect in breast cancer: qualitative study, BMJ, 2004. 328(7444): p. 864., https://pubmed.ncbi.nlm.nih.gov/15054034/

65. Weis, J., Giesler, J. M., Subjective dimensions of patient competence: relationships with selected healthcare usage behaviors and general features of self-rated competence, Patient Educ Couns, 2008. 73(3): p. 511-8., https://pubmed.ncbi.nlm.nih.gov/18952394/

66. Jansen, S. J., Otten, W., Baas-Thijssen, M. C., van de Velde, C. J., Nortier, J. W., Stiggelbout, A. M., Explaining differences in attitude toward adjuvant chemotherapy between experienced and inexperienced breast cancer patients, J Clin Oncol, 2005. 23(27): p. 6623-30., https://pubmed.ncbi.nlm.nih.gov/16170169/

67. Katz, S. J., Lantz, P. M., Janz, N. K., Fagerlin, A., Schwartz, K., Liu, L., et.al. Patient involvement in surgery treatment decisions for breast cancer, J Clin Oncol, 2005. 23(24): p. 5526-33., https://pubmed.ncbi.nlm.nih.gov/16110013/

68. Wagner, K., Koller, M., Keil, A., Strahlentherapie bei chirurgischen und nichtchirurgien Patienten: Therapieerwartungen, Lebensqualität und Arzteinschätzung, Chirurg, 1998. 69: p. 252-258.

69. Albert, U. S., Koller, M., Wagner, U., Schulz, K. D., Survival chances and psychological aspects of quality of life in patients with localized early stage breast cancer, Inflamm Res, 2004. 53 Suppl 2: p. S136-41., https://pubmed.ncbi.nlm.nih.gov/15338065/

70. Chouliara, Z., Kearney, N., Stott, D., Molassiotis, A., Miller, M., Perceptions of older people with cancer of information, decision making and treatment: a systematic review of selected literature, Ann Oncol, 2004. 15(11): p. 1596-602., https://pubmed.ncbi.nlm.nih.gov/15520059/

71. Hagerty, R. G., Butow, P. N., Ellis, P. M., Dimitry, S., Tattersall, M. H., Communicating prognosis in cancer care: a systematic review of the literature, Ann Oncol, 2005. 16(7): p. 1005-53., https://pubmed.ncbi.nlm.nih.gov/15939716/

72. Albert, U. S., Schulz, K. D., Alt, D., Beck, V., Doherty, J., Holsteg, K., et.al. [A guideline for guidelines--methodological report and use of the guideline women's information], Zentralbl Gynakol, 2003. 125(12): p. 484-93., https://pubmed.ncbi.nlm.nih.gov/14755359/

73. O'Connor, A. M., Rostom, A., Fiset, V., Tetroe, J., Entwistle, V., Llewellyn-Thomas, H., et.al. Decision aids for patients facing health treatment or screening decisions: systematic review, BMJ, 1999. 319(7212): p. 731-4., https://pubmed.ncbi.nlm.nih.gov/10487995/

74. Bruera, E., Willey, J. S., Palmer, J. L., Rosales, M., Treatment decisions for breast carcinoma: patient preferences and physician perceptions, Cancer, 2002. 94(7): p. 2076-80., https://pubmed.ncbi.nlm.nih.gov/11932912/

75. Butow, P., Harrison, J. D., Choy, E. T., Young, J. M., Spillane, A., Evans, A., Health professional and consumer views on involving breast cancer patients in the multidisciplinary discussion of their disease and treatment plan, Cancer, 2007. 110(9): p. 1937-44., https://pubmed.ncbi.nlm.nih.gov/17823912/

76. Elkin, E. B., Kim, S. H., Casper, E. S., Kissane, D. W., Schrag, D., Desire for information and involvement in treatment decisions: elderly cancer patients' preferences and their physicians' perceptions, J Clin Oncol, 2007. 25(33): p. 5275-80., https://pubmed.ncbi.nlm.nih.gov/18024875/

77. Ford, S., Schofield, T., Hope, T., Observing decision-making in the general practice consultation: who makes which decisions?, Health Expect, 2006. 9(2): p. 130-7., https://pubmed.ncbi.nlm.nih.gov/16677192/

78. Politi, M. C., Han, P. K., Col, N. F., Communicating the uncertainty of harms and benefits of medical interventions, Med Decis Making, 2007. 27(5): p. 681-95., https://pubmed.ncbi.nlm.nih.gov/17873256/

79. Kinnersley, P., Edwards, A., Hood, K., Ryan, R., Prout, H., Cadbury, N., et.al. Interventions before consultations to help patients address their information needs by encouraging question asking: systematic review, BMJ, 2008. 337: p. a485., https://pubmed.ncbi.nlm.nih.gov/18632672/

80. Thomas, R., Richardson, A., The NICE guidance on supportive and palliative care--implications for oncology teams, Clin Oncol (R Coll Radiol), 2004. 16(6): p. 420-4., https://pubmed.ncbi.nlm.nih.gov/15487134/

81. Zealand, Cancer Society of New, National stocktake and review of a selection of consumer cancer information resources, Cancer Society of New Zealand, Auckland, 2006.

82. van Oorschot, B., Hausmann, C., Kohler, N., Leppert, K., Schweitzer, S., Steinbach, K., et.al. [Patients as partners. Tumor patients and their participation in medical decisions], Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2004. 47(10): p. 992-9., https://pubmed.ncbi.nlm.nih.gov/15543666/

83. Crockett, R. A., Sutton, S., Walter, F. M., Clinch, M., Marteau, T. M., Benson, J., Impact on decisions to start or continue medicines of providing information to patients about possible benefits and/or harms: a systematic review and meta-analysis, Med Decis Making, 2011. 31(5): p. 767-77., https://pubmed.ncbi.nlm.nih.gov/21447731/

84. Degner, L. F., Kristjanson, L. J., Bowman, D., Sloan, J. A., Carriere, K. C., O'Neil, J., et.al. Information needs and decisional preferences in women with breast cancer, JAMA, 1997. 277(18): p. 1485-92., https://pubmed.ncbi.nlm.nih.gov/9145723/

85. Leinster, S.J., Ashcroft, J.J., Slade, Mastectomy versus conservative surgery: psychosocial effects of the patients choice of treatment, J Psychosoc Oncol, 1989. 1/2: p. 179-192., https://www.tandfonline.com/doi/abs/10.1300/J077v07n01_12

86. Deutsche Krebsgesellschaft, Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Aktualisierung 2012Leitlinienprogramm Onkologie der AWMW, Deutschen Krebsgesellschaft e.V. und Deutschen Krebshilfe e.V., 2012., https://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/

87. Harter, P., Hauke, J., Heitz, F., Reuss, A., Kommoss, S., Marme, F., et.al. Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1), PLoS One, 2017. 12(10): p. e0186043., https://www.ncbi.nlm.nih.gov/pubmed/29053726

88. Walsh, T., Casadei, S., Lee, M. K., Pennil, C. C., Nord, A. S., Thornton, A. M., et.al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing, Proc Natl Acad Sci U S A, 2011. 108(44): p. 18032-7., https://pubmed.ncbi.nlm.nih.gov/22006311/

89. Soegaard, M., Kjaer, S. K., Cox, M., Wozniak, E., Hogdall, E., Hogdall, C., et.al. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark, Clin Cancer Res, 2008. 14(12): p. 3761-7., https://pubmed.ncbi.nlm.nih.gov/18559594/

90. Malander, S., Ridderheim, M., Masback, A., Loman, N., Kristoffersson, U., Olsson, H., et.al. One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden, Eur J Cancer, 2004. 40(3): p. 422-8., https://pubmed.ncbi.nlm.nih.gov/14746861/

91. Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J., et.al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group, J Clin Oncol, 2012. 30(21): p. 2654-63., https://pubmed.ncbi.nlm.nih.gov/22711857/

92. Carver, T, Hartley, S, Lee, A, Cunningham, AP, Archer, S, Babb de Villiers, C, et.al. CanRisk Tool-A Web Interface for the Prediction of Breast and Ovarian Cancer Risk and the Likelihood of Carrying Genetic Pathogenic Variants., Cancer Epidemiol Biomarkers Prev, 2021. 30 (3)(3): p. 469-473., https://pubmed.ncbi.nlm.nih.gov/33335023/

93. Kast, K., Arnold, N., Gendiagnostik bei familiären Tumoren, Der Gynäkologe, 2012. 45(1): p. 28-34.

94. Yang, X, Leslie, G, Doroszuk, A, Schneider, S, Allen, J, Decker, B, et.al. Cancer Risks Associated With Germline , J Clin Oncol, 2020. 38 (7)(7): p. 674-685., https://pubmed.ncbi.nlm.nih.gov/31841383/

95. Ficorella, L, Yang, X, Easton, DF, Antoniou, AC, BOADICEA model: updates to the , BJC Rep, 2024. 2 (1)(1): p. 53., https://pubmed.ncbi.nlm.nih.gov/39072245/

96. Kuchenbaecker, KB, Hopper, JL, Barnes, DR, Phillips, KA, Mooij, TM, Roos-Blom, MJ, et.al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers., JAMA, 2017. 317 (23)(23): p. 2402-2416., https://pubmed.ncbi.nlm.nih.gov/28632866/

97. Butow, P.N. et al., The dynamics of change: cancer patients' preferences for information, involvement and support, 1997., https://pubmed.ncbi.nlm.nih.gov/9358935/

98. Kirchhoff, T., Gaudet, M. M., Antoniou, A. C., McGuffog, L., Humphreys, M. K., Dunning, A. M., et.al. Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2, PLoS One, 2012. 7(6): p. e35706., https://pubmed.ncbi.nlm.nih.gov/22768030/

99. Dareng, EO, Tyrer, JP, Barnes, DR, Jones, MR, Yang, X, Aben, KKH, et.al. Polygenic risk modeling for prediction of epithelial ovarian cancer risk., Eur J Hum Genet, 2022. 30 (3)(3): p. 349-362., https://pubmed.ncbi.nlm.nih.gov/35027648/

100. Dominguez-Valentin, M, Sampson, JR, Seppälä, TT, Ten Broeke, SW, Plazzer, JP, Nakken, S, et.al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database., Genet Med, 2020. 22 (1)(1): p. 15-25., https://pubmed.ncbi.nlm.nih.gov/31337882/

101. Antoniou, A., Pharoah, P. D., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., et.al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies, Am J Hum Genet, 2003. 72(5): p. 1117-30., https://pubmed.ncbi.nlm.nih.gov/12677558/

102. King, M. C., Marks, J. H., Mandell, J. B., Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2, Science, 2003. 302(5645): p. 643-6., https://pubmed.ncbi.nlm.nih.gov/14576434/

103. Bonadona, V., Bonaiti, B., Olschwang, S., Grandjouan, S., Huiart, L., Longy, M., et.al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome, JAMA, 2011. 305(22): p. 2304-10., https://pubmed.ncbi.nlm.nih.gov/21642682/

104. Chen, S., Iversen, E. S., Friebel, T., Finkelstein, D., Weber, B. L., Eisen, A., et.al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample, J Clin Oncol, 2006. 24(6): p. 863-71., https://pubmed.ncbi.nlm.nih.gov/16484695/

105. Tinelli, A., Malvasi, A., Leo, G., Vergara, D., Pisano, M., Ciccarese, M., et.al. Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal, Cancer Metastasis Rev, 2010. 29(2): p. 339-50., https://pubmed.ncbi.nlm.nih.gov/20405170/

106. Dreyer, G., Screening for gynaecologic cancers in genetically predisposed women, Best Pract Res Clin Obstet Gynaecol, 2012. 26(2): p. 267-82., https://pubmed.ncbi.nlm.nih.gov/22361688/

107. Sjursen, W, Hyldebrandt, HK, Lavik, LAS, Haukanes, BI, Ariansen, S, Briskemyr, S, et.al. PMS2 mutation spectra in Norway and risk of cancer for carriers of pathogenic variants., Hered Cancer Clin Pract, 2024. 22 (1)(1): p. 20., https://pubmed.ncbi.nlm.nih.gov/39334433/

108. Wang, Q, Leclerc, J, Bougeard, G, Olschwang, S, Vasseur, S, Cassinari, K, et.al. Characterisation of heterozygous , J Med Genet, 2020. 57 (7)(7): p. 487-499., https://pubmed.ncbi.nlm.nih.gov/31992580/

109. Deutsche Krebshilfe, Familiärer Krebs, 2012. 2012:

110. GenDG, Gesetz über genetische Untersuchungen bei Menschen (Gendiagnostikgesetz – GenDG) vom 31.7.2009,, 2009.

111. Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., Van't Veer, L., Garber, J. E., et.al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations, N Engl J Med, 2002. 346(21): p. 1616-22., https://pubmed.ncbi.nlm.nih.gov/12023993/

112. Kauff, N. D., Satagopan, J. M., Robson, M. E., Scheuer, L., Hensley, M., Hudis, C. A., et.al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation, N Engl J Med, 2002. 346(21): p. 1609-15., https://pubmed.ncbi.nlm.nih.gov/12023992/

113. Haber, D., Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations, N Engl J Med, 2002. 346(21): p. 1660-2., https://pubmed.ncbi.nlm.nih.gov/12024000/

114. Finch, A., Beiner, M., Lubinski, J., Lynch, H. T., Moller, P., Rosen, B., et.al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation, JAMA, 2006. 296(2): p. 185-92., https://pubmed.ncbi.nlm.nih.gov/16835424/

115. Rebbeck, T. R., Friebel, T., Wagner, T., Lynch, H. T., Garber, J. E., Daly, M. B., et.al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group, 2005., https://pubmed.ncbi.nlm.nih.gov/16219936/

116. Madalinska, J. B., van Beurden, M., Bleiker, E. M., Valdimarsdottir, H. B., Hollenstein, J., Massuger, L. F., et.al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy, 2006., https://pubmed.ncbi.nlm.nih.gov/16877724/

117. Parker, W. H., Broder, M. S., Chang, E., Feskanich, D., Farquhar, C., Liu, Z., et.al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study, Obstet Gynecol, 2009. 113(5): p. 1027-37., https://pubmed.ncbi.nlm.nih.gov/19384117/

118. Madalinska, J. B., Hollenstein, J., Bleiker, E., van Beurden, M., Valdimarsdottir, H. B., Massuger, L. F., et.al. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer, J Clin Oncol, 2005. 23(28): p. 6890-8., https://pubmed.ncbi.nlm.nih.gov/16129845/

119. Wagner, T. M., Moslinger, R., Langbauer, G., Ahner, R., Fleischmann, E., Auterith, A., et.al. Attitude towards prophylactic surgery and effects of genetic counselling in families with BRCA mutations. Austrian Hereditary Breast and Ovarian Cancer Group, Br J Cancer, 2000. 82(7): p. 1249-53., https://pubmed.ncbi.nlm.nih.gov/10755396/

120. Hallowell, N., A qualitative study of the information needs of high-risk women undergoing prophylactic oophorectomy, Psychooncology, 2000. 9(6): p. 486-95., https://pubmed.ncbi.nlm.nih.gov/11180583/

121. Fry, A., Busby-Earle, C., Rush, R., Cull, A., Prophylactic oophorectomy versus screening: psychosocial outcomes in women at increased risk of ovarian cancer, Psychooncology, 2001. 10(3): p. 231-41., https://pubmed.ncbi.nlm.nih.gov/11351375/

122. Finch, A. P., Lubinski, J., Moller, P., Singer, C. F., Karlan, B., Senter, L., et.al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation, J Clin Oncol, 2014. 32(15): p. 1547-53., https://pubmed.ncbi.nlm.nih.gov/24567435/

123. Marchetti, C., De Felice, F., Palaia, I., Perniola, G., Musella, A., Musio, D., et.al. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers, BMC Womens Health, 2014. 14: p. 150., https://pubmed.ncbi.nlm.nih.gov/25494812/

124. Fry, A., Busby-Earle, C., Rush, R., Cull, A., Prophylactic oophorectomy versus screening: psychosocial outcomes in women at increased risk of ovarian cancer, Psychooncology, 2001. 10(3): p. 231-41., https://pubmed.ncbi.nlm.nih.gov/11351375/

125. Ingham, S. L., Warwick, J., Buchan, I., Sahin, S., O'Hara, C., Moran, A., et.al. Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2, J Med Genet, 2013. 50(6): p. 368-72., https://pubmed.ncbi.nlm.nih.gov/23539753/

126. Iodice, S., Barile, M., Rotmensz, N., Feroce, I., Bonanni, B., Radice, P., et.al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis, Eur J Cancer, 2010. 46(12): p. 2275-84., https://pubmed.ncbi.nlm.nih.gov/20537530/

127. Cibula, D., Widschwendter, M., Majek, O., Dusek, L., Tubal ligation and the risk of ovarian cancer: review and meta-analysis, Hum Reprod Update, 2011. 17(1): p. 55-67., https://pubmed.ncbi.nlm.nih.gov/20634209/

128. Lurie, G., Thompson, P., McDuffie, K. E., Carney, M. E., Terada, K. Y., Goodman, M. T., Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk, Obstet Gynecol, 2007. 109(3): p. 597-607., https://pubmed.ncbi.nlm.nih.gov/17329510/

129. Moorman, P. G., Havrilesky, L. J., Gierisch, J. M., Coeytaux, R. R., Lowery, W. J., Peragallo Urrutia, R., et.al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis, J Clin Oncol, 2013. 31(33): p. 4188-98., https://pubmed.ncbi.nlm.nih.gov/24145348/

130. Madalinska, J. B., van Beurden, M., Bleiker, E. M., Valdimarsdottir, H. B., Hollenstein, J., Massuger, L. F., et.al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy, J Clin Oncol, 2006. 24(22): p. 3576-82., https://pubmed.ncbi.nlm.nih.gov/16877724/

131. Sherman, M. E., Piedmonte, M., Mai, P. L., Ioffe, O. B., Ronnett, B. M., Van Le, L., et.al. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199, J Clin Oncol, 2014. 32(29): p. 3275-83., https://pubmed.ncbi.nlm.nih.gov/25199754/

132. Polcher, M., Hauptmann, S., Fotopoulou, C., Schmalfeldt, B., Meinhold-Heerlein, I., Mustea, A., et.al. Should Fallopian Tubes Be Removed During Hysterectomy Procedures?- A Statement by AGO Ovar, Geburtshilfe Und Frauenheilkunde, 2015. 75(4): p. 339-341., https://pubmed.ncbi.nlm.nih.gov/26028692/

133. Antoniou, A. C., Rookus, M., Andrieu, N., Brohet, R., Chang-Claude, J., Peock, S., et.al. Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study, Cancer Epidemiol Biomarkers Prev, 2009. 18(2): p. 601-10., https://pubmed.ncbi.nlm.nih.gov/19190154/

134. Falconer, H., Yin, L., Gronberg, H., Altman, D., Ovarian cancer risk after salpingectomy: a nationwide population-based study, J Natl Cancer Inst, 2015. 107(2):, https://pubmed.ncbi.nlm.nih.gov/25628372/

135. Polcher, M., Hauptmann, S., Fotopoulou, C., Schmalfeldt, B., Meinhold-Heerlein, I., Mustea, A., et.al. Opportunistic salpingectomies for the prevention of a high-grade serous carcinoma: a statement by the Kommission Ovar of the AGO, Arch Gynecol Obstet, 2015. 292(1): p. 231-4., https://pubmed.ncbi.nlm.nih.gov/25914073/

136. Falconer, H, Yin, L, Salehi, S, Altman, D, Association between pelvic inflammatory disease and subsequent salpingectomy on the risk for ovarian cancer., Eur J Cancer, 2021. 145 (): p. 38-43., https://pubmed.ncbi.nlm.nih.gov/33418235/

137. Darelius, A, Kristjansdottir, B, Dahm-Kähler, P, Strandell, A, Risk of epithelial ovarian cancer Type I and II after hysterectomy, salpingectomy and tubal ligation-A nationwide case-control study., Int J Cancer, 2021. 149 (8)(8): p. 1544-1552., https://pubmed.ncbi.nlm.nih.gov/34152012/

138. Dilley, SE, Havrilesky, LJ, Bakkum-Gamez, J, Cohn, DE, Michael Straughn, J, Caughey, AB, et.al. Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention., Gynecol Oncol, 2017. 146 (2)(2): p. 373-379., https://pubmed.ncbi.nlm.nih.gov/28577884/

139. Subramaniam, A, Einerson, BD, Blanchard, CT, Erickson, BK, Szychowski, J, Leath, CA, et.al. The cost-effectiveness of opportunistic salpingectomy versus standard tubal ligation at the time of cesarean delivery for ovarian cancer risk reduction., Gynecol Oncol, 2019. 152 (1)(1): p. 127-132., https://pubmed.ncbi.nlm.nih.gov/30477808/

140. Naumann, RW, Hughes, BN, Brown, J, Drury, LK, Herzog, TJ, The impact of opportunistic salpingectomy on ovarian cancer mortality and healthcare costs: a call for universal insurance coverage., Am J Obstet Gynecol, 2021. 225 (4)(4): p. 397.e1-397.e6., https://pubmed.ncbi.nlm.nih.gov/33798477/

141. Labidi-Galy, SI, Papp, E, Hallberg, D, Niknafs, N, Adleff, V, Noe, M, et.al. High grade serous ovarian carcinomas originate in the fallopian tube., Nat Commun, 2017. 8 (1)(1): p. 1093., https://pubmed.ncbi.nlm.nih.gov/29061967/

142. Kindelberger, DW, Lee, Y, Miron, A, Hirsch, MS, Feltmate, C, Medeiros, F, et.al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship., Am J Surg Pathol, 2007. 31 (2)(2): p. 161-9., https://pubmed.ncbi.nlm.nih.gov/17255760/

143. Runnebaum, IB, Kather, A, Sehouli, J, Opportunistic Salpingectomy for the Primary Prevention of Ovarian Cancer., Dtsch Arztebl Int, 2022. 119 (49)(49): p. 846-847., https://pubmed.ncbi.nlm.nih.gov/36814422/

144. Runnebaum, IB, Kather, A, Vorwergk, J, Cruz, JJ, Mothes, AR, Beteta, CR, et.al. Ovarian cancer prevention by opportunistic salpingectomy is a new de facto standard in Germany., J Cancer Res Clin Oncol, 2023. 149 (10)(10): p. 6953-6966., https://pubmed.ncbi.nlm.nih.gov/36847838/

145. Vorwergk, J, Radosa, MP, Nicolaus, K, Baus, N, Jimenez Cruz, J, Rengsberger, M, et.al. Prophylactic bilateral salpingectomy (PBS) to reduce ovarian cancer risk incorporated in standard premenopausal hysterectomy: complications and re-operation rate., J Cancer Res Clin Oncol, 2014. 140 (5)(5): p. 859-65., https://pubmed.ncbi.nlm.nih.gov/24573653/

146. Kotlyar, A., Gingold, J., Shue, S., Falcone, T., The Effect of Salpingectomy on Ovarian Function, J Minim Invasive Gynecol, 2017., https://pubmed.ncbi.nlm.nih.gov/28223181/

147. Medeiros, F., Muto, M. G., Lee, Y., Elvin, J. A., Callahan, M. J., Feltmate, C., et.al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome, Am J Surg Pathol, 2006. 30(2): p. 230-6., http://www.ncbi.nlm.nih.gov/pubmed/16434898

148. Swanson, CL, Bakkum-Gamez, JN, Options in Prophylactic Surgery to Prevent Ovarian Cancer in High-Risk Women: How New Hypotheses of Fallopian Tube Origin Influence Recommendations., Curr Treat Options Oncol, 2016. 17 (5)(5): p. 20., https://pubmed.ncbi.nlm.nih.gov/27032642/

149. Potz, FL, Tomasch, G, Polterauer, S, Laky, R, Marth, C, Tamussino, K, Incidental (Prophylactic) Salpingectomy at Benign Gynecologic Surgery and Cesarean Section: a Survey of Practice in Austria., Geburtshilfe Frauenheilkd, 2016. 76 (12)(12): p. 1325-1329., https://pubmed.ncbi.nlm.nih.gov/28017973/

150. Pölcher, M, Wimberger, P, Meinhold-Heerlein, I, Runnebaum, I, Schüler-Toprak, S, Mahner, S, et.al. Intergroup statement: opportunistic salpingectomy-molecular pathology, clinical outcomes and implications for practice (German Ovarian Cancer Commission, the North-Eastern German Society of Gynecologic Oncology (NOGGO), AGO Austria and AGO Swiss)., Arch Gynecol Obstet, 2025. 311 (5)(5): p. 1451-1459., https://pubmed.ncbi.nlm.nih.gov/40172609/

151. WHO, IARC, HORMONAL CONTRACEPTION AND POST-MENOPAUSAL HORMONAL THERAPY, 1999. 72:, https://www.ncbi.nlm.nih.gov/books/NBK396191/

152. Beral, V., Doll, R., Hermon, C., Peto, R., Reeves, G., Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls, Lancet, 2008. 371(9609): p. 303-14., https://pubmed.ncbi.nlm.nih.gov/18294997/

153. Rice, M. S., Hankinson, S. E., Tworoger, S. S., Tubal ligation, hysterectomy, unilateral oophorectomy, and risk of ovarian cancer in the Nurses' Health Studies, Fertil Steril, 2014. 102(1): p. 192-198 e3., https://pubmed.ncbi.nlm.nih.gov/24825424/

154. Anderson, G. L., Judd, H. L., Kaunitz, A. M., Barad, D. H., Beresford, S. A., Pettinger, M., et.al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial, JAMA, 2003. 290(13): p. 1739-48., https://pubmed.ncbi.nlm.nih.gov/14519708/

155. Beral, V., Bull, D., Green, J., Reeves, G., Ovarian cancer and hormone replacement therapy in the Million Women Study, Lancet, 2007. 369(9574): p. 1703-10., https://pubmed.ncbi.nlm.nih.gov/17512855/

156. Beral, V., Gaitskell, K., Hermon, C., Moser, K., Reeves, G., Peto, R., Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies, Lancet, 2015. 385(9980): p. 1835-42., https://pubmed.ncbi.nlm.nih.gov/25684585/

157. Morch, L. S., Lokkegaard, E., Andreasen, A. H., Kruger-Kjaer, S., Lidegaard, O., Hormone therapy and ovarian cancer, JAMA, 2009. 302(3): p. 298-305., https://pubmed.ncbi.nlm.nih.gov/19602689/

158. Beral, V., Gaitskell, K., Hermon, C., Moser, K., Reeves, G., Peto, R., Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies, Lancet, 2015. 385(9980): p. 1835-42., https://pubmed.ncbi.nlm.nih.gov/25684585/

159. Shi, L. F., Wu, Y., Li, C. Y., Hormone therapy and risk of ovarian cancer in postmenopausal women: a systematic review and meta-analysis, Menopause, 2016. 23(4): p. 417-24., https://pubmed.ncbi.nlm.nih.gov/26506499/

160. Whittemore, A. S., Harris, R., Itnyre, J., Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group, Am J Epidemiol, 1992. 136(10): p. 1184-203., https://pubmed.ncbi.nlm.nih.gov/1476141/

161. Jordan, S. J., Green, A. C., Whiteman, D. C., Moore, S. P., Bain, C. J., Gertig, D. M., et.al. Serous ovarian, fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis, Int J Cancer, 2008. 122(7): p. 1598-603., https://pubmed.ncbi.nlm.nih.gov/18058817/

162. Cetin, I., Cozzi, V., Antonazzo, P., Infertility as a cancer risk factor - a review, Placenta, 2008. 29 Suppl B: p. 169-77., https://pubmed.ncbi.nlm.nih.gov/18790330/

163. Venn, A., Watson, L., Bruinsma, F., Giles, G., Healy, D., Risk of cancer after use of fertility drugs with in-vitro fertilisation, Lancet, 1999. 354(9190): p. 1586-90., https://pubmed.ncbi.nlm.nih.gov/10560672/

164. Brinton, L. A., Moghissi, K. S., Scoccia, B., Westhoff, C. L., Lamb, E. J., Ovulation induction and cancer risk, Fertil Steril, 2005. 83(2): p. 261-74; quiz 525-6., https://pubmed.ncbi.nlm.nih.gov/15705362/

165. Jensen, A., Sharif, H., Frederiksen, K., Kjaer, S. K., Use of fertility drugs and risk of ovarian cancer: Danish Population Based Cohort Study, BMJ, 2009. 338: p. b249., https://pubmed.ncbi.nlm.nih.gov/19196744/

166. Olsen, C. M., Green, A. C., Whiteman, D. C., Sadeghi, S., Kolahdooz, F., Webb, P. M., Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis, Eur J Cancer, 2007. 43(4): p. 690-709., https://pubmed.ncbi.nlm.nih.gov/17223544/

167. Leitzmann, M. F., Koebnick, C., Danforth, K. N., Brinton, L. A., Moore, S. C., Hollenbeck, A. R., et.al. Body mass index and risk of ovarian cancer, Cancer, 2009. 115(4): p. 812-22., https://pubmed.ncbi.nlm.nih.gov/19127552/

168. Keum, N., Greenwood, D. C., Lee, D. H., Kim, R., Aune, D., Ju, W., et.al. Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies, J Natl Cancer Inst, 2015. 107(2):, https://pubmed.ncbi.nlm.nih.gov/25757865/

169. Liu, Z., Zhang, T. T., Zhao, J. J., Qi, S. F., Du, P., Liu, D. W., et.al. The association between overweight, obesity and ovarian cancer: a meta-analysis, Jpn J Clin Oncol, 2015. 45(12): p. 1107-15., https://pubmed.ncbi.nlm.nih.gov/26491203/

170. Bandera, E. V., Qin, B., Moorman, P. G., Alberg, A. J., Barnholtz-Sloan, J. S., Bondy, M., et.al. Obesity, weight gain, and ovarian cancer risk in African American women, Int J Cancer, 2016. 139(3): p. 593-600., https://pubmed.ncbi.nlm.nih.gov/27038123/

171. Beavis, A. L., Smith, A. J., Fader, A. N., Lifestyle changes and the risk of developing endometrial and ovarian cancers: opportunities for prevention and management, Int J Womens Health, 2016. 8: p. 151-67., https://pubmed.ncbi.nlm.nih.gov/27284267/

172. Cirillo, P. M., Wang, E. T., Cedars, M. I., Chen, L. M., Cohn, B. A., Irregular menses predicts ovarian cancer: Prospective evidence from the Child Health and Development Studies, Int J Cancer, 2016. 139(5): p. 1009-17., http://www.ncbi.nlm.nih.gov/pubmed/27082375

173. DastranjTabrizi, A., MostafaGharabaghi, P., SheikhzadehHesari, F., Sadeghi, L., Zamanvandi, S., Sarbakhsh, P., et.al. Impact and mechanistic role of oral contraceptive pills on the number and epithelial type of ovarian cortical inclusion cysts; a clinicopathology and immunohistochemical study, Diagn Pathol, 2016. 11: p. 30., https://pubmed.ncbi.nlm.nih.gov/27000861/

174. Dixon, S. C., Nagle, C. M., Thrift, A. P., Pharoah, P. D., Pearce, C. L., Zheng, W., et.al. Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study, Int J Epidemiol, 2016. 45(3): p. 884-95., https://pubmed.ncbi.nlm.nih.gov/27401727/

175. Fathalla, M. F., Non-hormonal interruption of incessant ovulation as a potential approach for ovarian cancer prevention, Int J Gynaecol Obstet, 2016. 132(3): p. 356-8., https://pubmed.ncbi.nlm.nih.gov/26876699/

176. Fernandes, G. C., Michelli, R. A., Galvao, H. C., Paula, A. E., Pereira, R., Andrade, C. E., et.al. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry, Oncotarget, 2016. 7(49): p. 80465-80481., https://pubmed.ncbi.nlm.nih.gov/27741520/

177. Gaitskell, K., Coffey, K., Green, J., Pirie, K., Reeves, G. K., Ahmed, A. A., et.al. Tubal ligation and incidence of 26 site-specific cancers in the Million Women Study, Br J Cancer, 2016. 114(9): p. 1033-7., https://pubmed.ncbi.nlm.nih.gov/27115569/

178. Gaitskell, K., Green, J., Pirie, K., Reeves, G., Beral, V., Tubal ligation and ovarian cancer risk in a large cohort: Substantial variation by histological type, Int J Cancer, 2016. 138(5): p. 1076-84., https://pubmed.ncbi.nlm.nih.gov/26378908/

179. Gong, L., Wang, C., Gao, Y., Wang, J., Decreased expression of microRNA-148a predicts poor prognosis in ovarian cancer and associates with tumor growth and metastasis, Biomed Pharmacother, 2016. 83: p. 58-63., https://pubmed.ncbi.nlm.nih.gov/27470550/

180. Gu, F., Xiao, Q., Chu, L. W., Yu, K., Matthews, C. E., Hsing, A. W., et.al. Sleep Duration and Cancer in the NIH-AARP Diet and Health Study Cohort, PLoS One, 2016. 11(9): p. e0161561., https://pubmed.ncbi.nlm.nih.gov/27611440/

181. Hartmann, L. C., Lindor, N. M., Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer, N Engl J Med, 2016. 374(24): p. 2404., https://pubmed.ncbi.nlm.nih.gov/27305204/

182. Hibler, E. A., Kauderer, J., Greene, M. H., Rodriguez, G. C., Alberts, D. S., Bone loss after oophorectomy among high-risk women: an NRG oncology/gynecologic oncology group study, Menopause, 2016. 23(11): p. 1228-1232., https://pubmed.ncbi.nlm.nih.gov/27433858/

183. Kar, S. P., Beesley, J., Amin Al Olama, A., Michailidou, K., Tyrer, J., Kote-Jarai, Z., et.al. Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types, Cancer Discov, 2016. 6(9): p. 1052-67., https://pubmed.ncbi.nlm.nih.gov/27432226/

184. Karam, A., Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer, N Engl J Med, 2016. 374(24): p. 2403., https://pubmed.ncbi.nlm.nih.gov/27305205/

185. Kohler, L. N., Garcia, D. O., Harris, R. B., Oren, E., Roe, D. J., Jacobs, E. T., Adherence to Diet and Physical Activity Cancer Prevention Guidelines and Cancer Outcomes: A Systematic Review, Cancer Epidemiol Biomarkers Prev, 2016. 25(7): p. 1018-28., https://pubmed.ncbi.nlm.nih.gov/27340121/

186. Lauretta, R., Lanzolla, G., Vici, P., Mariani, L., Moretti, C., Appetecchia, M., Insulin-Sensitizers, Polycystic Ovary Syndrome and Gynaecological Cancer Risk, Int J Endocrinol, 2016. 2016: p. 8671762., https://pubmed.ncbi.nlm.nih.gov/27725832/

187. Lee, A. W., Ness, R. B., Roman, L. D., Terry, K. L., Schildkraut, J. M., Chang-Claude, J., et.al. Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk, Obstet Gynecol, 2016. 127(5): p. 828-36., https://pubmed.ncbi.nlm.nih.gov/27054934/

188. Leung, A. C., Cook, L. S., Swenerton, K., Gilks, B., Gallagher, R. P., Magliocco, A., et.al. Tea, coffee, and caffeinated beverage consumption and risk of epithelial ovarian cancers, Cancer Epidemiol, 2016. 45: p. 119-125., https://pubmed.ncbi.nlm.nih.gov/27810483/

189. Licaj, I., Lukic, M., Jareid, M., Lund, E., Braaten, T., Gram, I. T., Epithelial ovarian cancer subtypes attributable to smoking in the Norwegian Women and Cancer Study, 2012, Cancer Med, 2016. 5(4): p. 720-7., https://pubmed.ncbi.nlm.nih.gov/26762486/

190. MacInnis, R. J., Pike, M. C., Hopper, J. L., Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer, N Engl J Med, 2016. 374(24): p. 2403-4., https://pubmed.ncbi.nlm.nih.gov/27305206/

191. Manchanda, R., Legood, R., Antoniou, A. C., Gordeev, V. S., Menon, U., Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis, J Med Genet, 2016. 53(9): p. 591-9., https://pubmed.ncbi.nlm.nih.gov/27354448/

192. Moorman, P. G., Alberg, A. J., Bandera, E. V., Barnholtz-Sloan, J., Bondy, M., Cote, M. L., et.al. Reproductive factors and ovarian cancer risk in African-American women, Ann Epidemiol, 2016. 26(9): p. 654-62., https://pubmed.ncbi.nlm.nih.gov/27528178/

193. Norquist, B. M., Harrell, M. I., Brady, M. F., Walsh, T., Lee, M. K., Gulsuner, S., et.al. Inherited Mutations in Women With Ovarian Carcinoma, JAMA Oncol, 2016. 2(4): p. 482-90., https://pubmed.ncbi.nlm.nih.gov/26720728/

194. Perez-Lopez, F. R., Chedraui, P., Surgical prevention of epithelial ovary cancer without oophorectomy: changing the future, Climacteric, 2016. 19(5): p. 417-8., https://pubmed.ncbi.nlm.nih.gov/27404380/

195. Schildkraut, J. M., Abbott, S. E., Alberg, A. J., Bandera, E. V., Barnholtz-Sloan, J. S., Bondy, M. L., et.al. Association between Body Powder Use and Ovarian Cancer: The African American Cancer Epidemiology Study (AACES), Cancer Epidemiol Biomarkers Prev, 2016. 25(10): p. 1411-1417., https://pubmed.ncbi.nlm.nih.gov/27197282/

196. Schorge, J. O., What Is New in Prevention of Ovarian Cancer?: Best Articles From the Past Year, Obstet Gynecol, 2016. 127(4): p. 795-6., https://pubmed.ncbi.nlm.nih.gov/26959218/

197. Shivappa, N., Hebert, J. R., Rosato, V., Rossi, M., Montella, M., Serraino, D., et.al. Dietary inflammatory index and ovarian cancer risk in a large Italian case-control study, Cancer Causes Control, 2016. 27(7): p. 897-906., https://pubmed.ncbi.nlm.nih.gov/27262447/

198. Soini, T., Hurskainen, R., Grenman, S., Maenpaa, J., Paavonen, J., Pukkala, E., Impact of levonorgestrel-releasing intrauterine system use on the cancer risk of the ovary and fallopian tube, Acta Oncol, 2016. 55(11): p. 1281-1284., https://pubmed.ncbi.nlm.nih.gov/27148621/

199. Sun, Q., Huang, X., Zhang, Q., Qu, J., Shen, Y., Wang, X., et.al. SNAP23 promotes the malignant process of ovarian cancer, J Ovarian Res, 2016. 9(1): p. 80., https://pubmed.ncbi.nlm.nih.gov/27855700/

200. Sun, W., Lu, J., Wu, S., Bi, Y., Mu, Y., Zhao, J., et.al. Association of insulin resistance with breast, ovarian, endometrial and cervical cancers in non-diabetic women, Am J Cancer Res, 2016. 6(10): p. 2334-2344., https://pubmed.ncbi.nlm.nih.gov/27822422/

201. Sun, X. C., Zhang, A. C., Tong, L. L., Wang, K., Wang, X., Sun, Z. Q., et.al. miR-146a and miR-196a2 polymorphisms in ovarian cancer risk, Genet Mol Res, 2016. 15(3):, https://pubmed.ncbi.nlm.nih.gov/27706635/

202. Sung, H. K., Ma, S. H., Choi, J. Y., Hwang, Y., Ahn, C., Kim, B. G., et.al. The Effect of Breastfeeding Duration and Parity on the Risk of Epithelial Ovarian Cancer: A Systematic Review and Meta-analysis, J Prev Med Public Health, 2016. 49(6): p. 349-366., https://pubmed.ncbi.nlm.nih.gov/27951628/

203. Venturella, R., Rocca, M., Lico, D., Trapasso, S., Di Cello, A., Gizzo, S., et.al. Prophylactic bilateral salpingectomy for the prevention of ovarian cancers: What is happening in Italy?, Eur J Cancer Prev, 2016. 25(5): p. 410-5., https://pubmed.ncbi.nlm.nih.gov/26275007/

204. Wentzensen, N., Poole, E. M., Trabert, B., White, E., Arslan, A. A., Patel, A. V., et.al. Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium, J Clin Oncol, 2016. 34(24): p. 2888-98., https://pubmed.ncbi.nlm.nih.gov/27325851/

205. Yang, H. P., Murphy, K. R., Pfeiffer, R. M., George, N., Garcia-Closas, M., Lissowska, J., et.al. Lifetime Number of Ovulatory Cycles and Risks of Ovarian and Endometrial Cancer Among Postmenopausal Women, Am J Epidemiol, 2016. 183(9): p. 800-14., https://pubmed.ncbi.nlm.nih.gov/27190045/

206. Yoon, S. H., Kim, S. N., Shim, S. H., Kang, S. B., Lee, S. J., Bilateral salpingectomy can reduce the risk of ovarian cancer in the general population: A meta-analysis, Eur J Cancer, 2016. 55: p. 38-46., https://pubmed.ncbi.nlm.nih.gov/26773418/

207. Chudecka-Glaz, A., Cymbaluk-Ploska, A., Strojna, A., Menkiszak, J., HE4 Serum Levels in Patients with BRCA1 Gene Mutation Undergoing Prophylactic Surgery as well as in Other Benign and Malignant Gynecological Diseases, Dis Markers, 2017. 2017: p. 9792756., https://pubmed.ncbi.nlm.nih.gov/28182133/

208. Brilhante, A. V., Augusto, K. L., Portela, M. C., Sucupira, L. C., Oliveira, L. A., Pouchaim, A. J., et.al. Endometriosis and Ovarian Cancer: an Integrative Review (Endometriosis and Ovarian Cancer), Asian Pac J Cancer Prev, 2017. 18(1): p. 11-16., https://pubmed.ncbi.nlm.nih.gov/28240000/

209. Berge, W., Mundt, K., Luu, H., Boffetta, P., Genital use of talc and risk of ovarian cancer: a meta-analysis, Eur J Cancer Prev, 2017., https://pubmed.ncbi.nlm.nih.gov/28079603/

210. Bayraktar, S., Arun, B., BRCA mutation genetic testing implications in the United States, Breast, 2017. 31: p. 224-232., https://pubmed.ncbi.nlm.nih.gov/27931006/

211. Burghaus, S., Fasching, P. A., Haberle, L., Rubner, M., Buchner, K., Blum, S., et.al. Genetic risk factors for ovarian cancer and their role for endometriosis risk, Gynecol Oncol, 2017. 145(1): p. 142-147., https://pubmed.ncbi.nlm.nih.gov/28214017/

212. Duncan, J. R., Schenone, M. H., Mari, G., Technique for bilateral salpingectomy at the time of Cesarean delivery: a case series, Contraception, 2017., https://pubmed.ncbi.nlm.nih.gov/28263747/

213. Darelius, A., Lycke, M., Kindblom, J. M., Kristjansdottir, B., Sundfeldt, K., Strandell, A., Efficacy of salpingectomy at hysterectomy to reduce the risk of epithelial ovarian cancer: a systematic review, BJOG, 2017., https://pubmed.ncbi.nlm.nih.gov/28190289/

214. Crawford, B., Adams, S. B., Sittler, T., van den Akker, J., Chan, S., Leitner, O., et.al. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients, Breast Cancer Res Treat, 2017., https://pubmed.ncbi.nlm.nih.gov/28281021/

215. Corzo, C., Iniesta, M. D., Patrono, M. G., Lu, K. H., Ramirez, P. T., Role of Fallopian Tubes in the Development of Ovarian Cancer, J Minim Invasive Gynecol, 2017. 24(2): p. 230-234., https://pubmed.ncbi.nlm.nih.gov/28007588/

216. Cook, L. S., Pestak, C. R., Leung, A. C., Steed, H., Nation, J., Swenerton, K., et.al. Combined oral contraceptive use before the first birth and epithelial ovarian cancer risk, Br J Cancer, 2017. 116(2): p. 265-269., https://pubmed.ncbi.nlm.nih.gov/27959890/

217. Egeberg, A., Fowler, J. F., Jr., Gislason, G. H., Thyssen, J. P., Rosacea and risk of cancer in Denmark, Cancer Epidemiol, 2017. 47: p. 76-80., https://pubmed.ncbi.nlm.nih.gov/28131793/

218. Hanley, G. E., McAlpine, J. N., Pearce, C. L., Miller, D., The performance and safety of bilateral salpingectomy for ovarian cancer prevention in the United States, Am J Obstet Gynecol, 2017. 216(3): p. 270 e1-270 e9., https://pubmed.ncbi.nlm.nih.gov/27810554/

219. Gorodetska, I., Serga, S., Lahuta, T., Ostapchenko, L., Demydov, S., Khranovska, N., et.al. Prevalence of two BRCA1 mutations, 5382insC and 300T > G, in ovarian cancer patients from Ukraine, Fam Cancer, 2017., https://pubmed.ncbi.nlm.nih.gov/28285342/

220. Ely, L. K., Truong, M., The Role of Opportunistic Bilateral Salpingectomy vs Tubal Occlusion or Ligation for Ovarian Cancer Prophylaxis, J Minim Invasive Gynecol, 2017. 24(3): p. 371-378., https://pubmed.ncbi.nlm.nih.gov/28087480/

221. Eliade, M., Skrzypski, J., Baurand, A., Jacquot, C., Bertolone, G., Loustalot, C., et.al. The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?, Oncotarget, 2017. 8(2): p. 1957-1971., https://pubmed.ncbi.nlm.nih.gov/27779110/

222. Johansen, N., Liavaag, A. H., Iversen, O. E., Dorum, A., Braaten, T., Michelsen, T. M., Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy, Acta Obstet Gynecol Scand, 2017., https://pubmed.ncbi.nlm.nih.gov/28236297/

223. He, L., Shen, Y., MTHFR C677T polymorphism and breast, ovarian cancer risk: a meta-analysis of 19,260 patients and 26,364 controls, Onco Targets Ther, 2017. 10: p. 227-238., https://pubmed.ncbi.nlm.nih.gov/28123304/

224. Hassan, Z. K., Hafez, M. M., Kamel, M. M., Zekri, A. R., Human Papillomavirus Genotypes and Methylation of CADM1, PAX1, MAL and ADCYAP1 Genes in Epithelial Ovarian Cancer Patients, Asian Pac J Cancer Prev, 2017. 18(1): p. 169-176., https://pubmed.ncbi.nlm.nih.gov/28240513/

225. Iversen, L., Sivasubramaniam, S., Lee, A. J., Fielding, S., Hannaford, P. C., Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study, Am J Obstet Gynecol, 2017. 216(6): p. 580 e1-580 e9., https://pubmed.ncbi.nlm.nih.gov/28188769/

226. Kar, S. P., Adler, E., Tyrer, J., Hazelett, D., Anton-Culver, H., Bandera, E. V., et.al. Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci, Br J Cancer, 2017. 116(4): p. 524-535., https://pubmed.ncbi.nlm.nih.gov/28103614/

227. Koushik, A., Grundy, A., Abrahamowicz, M., Arseneau, J., Gilbert, L., Gotlieb, W. H., et.al. Hormonal and reproductive factors and the risk of ovarian cancer, Cancer Causes Control, 2017. 28(5): p. 393-403., https://pubmed.ncbi.nlm.nih.gov/28102526/

228. Kuo, H. H., Huang, C. Y., Ueng, S. H., Huang, K. G., Lee, C. L., Yen, C. F., Unexpected epithelial ovarian cancers arising from presumed endometrioma: A 10-year retrospective analysis, Taiwan J Obstet Gynecol, 2017. 56(1): p. 55-61., https://pubmed.ncbi.nlm.nih.gov/28254227/

229. Kyrgiou, M., Kalliala, I., Markozannes, G., Gunter, M. J., Paraskevaidis, E., Gabra, H., et.al. Adiposity and cancer at major anatomical sites: umbrella review of the literature, BMJ, 2017. 356: p. j477., https://pubmed.ncbi.nlm.nih.gov/28246088/

230. Long Roche, K. C., Abu-Rustum, N. R., Nourmoussavi, M., Zivanovic, O., Risk-reducing salpingectomy: Let us be opportunistic, Cancer, 2017., https://pubmed.ncbi.nlm.nih.gov/28334425/

231. Lin, S. F., Gerry, E., Shih, I. M., Tubal origin of ovarian cancer - the double-edged sword of haemoglobin, J Pathol, 2017., https://pubmed.ncbi.nlm.nih.gov/28054715/

232. Miller, H., Pipkin, L. S., Tung, C., Hall, T. R., Masand, R. P., Anderson, M. L., The role of routine peritoneal and omental biopsies at risk reducing salpingo-oophorectomy, J Minim Invasive Gynecol, 2017., https://pubmed.ncbi.nlm.nih.gov/28285055/

233. Manchanda, R., Opportunistic salpingectomy for prevention of ovarian cancer, BJOG, 2017., https://pubmed.ncbi.nlm.nih.gov/28334492/

234. Mai, P. L., Piedmonte, M., Han, P. K., Moser, R. P., Walker, J. L., Rodriguez, G., et.al. Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study, Gynecol Oncol, 2017. 145(1): p. 122-129., https://pubmed.ncbi.nlm.nih.gov/28190649/

235. Nunez, C., Bauman, A., Egger, S., Sitas, F., Nair-Shalliker, V., Obesity, physical activity and cancer risks: Results from the Cancer, Lifestyle and Evaluation of Risk Study (CLEAR), Cancer Epidemiol, 2017. 47: p. 56-63., https://pubmed.ncbi.nlm.nih.gov/28126584/

236. Minlikeeva, A. N., Freudenheim, J. L., Cannioto, R. A., Szender, J. B., Eng, K. H., Modugno, F., et.al. History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium, Cancer Causes Control, 2017., https://pubmed.ncbi.nlm.nih.gov/28293802/

237. Ma, L., Zhang, W., Ding, Z., Wu, S. G., Jin, Y., Jiang, N., et.al. Association of a common variant of SYNPO2 gene with increased risk of serous epithelial ovarian cancer, Tumour Biol, 2017. 39(2): p. 1010428317691185., https://pubmed.ncbi.nlm.nih.gov/28231729/

238. Mytton, J., Evison, F., Chilton, P. J., Lilford, R. J., Removal of all ovarian tissue versus conserving ovarian tissue at time of hysterectomy in premenopausal patients with benign disease: study using routine data and data linkage, BMJ, 2017. 356: p. j372., https://pubmed.ncbi.nlm.nih.gov/28167486/

239. Ose, J., Schock, H., Poole, E. M., Lehtinen, M., Visvanathan, K., Helzlsouer, K., et.al. Pre-diagnosis insulin-like growth factor-I and risk of epithelial invasive ovarian cancer by histological subtypes: A collaborative re-analysis from the Ovarian Cancer Cohort Consortium, Cancer Causes Control, 2017., https://pubmed.ncbi.nlm.nih.gov/28205047/

240. Peres, L. C., Bandera, E. V., Qin, B., Guertin, K. A., Shivappa, N., Hebert, J. R., et.al. Dietary inflammatory index and risk of epithelial ovarian cancer in African American women, Int J Cancer, 2017. 140(3): p. 535-543., https://pubmed.ncbi.nlm.nih.gov/27727481/

241. Peres, L. C., Moorman, P. G., Alberg, A. J., Bandera, E. V., Barnholtz-Sloan, J., Bondy, M., et.al. Lifetime number of ovulatory cycles and epithelial ovarian cancer risk in African American women, Cancer Causes Control, 2017., https://pubmed.ncbi.nlm.nih.gov/28251458/

242. Piek, J., From paradigm shift towards ovarian cancer prevention, BJOG, 2017. 124(2): p. 321., https://pubmed.ncbi.nlm.nih.gov/27561362/

243. Praestegaard, C., Jensen, A., Jensen, S. M., Nielsen, T. S., Webb, P. M., Nagle, C. M., et.al. Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies, Int J Cancer, 2017., https://pubmed.ncbi.nlm.nih.gov/28063166/

244. Qiu, H., Wang, X., Guo, R., Liu, Q., Wang, Y., Yuan, Z., et.al. HOTAIR rs920778 polymorphism is associated with ovarian cancer susceptibility and poor prognosis in a Chinese population, Future Oncol, 2017. 13(4): p. 347-355., https://pubmed.ncbi.nlm.nih.gov/27690631/

245. Rahman, B., Side, L., Gibbon, S., Meisel, S. F., Fraser, L., Gessler, S., et.al. Moving towards population-based genetic risk prediction for ovarian cancer, BJOG, 2017., https://pubmed.ncbi.nlm.nih.gov/28217902/

246. Rasmussen, C. B., Kjaer, S. K., Albieri, V., Bandera, E. V., Doherty, J. A., Hogdall, E., et.al. Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies, Am J Epidemiol, 2017. 185(1): p. 8-20., https://pubmed.ncbi.nlm.nih.gov/27941069/

247. Rasmussen, E. L., Hannibal, C. G., Dehlendorff, C., Baandrup, L., Junge, J., Vang, R., et.al. Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: A nationwide case-control study, Gynecol Oncol, 2017. 144(3): p. 571-576., https://pubmed.ncbi.nlm.nih.gov/28108026/

248. Samimi, G., Minasian, L. M., Opportunistic salpingectomy: What about the role of the ovary in ovarian cancer?, Cancer, 2017., https://pubmed.ncbi.nlm.nih.gov/28334415/

249. Setubal, A. G., Alves, J. S., Lavado, O., Faria, J., Mini-Laparoscopy for Removal (Partial) of Adnexae at the Time of Hysterectomy, J Minim Invasive Gynecol, 2017. 24(2): p. 201-202., https://pubmed.ncbi.nlm.nih.gov/27856389/

250. Shafrir, A. L., Schock, H., Poole, E. M., Terry, K. L., Tamimi, R. M., Hankinson, S. E., et.al. A prospective cohort study of oral contraceptive use and ovarian cancer among women in the United States born from 1947 to 1964, Cancer Causes Control, 2017. 28(5): p. 371-383., https://pubmed.ncbi.nlm.nih.gov/28290016/

251. Stuparich, M. A., Lee, T. T., Tips and Tricks for Performing Salpingectomy at the Time of Laparoscopic Hysterectomy, J Minim Invasive Gynecol, 2017. 24(2): p. 205., https://pubmed.ncbi.nlm.nih.gov/27956107/

252. Terry, P. D., Qin, B., Camacho, F., Moorman, P. G., Alberg, A. J., Barnholtz-Sloan, J. S., et.al. Supplemental Selenium May Decrease Ovarian Cancer Risk in African-American Women, J Nutr, 2017., https://pubmed.ncbi.nlm.nih.gov/28202637/

253. Tschernichovsky, R., Goodman, A., Risk-Reducing Strategies for Ovarian Cancer in BRCA Mutation Carriers: A Balancing Act, Oncologist, 2017., https://pubmed.ncbi.nlm.nih.gov/28314837/

254. Tucker, P. E., Cohen, P. A., Review Article: Sexuality and Risk-Reducing Salpingo-oophorectomy, Int J Gynecol Cancer, 2017., https://pubmed.ncbi.nlm.nih.gov/28333842/

255. Venturella, R., Lico, D., Borelli, M., Imbrogno, M. G., Cevenini, G., Zupi, E., et.al. 3 to 5 Years Later: Long-term Effects of Prophylactic Bilateral Salpingectomy on Ovarian Function, J Minim Invasive Gynecol, 2017. 24(1): p. 145-150., https://pubmed.ncbi.nlm.nih.gov/27621194/

256. Yang, M., Prescott, J., Poole, E. M., Rice, M. S., Kubzansky, L. D., Idahl, A., et.al. Prediagnosis Leukocyte Telomere Length and Risk of Ovarian Cancer, Cancer Epidemiol Biomarkers Prev, 2017. 26(3): p. 339-345., https://pubmed.ncbi.nlm.nih.gov/28209595/

257. Zuntini, R., Cortesi, L., Calistri, D., Pippucci, T., Luigi Martelli, P., Casadio, R., et.al. BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype, Oncotarget, 2017., https://pubmed.ncbi.nlm.nih.gov/28186987/

258. Female genital tumorsInternational Agency for Research on Cancer, WHO Classification of tumours. 5th edition Volume 4, 2020.

259. Kurman, RJ, Shih, IeM, The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded., Am J Pathol, 2016. 186 (4)(4): p. 733-47., https://pubmed.ncbi.nlm.nih.gov/27012190/

260. Taylor, J., McCluggage, W. G., Ovarian Seromucinous Carcinoma: Report of a Series of a Newly Categorized and Uncommon Neoplasm, Am J Surg Pathol, 2015. 39(7): p. 983-92., https://pubmed.ncbi.nlm.nih.gov/25723110/

261. Kobel, M., Rahimi, K., Rambau, P. F., Naugler, C., Le Page, C., Meunier, L., et.al. An Immunohistochemical Algorithm for Ovarian Carcinoma Typing, Int J Gynecol Pathol, 2016., https://pubmed.ncbi.nlm.nih.gov/26974996/

262. Kurman, R. J., Carcangiu, M. L., Herrington, C. S., WHO Classification of Tumours of the Female Genital TractIARC Press, 2014. p. 169-206., https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-Female-Reproductive-Organs-2014

263. Cohen, PA, Powell, A, Böhm, S, Gilks, CB, Stewart, CJR, Meniawy, TM, et.al. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data., Gynecol Oncol, 2019. 154 (2)(2): p. 441-448., https://pubmed.ncbi.nlm.nih.gov/31118141/

264. Böhm, S, Faruqi, A, Said, I, Lockley, M, Brockbank, E, Jeyarajah, A, et.al. Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma., J Clin Oncol, 2015. 33 (22)(22): p. 2457-63., https://pubmed.ncbi.nlm.nih.gov/26124480/

265. Böhm, S, Le, N, Lockley, M, Brockbank, E, Faruqi, A, Said, I, et.al. Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results., Int J Gynecol Cancer, 2019. 29 (2)(2): p. 353-356., https://pubmed.ncbi.nlm.nih.gov/30683759/

266. Vang, R, Visvanathan, K, Gross, A, Maambo, E, Gupta, M, Kuhn, E, et.al. Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma., Int J Gynecol Pathol, 2012. 31 (3)(3): p. 243-53., https://pubmed.ncbi.nlm.nih.gov/22498942/

267. Singh, N, Gilks, CB, Wilkinson, N, McCluggage, WG, Assessment of a new system for primary site assignment in high-grade serous carcinoma of the fallopian tube, ovary, and peritoneum., Histopathology, 2015. 67 (3)(3): p. 331-7., https://pubmed.ncbi.nlm.nih.gov/25640750/

268. Colombo, N, Sessa, C, du Bois, A, Ledermann, J, McCluggage, WG, McNeish, I, et.al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†., Ann Oncol, 2019. 30 (5)(5): p. 672-705., https://pubmed.ncbi.nlm.nih.gov/31046081/

269. McCluggage, W. G., Judge, M. J., Clarke, B. A., Davidson, B., Gilks, C. B., Hollema, H., et.al. Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR), Mod Pathol, 2015. 28(8): p. 1101-22., https://pubmed.ncbi.nlm.nih.gov/26089092/

270. Verhaak, R. G., Tamayo, P., Yang, J. Y., Hubbard, D., Zhang, H., Creighton, C. J., et.al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma, J Clin Invest, 2013. 123(1): p. 517-25., https://pubmed.ncbi.nlm.nih.gov/23257362/

271. Waldron, L., Haibe-Kains, B., Culhane, A. C., Riester, M., Ding, J., Wang, X. V., et.al. Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer, J Natl Cancer Inst, 2014. 106(5):, https://pubmed.ncbi.nlm.nih.gov/24700801/

272. Yoshihara, K., Tsunoda, T., Shigemizu, D., Fujiwara, H., Hatae, M., Masuzaki, H., et.al. High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway, Clin Cancer Res, 2012. 18(5): p. 1374-1385., https://pubmed.ncbi.nlm.nih.gov/22241791/

273. Hwang, W. T., Adams, S. F., Tahirovic, E., Hagemann, I. S., Coukos, G., Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis, Gynecol Oncol, 2012. 124(2): p. 192-8., https://pubmed.ncbi.nlm.nih.gov/22040834/

274. Li, J., Wang, J., Chen, R., Bai, Y., Lu, X., The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer, Oncotarget, 2017. 8(9): p. 15621-15631., https://pubmed.ncbi.nlm.nih.gov/28152503/

275. Ovarian Tumor Tissue Analysis, Consortium, Goode, E. L., Block, M. S., Kalli, K. R., Vierkant, R. A., Chen, W., et.al. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer, JAMA Oncol, 2017. p. e173290., https://pubmed.ncbi.nlm.nih.gov/29049607/

276. Kommoss, S., du Bois, A., Ridder, R., Trunk, M. J., Schmidt, D., Pfisterer, J., et.al. Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group, Br J Cancer, 2007. 96(2): p. 306-13., https://pubmed.ncbi.nlm.nih.gov/17242700/

277. Kommoss, S., du Bois, A., Ridder, R., Trunk, M. J., Schmidt, D., Pfisterer, J., et.al. Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group, Br J Cancer, 2007. 96(2): p. 306-13., https://pubmed.ncbi.nlm.nih.gov/17242700/

278. Miller, RE, Leary, A, Scott, CL, Serra, V, Lord, CJ, Bowtell, D, et.al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer., Ann Oncol, 2020. 31 (12)(12): p. 1606-1622., https://pubmed.ncbi.nlm.nih.gov/33004253/

279. D'Angelo, E., Mozos, A., Nakayama, D., Espinosa, I., Catasus, L., Munoz, J., et.al. Prognostic significance of FOXL2 mutation and mRNA expression in adult and juvenile granulosa cell tumors of the ovary, Mod Pathol, 2011. 24(10): p. 1360-7., https://pubmed.ncbi.nlm.nih.gov/21623383/

280. Kommoss, S., Anglesio, M. S., Mackenzie, R., Yang, W., Senz, J., Ho, J., et.al. FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines, Mod Pathol, 2013. 26(6): p. 860-7., https://pubmed.ncbi.nlm.nih.gov/23348906/

281. de Kock, L., Terzic, T., McCluggage, W. G., Stewart, C. J. R., Shaw, P., Foulkes, W. D., et.al. DICER1 Mutations Are Consistently Present in Moderately and Poorly Differentiated Sertoli-Leydig Cell Tumors, Am J Surg Pathol, 2017. 41(9): p. 1178-1187., https://pubmed.ncbi.nlm.nih.gov/28654427/

282. Heravi-Moussavi, A., Anglesio, M. S., Cheng, S. W., Senz, J., Yang, W., Prentice, L., et.al. Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers, N Engl J Med, 2012. 366(3): p. 234-42., https://pubmed.ncbi.nlm.nih.gov/22187960/

283. Kommoss, F., Lehr, H. A., [Sex cord-stromal tumors of the ovary : Current aspects with a focus on granulosa cell tumors, Sertoli-Leydig cell tumors, and gynandroblastomas], Pathologe, 2019. 40(1): p. 61-72., https://pubmed.ncbi.nlm.nih.gov/30659330/

284. UICC, TNM Classification of Malignant Tumours.Wiley Blackwell, 2017.

285. Young, R. H., Ovarian Sex Cord-Stromal Tumors: Reflections on a 40-Year Experience With a Fascinating Group of Tumors, Including Comments on the Seminal Observations of Robert E. Scully, MD, Arch Pathol Lab Med, 2018. 142(12): p. 1459-1484., https://pubmed.ncbi.nlm.nih.gov/30500284/

286. Young, R. H., Ovarian sex cord-stromal tumours and their mimics, Pathology, 2018. 50(1): p. 5-15., https://pubmed.ncbi.nlm.nih.gov/29132723/

287. Young, RH, Ovarian tumors and tumor-like lesions in the first three decades., Semin Diagn Pathol, 2014. 31 (5)(5): p. 382-426., https://pubmed.ncbi.nlm.nih.gov/25440719/

288. Lim, D., Oliva, E., Ovarian sex cord-stromal tumours: an update in recent molecular advances, Pathology, 2018. 50(2): p. 178-189., https://pubmed.ncbi.nlm.nih.gov/29275930/

289. Vougiouklakis, T, Zhu, K, Vasudevaraja, V, Serrano, J, Shen, G, Linn, RL, et.al. Integrated Analysis of Ovarian Juvenile Granulosa Cell Tumors Reveals Distinct Epigenetic Signatures and Recurrent TERT Rearrangements., Clin Cancer Res, 2022. 28 (8)(8): p. 1724-1733., https://pubmed.ncbi.nlm.nih.gov/35031544/

290. A L Husaini, H, Soudy, H, El Din Darwish, A, Ahmed, M, Eltigani, A, A L Mubarak, M, et.al. Pure dysgerminoma of the ovary: a single institutional experience of 65 patients., Med Oncol, 2012. 29 (4)(4): p. 2944-8., https://pubmed.ncbi.nlm.nih.gov/22407668/

291. Safdar, NS, Stall, JN, Young, RH, Malignant Mixed Germ Cell Tumors of the Ovary: An Analysis of 100 Cases Emphasizing the Frequency and Interrelationships of Their Tumor Types., Am J Surg Pathol, 2021. 45 (6)(6): p. 727-741., https://pubmed.ncbi.nlm.nih.gov/33284192/

292. Song, Z, Wang, Y, Zhou, Y, Zhang, D, Nomograms to predict the prognosis in malignant ovarian germ cell tumors: a large cohort study., BMC Cancer, 2022. 22 (1)(1): p. 257., https://pubmed.ncbi.nlm.nih.gov/35272629/

293. Kurman, R. J., Carcangiu, M. L., Herrington, C. S., Young, R. H. (Eds)., WHO Classification of Tumors of Female Reproductive OrgansIARC, 2014.

294. Tischkowitz, M, Huang, S, Banerjee, S, Hague, J, Hendricks, WPD, Huntsman, DG, et.al. Small-Cell Carcinoma of the Ovary, Hypercalcemic Type-Genetics, New Treatment Targets, and Current Management Guidelines., Clin Cancer Res, 2020. 26 (15)(15): p. 3908-3917., https://pubmed.ncbi.nlm.nih.gov/32156746/

295. Berek, J. S., Kehoe, S. T., Kumar, L., Friedlander, M., Cancer of the ovary, fallopian tube, and peritoneum, Int J Gynaecol Obstet, 2018. 143 Suppl 2: p. 59-78., https://pubmed.ncbi.nlm.nih.gov/30306591/

296. Wittekind, Christian, TNM - Klassifikation maligner Tumoren, 8. AuflageWiley-VCH, TNM Klassifikation maligner Tumoren, 2020.

297. Chay, W. Y., McCluggage, W. G., Lee, C. H., Kobel, M., Irving, J., Millar, J., et.al. Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer, Int J Gynecol Cancer, 2016. 26(3): p. 431-6., https://pubmed.ncbi.nlm.nih.gov/26807643/

298. Steenbeek, MP, van Bommel, MHD, Bulten, J, Hulsmann, JA, Bogaerts, J, Garcia, C, et.al. Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis., J Clin Oncol, 2022. 40 (17)(17): p. 1879-1891., https://pubmed.ncbi.nlm.nih.gov/35302882/

299. Gershenson, DM, Miller, A, Brady, WE, Paul, J, Carty, K, Rodgers, W, et.al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial., Lancet, 2022. 399 (10324)(10324): p. 541-553., https://pubmed.ncbi.nlm.nih.gov/35123694/

300. Singer, G, Oldt, R, Cohen, Y, Wang, BG, Sidransky, D, Kurman, RJ, et.al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma., J Natl Cancer Inst, 2003. 95 (6)(6): p. 484-6., https://pubmed.ncbi.nlm.nih.gov/12644542/

301. Grabowski, JP, Harter, P, Heitz, F, Pujade-Lauraine, E, Reuss, A, Kristensen, G, et.al. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase., Gynecol Oncol, 2016. 140 (3)(3): p. 457-62., https://pubmed.ncbi.nlm.nih.gov/26807488/

302. Trimbos, B., Timmers, P., Pecorelli, S., Coens, C., Ven, K., van der Burg, M., et.al. Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial, J Natl Cancer Inst, 2010. 102(13): p. 982-7., https://pubmed.ncbi.nlm.nih.gov/20445161/

303. Harter, P, Sehouli, J, Lorusso, D, Reuss, A, Vergote, I, Marth, C, et.al. A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms., N Engl J Med, 2019. 380 (9)(9): p. 822-832., https://pubmed.ncbi.nlm.nih.gov/30811909/

304. Stier, E. A., Barakat, R. R., Curtin, J. P., Brown, C. L., Jones, W. B., Hoskins, W. J., Laparotomy to complete staging of presumed early ovarian cancer, Obstet Gynecol, 1996. 87(5 Pt 1): p. 737-40., https://pubmed.ncbi.nlm.nih.gov/8677077/

305. Soper, J. T., Johnson, P., Johnson, V., Berchuck, A., Clarke-Pearson, D. L., Comprehensive restaging laparotomy in women with apparent early ovarian carcinoma, Obstet Gynecol, 1992. 80(6): p. 949-53., https://pubmed.ncbi.nlm.nih.gov/1333065/

306. Young, R. C., Decker, D. G., Wharton, J. T., Piver, M. S., Sindelar, W. F., Edwards, B. K., et.al. Staging laparotomy in early ovarian cancer, JAMA, 1983. 250(22): p. 3072-6., https://pubmed.ncbi.nlm.nih.gov/6358558/

307. Grabowski, J. P., Harter, P., Buhrmann, C., Lorenz, D., Hils, R., Kommoss, S., et.al. Re-operation outcome in patients referred to a gynecologic oncology center with presumed ovarian cancer FIGO I-IIIA after sub-standard initial surgery, Surg Oncol, 2012. 21(1): p. 31-5., https://pubmed.ncbi.nlm.nih.gov/20875732/

308. Shaw, M. C., Wolfe, C. D., Devaja, O., Raju, K. S., Development of an evidence-based algorithm for the management of ovarian cancer, Eur J Gynaecol Oncol, 2003. 24(2): p. 117-25., https://pubmed.ncbi.nlm.nih.gov/14584646/

309. Ayhan, A., Celik, H., Taskiran, C., Bozdag, G., Aksu, T., Oncologic and reproductive outcome after fertility-saving surgery in ovarian cancer, Eur J Gynaecol Oncol, 2003. 24(3-4): p. 223-32., https://pubmed.ncbi.nlm.nih.gov/12807228/

310. Gershenson, D. M., Fertility-sparing surgery for malignancies in women, J Natl Cancer Inst Monogr, 2005. p. 43-7., https://pubmed.ncbi.nlm.nih.gov/15784822/

311. Morice, P., Leblanc, E., Rey, A., Baron, M., Querleu, D., Blanchot, J., et.al. Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG (Societe Francaise d'Oncologie Gynecologique), Hum Reprod, 2005. 20(5): p. 1379-85., https://pubmed.ncbi.nlm.nih.gov/15817592/

312. Leitao, M. M., Jr., Chi, D. S., Fertility-sparing options for patients with gynecologic malignancies, Oncologist, 2005. 10(8): p. 613-22., https://pubmed.ncbi.nlm.nih.gov/16177285/

313. Dexeus, S., Labastida, R., Dexeus, D., Conservative management of epithelial ovarian cancer, Eur J Gynaecol Oncol, 2005. 26(5): p. 473-8., https://pubmed.ncbi.nlm.nih.gov/16285560/

314. Monk, B. J., Disaia, P. J., What is the role of conservative primary surgical management of epithelial ovarian cancer: the United States experience and debate, Int J Gynecol Cancer, 2005. 15 Suppl 3: p. 199-205., https://pubmed.ncbi.nlm.nih.gov/16343231/

315. Colombo, N., Parma, G., Lapresa, M. T., Maggi, F., Piantanida, P., Maggioni, A., Role of conservative surgery in ovarian cancer: the European experience, Int J Gynecol Cancer, 2005. 15 Suppl 3: p. 206-11., https://pubmed.ncbi.nlm.nih.gov/16343232/

316. Marhhom, E., Cohen, I., Fertility preservation options for women with malignancies, Obstet Gynecol Surv, 2007. 62(1): p. 58-72., https://pubmed.ncbi.nlm.nih.gov/17176489/

317. Denschlag, D., von Wolff, M., Amant, F., Kesic, V., Reed, N., Schneider, A., et.al. Clinical recommendation on fertility preservation in borderline ovarian neoplasm: ovarian stimulation and oocyte retrieval after conservative surgery, Gynecol Obstet Invest, 2010. 70(3): p. 160-5., https://pubmed.ncbi.nlm.nih.gov/20558989/

318. Sarnacki, S., Brisse, H., Surgery of ovarian tumors in children, Horm Res Paediatr, 2011. 75(3): p. 220-4., https://pubmed.ncbi.nlm.nih.gov/21160172/

319. Zanetta, G., Chiari, S., Rota, S., Bratina, G., Maneo, A., Torri, V., et.al. Conservative surgery for stage I ovarian carcinoma in women of childbearing age, Br J Obstet Gynaecol, 1997. 104(9): p. 1030-5., https://pubmed.ncbi.nlm.nih.gov/9307530/

320. Schilder, J. M., Thompson, A. M., DePriest, P. D., Ueland, F. R., Cibull, M. L., Kryscio, R. J., et.al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy, Gynecol Oncol, 2002. 87(1): p. 1-7., https://pubmed.ncbi.nlm.nih.gov/12468335/

321. Morice, P., Camatte, S., Wicart-Poque, F., Atallah, D., Rouzier, R., Pautier, P., et.al. Results of conservative management of epithelial malignant and borderline ovarian tumours, Hum Reprod Update, 2003. 9(2): p. 185-92., https://pubmed.ncbi.nlm.nih.gov/12751780/

322. Duska, L. R., Chang, Y. C., Flynn, C. E., Chen, A. H., Goodman, A., Fuller, A. F., et.al. Epithelial ovarian carcinoma in the reproductive age group, Cancer, 1999. 85(12): p. 2623-9., https://pubmed.ncbi.nlm.nih.gov/10375111/

323. Denschlag, D., von Wolff, M., Amant, F., Kesic, V., Reed, N., Schneider, A., et.al. Clinical recommendation on fertility preservation in borderline ovarian neoplasm: ovarian stimulation and oocyte retrieval after conservative surgery, Gynecol Obstet Invest, 2010. 70(3): p. 160-5., https://pubmed.ncbi.nlm.nih.gov/20558989/

324. Ditto, A., Martinelli, F., Bogani, G., Lorusso, D., Carcangiu, M., Chiappa, V., et.al. Long-term safety of fertility sparing surgery in early stage ovarian cancer: comparison to standard radical surgical procedures, Gynecol Oncol, 2015. 138(1): p. 78-82., https://pubmed.ncbi.nlm.nih.gov/25969349/

325. Medeiros, L. R., Rosa, D. D., Bozzetti, M. C., Rosa, M. I., Edelweiss, M. I., Stein, A. T., et.al. Laparoscopy versus laparotomy for FIGO Stage I ovarian cancer, Cochrane Database Syst Rev, 2008. p. CD005344., https://pubmed.ncbi.nlm.nih.gov/18843688/

326. Trope, C., Kaern, J., Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature, J Clin Oncol, 2007. 25(20): p. 2909-20., https://pubmed.ncbi.nlm.nih.gov/17617522/

327. Panici, P. B., Palaia, I., Bellati, F., Pernice, M., Angioli, R., Muzii, L., Laparoscopy compared with laparoscopically guided minilaparotomy for large adnexal masses: a randomized controlled trial, Obstet Gynecol, 2007. 110(2 Pt 1): p. 241-8., https://pubmed.ncbi.nlm.nih.gov/17666596/

328. Ghezzi, F., Cromi, A., Bergamini, V., Uccella, S., Siesto, G., Franchi, M., et.al. Should adnexal mass size influence surgical approach? A series of 186 laparoscopically managed large adnexal masses, BJOG, 2008. 115(8): p. 1020-7., https://pubmed.ncbi.nlm.nih.gov/18651883/

329. Fagotti, A., Fanfani, F., Vizzielli, G., Gallotta, V., Ercoli, A., Paglia, A., et.al. Should laparoscopy be included in the work-up of advanced ovarian cancer patients attempting interval debulking surgery?, Gynecol Oncol, 2010. 116(1): p. 72-7., https://pubmed.ncbi.nlm.nih.gov/19846211/

330. Kindermann G, Massen V, W, Kuhn, Laparoscopic management of ovarian tumours subsequently diagnosed as malignant., Lournal Pelvic Surgery, 1996. 2: p. 245-251., https://journals.lww.com/fpmrs/Abstract/1996/09000/Laparoscopic_Management_of_Ovarian_Tumors.5.aspx

331. Canis, M., Rabischong, B., Houlle, C., Botchorishvili, R., Jardon, K., Safi, A., et.al. Laparoscopic management of adnexal masses: a gold standard?, Curr Opin Obstet Gynecol, 2002. 14(4): p. 423-8., https://pubmed.ncbi.nlm.nih.gov/12151833/

332. Medeiros, L. R., Rosa, D. D., Bozzetti, M. C., Rosa, M. I., Edelweiss, M. I., Stein, A. T., et.al. Laparoscopy versus laparotomy for FIGO Stage I ovarian cancer, Cochrane Database Syst Rev, 2008. p. CD005344., https://pubmed.ncbi.nlm.nih.gov/18843688/

333. du Bois, A., Reuss, A., Pujade-Lauraine, E., Harter, P., Ray-Coquard, I., Pfisterer, J., Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO), Cancer, 2009. 115(6): p. 1234-44., https://pubmed.ncbi.nlm.nih.gov/19189349/

334. Ataseven, B, Grimm, C, Harter, P, Heitz, F, Traut, A, Prader, S, et.al. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV., Gynecol Oncol, 2016. 140 (2)(2): p. 215-20., https://pubmed.ncbi.nlm.nih.gov/26691222/

335. Chang, S. J., Hodeib, M., Chang, J., Bristow, R. E., Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis, Gynecol Oncol, 2013. 130(3): p. 493-8., https://pubmed.ncbi.nlm.nih.gov/23747291/

336. Horowitz, N. S., Miller, A., Rungruang, B., Richard, S. D., Rodriguez, N., Bookman, M. A., et.al. Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182, J Clin Oncol, 2015. 33(8): p. 937-43., https://pubmed.ncbi.nlm.nih.gov/25667285/

337. du Bois, A., Rochon, J., Pfisterer, J., Hoskins, W. J., Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review, Gynecol Oncol, 2009. 112(2): p. 422-36., https://pubmed.ncbi.nlm.nih.gov/18990435/

338. Harter, P, Sehouli, J, Vergote, I, Ferron, G, Reuss, A, Meier, W, et.al. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer., N Engl J Med, 2021. 385 (23)(23): p. 2123-2131., https://pubmed.ncbi.nlm.nih.gov/34874631/

339. du Bois, A., Reuss, A., Harter, P., Pujade-Lauraine, E., Ray-Coquard, I., Pfisterer, J., Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials, J Clin Oncol, 2010. 28(10): p. 1733-9., https://pubmed.ncbi.nlm.nih.gov/20194855/

340. Harter, P., Gnauert, K., Hils, R., Lehmann, T. G., Fisseler-Eckhoff, A., Traut, A., et.al. Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer, Int J Gynecol Cancer, 2007. 17(6): p. 1238-44., https://pubmed.ncbi.nlm.nih.gov/17433064/

341. Bristow, RE, Tomacruz, RS, Armstrong, DK, Trimble, EL, Montz, FJ, Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis., J Clin Oncol, 2002. 20 (5)(5): p. 1248-59., https://pubmed.ncbi.nlm.nih.gov/11870167/

342. du Bois, A., Reuss, A., Pujade-Lauraine, E., Harter, P., Ray-Coquard, I., Pfisterer, J., Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO), Cancer, 2009. 115(6): p. 1234-44., https://pubmed.ncbi.nlm.nih.gov/19189349/

343. du Bois, A., Rochon, J., Pfisterer, J., Hoskins, W. J., Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review, Gynecol Oncol, 2009. 112(2): p. 422-36., https://pubmed.ncbi.nlm.nih.gov/18990435/

344. Randall, T. C., Rubin, S. C., Surgical management of ovarian cancer, Semin Surg Oncol, 1999. 17(3): p. 173-80., https://pubmed.ncbi.nlm.nih.gov/10504665/

345. Wimberger, P., Wehling, M., Lehmann, N., Kimmig, R., Schmalfeldt, B., Burges, A., et.al. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group), Ann Surg Oncol, 2010. 17(6): p. 1642-8., https://pubmed.ncbi.nlm.nih.gov/20165986/

346. Gadducci, A., Sartori, E., Landoni, F., Zola, P., Maggino, T., Maggioni, A., et.al. Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study, J Clin Oncol, 2005. 23(4): p. 751-8., https://pubmed.ncbi.nlm.nih.gov/15613698/

347. Trope, C., Kaern, J., Primary surgery for ovarian cancer, Eur J Surg Oncol, 2006. 32(8): p. 844-52., https://pubmed.ncbi.nlm.nih.gov/16677797/

348. Bristow, R. E., Eisenhauer, E. L., Santillan, A., Chi, D. S., Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction, Gynecol Oncol, 2007. 104(2): p. 480-90., https://pubmed.ncbi.nlm.nih.gov/17166564/

349. Wimberger, P., Lehmann, N., Kimmig, R., Burges, A., Meier, W., Du Bois, A., Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR), Gynecol Oncol, 2007. 106(1): p. 69-74., https://pubmed.ncbi.nlm.nih.gov/17397910/

350. Vernooij, F., Heintz, P., Witteveen, E., van der Graaf, Y., The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review, Gynecol Oncol, 2007. 105(3): p. 801-12., https://pubmed.ncbi.nlm.nih.gov/17433422/

351. Elit, L. M., Bondy, S. J., Paszat, L. P., Holowaty, E. J., Thomas, G. M., Stukel, T. A., et.al. Surgical outcomes in women with ovarian cancer, Can J Surg, 2008. 51(5): p. 346-54., https://pubmed.ncbi.nlm.nih.gov/18841223/

352. Gerestein, C. G., Eijkemans, M. J., de Jong, D., van der Burg, M. E., Dykgraaf, R. H., Kooi, G. S., et.al. The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma, BJOG, 2009. 116(3): p. 372-80., https://pubmed.ncbi.nlm.nih.gov/19187369/

353. Gerestein, C. G., Damhuis, R. A., de Vries, M., Reedijk, A., Burger, C. W., Kooi, G. S., Causes of postoperative mortality after surgery for ovarian cancer, Eur J Cancer, 2009. 45(16): p. 2799-803., https://pubmed.ncbi.nlm.nih.gov/19615887/

354. Einenkel, J., Ott, R., Handzel, R., Braumann, U. D., Horn, L. C., Characteristics and management of diaphragm involvement in patients with primary advanced-stage ovarian, fallopian tube, or peritoneal cancer, Int J Gynecol Cancer, 2009. 19(7): p. 1288-97., https://pubmed.ncbi.nlm.nih.gov/19823067/

355. Tixier, H., Fraisse, J., Chauffert, B., Mayer, F., Causeret, S., Loustalot, C., et.al. Evaluation of pelvic posterior exenteration in the management of advanced-stage ovarian cancer, Arch Gynecol Obstet, 2010. 281(3): p. 505-10., https://pubmed.ncbi.nlm.nih.gov/19847452/

356. Gerestein, C. G., van der Spek, D. W., Eijkemans, M. J., Bakker, J., Kooi, G. S., Burger, C. W., Prediction of residual disease after primary cytoreductive surgery for advanced-stage ovarian cancer: accuracy of clinical judgment, Int J Gynecol Cancer, 2009. 19(9): p. 1511-5., https://pubmed.ncbi.nlm.nih.gov/19955927/

357. Aletti, G. D., Eisenhauer, E. L., Santillan, A., Axtell, A., Aletti, G., Holschneider, C., et.al. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment, Gynecol Oncol, 2011. 120(1): p. 23-8., https://pubmed.ncbi.nlm.nih.gov/20933255/

358. Vergote, I., Trope, C. G., Amant, F., Kristensen, G. B., Ehlen, T., Johnson, N., et.al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer, N Engl J Med, 2010. 363(10): p. 943-53., https://pubmed.ncbi.nlm.nih.gov/20818904/

359. Schwartz, P. E., Rutherford, T. J., Chambers, J. T., Kohorn, E. I., Thiel, R. P., Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival, Gynecol Oncol, 1999. 72(1): p. 93-9., https://pubmed.ncbi.nlm.nih.gov/9889037/

360. van der Burg, M. E., van Lent, M., Buyse, M., Kobierska, A., Colombo, N., Favalli, G., et.al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer, N Engl J Med, 1995. 332(10): p. 629-34., https://pubmed.ncbi.nlm.nih.gov/7845426/

361. Rose PG, Nerenstone S, Brady M, Clarke-Pearson D, Olt G, SC, Rubin, A phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group study, American Society of Clinical Oncology, 2002.

362. Redman, C. W., Warwick, J., Luesley, D. M., Varma, R., Lawton, F. G., Blackledge, G. R., Intervention debulking surgery in advanced epithelial ovarian cancer, Br J Obstet Gynaecol, 1994. 101(2): p. 142-6., https://pubmed.ncbi.nlm.nih.gov/8305389/

363. Tangjitgamol, S., Manusirivithaya, S., Laopaiboon, M., Lumbiganon, P., Bryant, A., Interval debulking surgery for advanced epithelial ovarian cancer, Cochrane Database Syst Rev, 2010. p. CD006014., https://pubmed.ncbi.nlm.nih.gov/20927744/

364. Vergote, I., Trope, C. G., Amant, F., Kristensen, G. B., Ehlen, T., Johnson, N., et.al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer, N Engl J Med, 2010. 363(10): p. 943-53., https://pubmed.ncbi.nlm.nih.gov/20818904/

365. van der Burg, M. E., van Lent, M., Buyse, M., Kobierska, A., Colombo, N., Favalli, G., et.al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer, N Engl J Med, 1995. 332(10): p. 629-34., https://pubmed.ncbi.nlm.nih.gov/7845426/

366. Rose PG, Nerenstone S, Brady M, Clarke-Pearson D, Olt G, SC, Rubin, A phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group study, American Society of Clinical Oncology, 2002.

367. Redman, C. W., Warwick, J., Luesley, D. M., Varma, R., Lawton, F. G., Blackledge, G. R., Intervention debulking surgery in advanced epithelial ovarian cancer, Br J Obstet Gynaecol, 1994. 101(2): p. 142-6., https://pubmed.ncbi.nlm.nih.gov/8305389/

368. Greimel, E., Kristensen, G. B., van der Burg, M. E., Coronado, P., Rustin, G., del Rio, A. S., et.al. Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy, Gynecol Oncol, 2013. 131(2): p. 437-44., https://pubmed.ncbi.nlm.nih.gov/23994107/

369. Vergote, I, Coens, C, Nankivell, M, Kristensen, GB, Parmar, MKB, Ehlen, T, et.al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials., Lancet Oncol, 2018. 19 (12)(12): p. 1680-1687., https://pubmed.ncbi.nlm.nih.gov/30413383/

370. Kehoe, S, Hook, J, Nankivell, M, Jayson, GC, Kitchener, H, Lopes, T, et.al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial., Lancet, 2015. 386 (9990)(9990): p. 249-57., https://pubmed.ncbi.nlm.nih.gov/26002111/

371. Tangjitgamol, S., Manusirivithaya, S., Laopaiboon, M., Lumbiganon, P., Bryant, A., Interval debulking surgery for advanced epithelial ovarian cancer, Cochrane Database Syst Rev, 2016. p. CD006014., https://pubmed.ncbi.nlm.nih.gov/23633332/

372. Williams, L., Brunetto, V. L., Yordan, E., DiSaia, P. J., Creasman, W. T., Secondary cytoreductive surgery at second-look laparotomy in advanced ovarian cancer: a Gynecologic Oncology Group Study, Gynecol Oncol, 1997. 66(2): p. 171-8., https://pubmed.ncbi.nlm.nih.gov/9264559/

373. Tuxen, M. K., Lund, B., Hansen, O. P., Hansen, M., Second-look laparotomy in the management of patients after radical surgery for ovarian cancer, Ann Oncol, 1993. 4(2): p. 169-71., https://pubmed.ncbi.nlm.nih.gov/8448085/

374. Sorbe, B., Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment, Int J Gynecol Cancer, 2003. 13(3): p. 278-86., https://pubmed.ncbi.nlm.nih.gov/12801256/

375. Nicoletto, M. O., Tumolo, S., Talamini, R., Salvagno, L., Franceschi, S., Visona, E., et.al. Surgical second look in ovarian cancer: a randomized study in patients with laparoscopic complete remission--a Northeastern Oncology Cooperative Group-Ovarian Cancer Cooperative Group Study, J Clin Oncol, 1997. 15(3): p. 994-9., https://pubmed.ncbi.nlm.nih.gov/9060538/

376. Lawton, F. G., Redman, C. W., Luesley, D. M., Chan, K. K., Blackledge, G., Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer, Obstet Gynecol, 1989. 73(1): p. 61-5., https://pubmed.ncbi.nlm.nih.gov/2462202/

377. Friedman, R. L., Eisenkop, S. M., Wang, H. J., Second-look laparotomy for ovarian cancer provides reliable prognostic information and improves survival, Gynecol Oncol, 1997. 67(1): p. 88-94., https://pubmed.ncbi.nlm.nih.gov/9345362/

378. Clough, K. B., Ladonne, J. M., Nos, C., Renolleau, C., Validire, P., Durand, J. C., Second look for ovarian cancer: laparoscopy or Laparotomy? A prospective comparative study, Gynecol Oncol, 1999. 72(3): p. 411-7., https://pubmed.ncbi.nlm.nih.gov/10053115/

379. Casey, A. C., Farias-Eisner, R., Pisani, A. L., Cirisano, F. D., Kim, Y. B., Muderspach, L., et.al. What is the role of reassessment laparoscopy in the management of gynecologic cancers in 1995?, Gynecol Oncol, 1996. 60(3): p. 454-61., https://pubmed.ncbi.nlm.nih.gov/8774657/

380. Bar-Am, A., Kovner, F., Lessing, J. B., Inbar, M., Chaitchik, S., Azem, F., et.al. A second thought on second look laparotomy, Acta Obstet Gynecol Scand, 1993. 72(5): p. 386-90., https://pubmed.ncbi.nlm.nih.gov/8392272/

381. Abu-Rustum, N. R., Barakat, R. R., Siegel, P. L., Venkatraman, E., Curtin, J. P., Hoskins, W. J., Second-look operation for epithelial ovarian cancer: laparoscopy or laparotomy?, Obstet Gynecol, 1996. 88(4 Pt 1): p. 549-53., https://pubmed.ncbi.nlm.nih.gov/8841216/

382. Varia, M. A., Stehman, F. B., Bundy, B. N., Benda, J. A., Clarke-Pearson, D. L., Alvarez, R. D., et.al. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group, J Clin Oncol, 2003. 21(15): p. 2849-55., https://pubmed.ncbi.nlm.nih.gov/12885800/

383. Berman, M. L., Future directions in the surgical management of ovarian cancer, Gynecol Oncol, 2003. 90(2 Pt 2): p. S33-9., https://pubmed.ncbi.nlm.nih.gov/12928004/

384. Sorbe, B., Consolidation treatment of advanced ovarian carcinoma with radiotherapy after induction chemotherapy, Int J Gynecol Cancer, 2003. 13 Suppl 2: p. 192-5., https://pubmed.ncbi.nlm.nih.gov/14656279/

385. Piccart, M. J., Floquet, A., Scarfone, G., Willemse, P. H., Emerich, J., Vergote, I., et.al. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy, Int J Gynecol Cancer, 2003. 13 Suppl 2: p. 196-203., https://pubmed.ncbi.nlm.nih.gov/14656280/

386. Topuz, E., Eralp, Y., Saglam, S., Saip, P., Aydiner, A., Berkman, S., et.al. Efficacy of intraperitoneal cisplatin as consolidation therapy in patients with pathologic complete remission following front-line therapy for epithelial ovarian cancer. Consolidative intraperitoneal cisplatin in ovarian cancer, Gynecol Oncol, 2004. 92(1): p. 147-51., https://pubmed.ncbi.nlm.nih.gov/14751150/

387. Morice, P., Joulie, F., Rey, A., Atallah, D., Camatte, S., Pautier, P., et.al. Are nodal metastases in ovarian cancer chemoresistant lesions? Analysis of nodal involvement in 105 patients treated with preoperative chemotherapy, Eur J Gynaecol Oncol, 2004. 25(2): p. 169-74., https://pubmed.ncbi.nlm.nih.gov/15032274/

388. Greer, B. E., Bundy, B. N., Ozols, R. F., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., et.al. Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study, Gynecol Oncol, 2005. 99(1): p. 71-9., https://pubmed.ncbi.nlm.nih.gov/16039699/

389. Alberts, D. S., Hannigan, E. V., Liu, P. Y., Jiang, C., Wilczynski, S., Copeland, L., et.al. Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study, Gynecol Oncol, 2006. 100(1): p. 133-8., https://pubmed.ncbi.nlm.nih.gov/16153694/

390. Hensley, M. L., Correa, D. D., Thaler, H., Wilton, A., Venkatraman, E., Sabbatini, P., et.al. Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning, Gynecol Oncol, 2006. 102(2): p. 270-7., https://pubmed.ncbi.nlm.nih.gov/16490239/

391. Bolis, G., Danese, S., Tateo, S., Rabaiotti, E., D'Agostino, G., Merisio, C., et.al. Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study, Int J Gynecol Cancer, 2006. 16 Suppl 1: p. 74-8., https://pubmed.ncbi.nlm.nih.gov/16515571/

392. Petit, T., Velten, M., d'Hombres, A., Marchal, C., Montbarbon, X., Mornex, F., et.al. Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy, Gynecol Oncol, 2007. 104(1): p. 104-8., https://pubmed.ncbi.nlm.nih.gov/16987544/

393. Trimbos, B., Timmers, P., Pecorelli, S., Coens, C., Ven, K., van der Burg, M., et.al. Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial, J Natl Cancer Inst, 2010. 102(13): p. 982-7., https://pubmed.ncbi.nlm.nih.gov/20445161/

394. Winter-Roach, B. A., Kitchener, H. C., Dickinson, H. O., Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer, Cochrane Database Syst Rev, 2009. p. CD004706., https://pubmed.ncbi.nlm.nih.gov/19588360/

395. Young, R. C., Walton, L. A., Ellenberg, S. S., Homesley, H. D., Wilbanks, G. D., Decker, D. G., et.al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials, N Engl J Med, 1990. 322(15): p. 1021-7., https://pubmed.ncbi.nlm.nih.gov/2181310/

396. Trope, C., Kaern, J., Vergote, I. B., Kristensen, G., Abeler, V., Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors, Gynecol Oncol, 1993. 51(2): p. 236-43., https://pubmed.ncbi.nlm.nih.gov/8276300/

397. Trimbos, J. B., Vergote, I., Bolis, G., Vermorken, J. B., Mangioni, C., Madronal, C., et.al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial, J Natl Cancer Inst, 2003. 95(2): p. 113-25., https://pubmed.ncbi.nlm.nih.gov/12529344/

398. Timmers, P. J., Zwinderman, A. H., Teodorovic, I., Vergote, I., Trimbos, J. B., Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: same prognosis in a large randomized trial, Int J Gynecol Cancer, 2009. 19(1): p. 88-93., https://pubmed.ncbi.nlm.nih.gov/19258948/

399. Adams, G., Zekri, J., Wong, H., Walking, J., Green, J. A., Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian cancer: single or combination chemotherapy?, BJOG, 2010. 117(12): p. 1459-67., https://pubmed.ncbi.nlm.nih.gov/20560942/

400. Takano, M., Sugiyama, T., Yaegashi, N., Sagae, S., Kuzuya, K., Udagawa, Y., et.al. Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study, Int J Gynecol Cancer, 2010. 20(9): p. 1506-10., https://pubmed.ncbi.nlm.nih.gov/21119366/

401. Garcia-Saenz, J. A., Custodio, A., Casado, A., Vidart, J. A., Coronado, P. J., Martin, M., et.al. Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review, Clin Transl Oncol, 2011. 13(2): p. 121-32., https://pubmed.ncbi.nlm.nih.gov/21324801/

402. Trimbos, J. B., Vergote, I., Bolis, G., Vermorken, J. B., Mangioni, C., Madronal, C., et.al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial, J Natl Cancer Inst, 2003. 95(2): p. 113-25., https://pubmed.ncbi.nlm.nih.gov/12529344/

403. Winter-Roach, B. A., Kitchener, H. C., Dickinson, H. O., Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer, Cochrane Database Syst Rev, 2009. p. CD004706., https://pubmed.ncbi.nlm.nih.gov/19588360/

404. Trimbos, J. B., Parmar, M., Vergote, I., Guthrie, D., Bolis, G., Colombo, N., et.al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma, J Natl Cancer Inst, 2003. 95(2): p. 105-12., https://pubmed.ncbi.nlm.nih.gov/12529343/

405. Colombo, N., Guthrie, D., Chiari, S., Parmar, M., Qian, W., Swart, A. M., et.al. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer, J Natl Cancer Inst, 2003. 95(2): p. 125-32., https://pubmed.ncbi.nlm.nih.gov/12529345/

406. Vergote, I., De Brabanter, J., Fyles, A., Bertelsen, K., Einhorn, N., Sevelda, P., et.al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma, Lancet, 2001. 357(9251): p. 176-82., https://pubmed.ncbi.nlm.nih.gov/11213094/

407. Ho, C. M., Chien, T. Y., Shih, B. Y., Huang, S. H., Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma, Gynecol Oncol, 2003. 88(3): p. 394-9., https://pubmed.ncbi.nlm.nih.gov/12648592/

408. Kitchener, H. C., Adjuvant chemotherapy improves survival after resection of stage 1 ovarian cancer, Cancer Treat Rev, 2005. 31(4): p. 323-7., https://pubmed.ncbi.nlm.nih.gov/15905036/

409. Shimada, M., Kigawa, J., Kanamori, Y., Itamochi, H., Oishi, T., Minagawa, Y., et.al. Outcome of patients with early ovarian cancer undergoing three courses of adjuvant chemotherapy following complete surgical staging, Int J Gynecol Cancer, 2005. 15(4): p. 601-5., https://pubmed.ncbi.nlm.nih.gov/16014112/

410. Bell, J., Brady, M. F., Young, R. C., Lage, J., Walker, J. L., Look, K. Y., et.al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study, Gynecol Oncol, 2006. 102(3): p. 432-9., https://pubmed.ncbi.nlm.nih.gov/16860852/

411. Obermair, A., Fuller, A., Lopez-Varela, E., van Gorp, T., Vergote, I., Eaton, L., et.al. A new prognostic model for FIGO stage 1 epithelial ovarian cancer, Gynecol Oncol, 2007. 104(3): p. 607-11., https://pubmed.ncbi.nlm.nih.gov/17092548/

412. Skirnisdottir, I., Sorbe, B., Survival and prognostic factors in early-stage epithelial ovarian carcinoma treated with taxane-based adjuvant chemotherapy, Int J Gynecol Cancer, 2007. 17(6): p. 1231-7., https://pubmed.ncbi.nlm.nih.gov/17425681/

413. Chan, J. K., Tian, C., Monk, B. J., Herzog, T., Kapp, D. S., Bell, J., et.al. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study, Cancer, 2008. 112(10): p. 2202-10., https://pubmed.ncbi.nlm.nih.gov/18348296/

414. Takano, M., Kikuchi, Y., Yaegashi, N., Kuzuya, K., Ueki, M., Tsuda, H., et.al. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging, Br J Cancer, 2006. 94(10): p. 1369-74., https://pubmed.ncbi.nlm.nih.gov/16641903/

415. Chan, J. K., Tian, C., Fleming, G. F., Monk, B. J., Herzog, T. J., Kapp, D. S., et.al. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study, Gynecol Oncol, 2010. 116(3): p. 301-6., https://pubmed.ncbi.nlm.nih.gov/19945740/

416. Mannel, R. S., Brady, M. F., Kohn, E. C., Hanjani, P., Hiura, M., Lee, R., et.al. A randomized phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study, Gynecol Oncol, 2011. 122(1): p. 89-94., https://pubmed.ncbi.nlm.nih.gov/21529904/

417. Bell, J., Brady, M. F., Young, R. C., Lage, J., Walker, J. L., Look, K. Y., et.al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study, Gynecol Oncol, 2006. 102(3): p. 432-9., https://pubmed.ncbi.nlm.nih.gov/16860852/

418. NHS National Institute for Health and Clinical Excellence, Technology Appraisal Guidance 91 Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer, 2005. 2012:, http://www.nice.org.uk/TA091

419. Scottish Intercollegiate Guidelines Network, SIGN #135: Management of epithelial ovarian cancerScottish Intercollegiate Guidelines Network,, 2013. 135:, https://www.sign.ac.uk/guidelines/management-of-epithelial-ovarian-cancer/

420. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study, Lancet, 1998. 352(9140): p. 1571-6., https://pubmed.ncbi.nlm.nih.gov/9843101/

421. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial, Lancet, 2002. 360(9332): p. 505-15., https://pubmed.ncbi.nlm.nih.gov/12241653/

422. McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., et.al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer, N Engl J Med, 1996. 334(1): p. 1-6., https://pubmed.ncbi.nlm.nih.gov/7494563/

423. Muggia, F. M., Braly, P. S., Brady, M. F., Sutton, G., Niemann, T. H., Lentz, S. L., et.al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study, J Clin Oncol, 2000. 18(1): p. 106-15., https://pubmed.ncbi.nlm.nih.gov/10623700/

424. Neijt, J. P., Engelholm, S. A., Tuxen, M. K., Sorensen, P. G., Hansen, M., Sessa, C., et.al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer, J Clin Oncol, 2000. 18(17): p. 3084-92., https://pubmed.ncbi.nlm.nih.gov/10963636/

425. Piccart, M. J., Bertelsen, K., James, K., Cassidy, J., Mangioni, C., Simonsen, E., et.al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results, J Natl Cancer Inst, 2000. 92(9): p. 699-708., https://pubmed.ncbi.nlm.nih.gov/10793106/

426. West, R. J., Zweig, S. F., Meta-analysis of chemotherapy regimens for ovarian carcinoma: a reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide, Eur J Gynaecol Oncol, 1997. 18(5): p. 343-8., https://pubmed.ncbi.nlm.nih.gov/9378150/

427. Ozols, R. F., Chemotherapy for ovarian cancer, Semin Oncol, 1999. 26(6 Suppl 18): p. 34-40., https://pubmed.ncbi.nlm.nih.gov/10892576/

428. du Bois, A., Neijt, J. P., Thigpen, J. T., First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer--a new standard of care?, Ann Oncol, 1999. 10 Suppl 1: p. 35-41., https://pubmed.ncbi.nlm.nih.gov/10219451/

429. Aabo, K., Adams, M., Adnitt, P., Alberts, D. S., Athanazziou, A., Barley, V., et.al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group, Br J Cancer, 1998. 78(11): p. 1479-87., https://pubmed.ncbi.nlm.nih.gov/9836481/

430. du Bois, A., Lück, H.J., Meier, W., Adams, H.P., Möbus, V., Costa, S., et.al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer, Journal of the National Cancer Institute, 2003. 95(17): p. 1320-1329., https://pubmed.ncbi.nlm.nih.gov/12953086/

431. Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., et.al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study, J Clin Oncol, 2003. 21(17): p. 3194-200., https://pubmed.ncbi.nlm.nih.gov/12860964/

432. NICE, NICE Clinical Guideline 122. The Recognition and Initial Management of Ovarian Cancer., 2011. 2012:, https://www.nice.org.uk/guidance/cg122

433. NICE, NICE Clinical Guideline 122. The Recognition and Initial Management of Ovarian Cancer., 2011. 2012:, http://guidance.nice.org.uk/CG122

434. Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., et.al. Incorporation of bevacizumab in the primary treatment of ovarian cancer, N Engl J Med, 2011. 365(26): p. 2473-83., https://pubmed.ncbi.nlm.nih.gov/22204724/

435. Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., et.al. A phase 3 trial of bevacizumab in ovarian cancer, N Engl J Med, 2011. 365(26): p. 2484-96., https://pubmed.ncbi.nlm.nih.gov/22204725/

436. Oza, A. M., Cook, A. D., Pfisterer, J., Embleton, A., Ledermann, J. A., Pujade-Lauraine, E., et.al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial, Lancet Oncol, 2015. 16(8): p. 928-36., https://pubmed.ncbi.nlm.nih.gov/26115797/

437. Tewari, K. S., Burger, R. A., Enserro, D., Norquist, B. M., Swisher, E. M., Brady, M. F., et.al. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer, J Clin Oncol, 2019. 37(26): p. 2317-2328., https://pubmed.ncbi.nlm.nih.gov/31216226/

438. Ray-Coquard, I., Pautier, P., Pignata, S., Perol, D., Gonzalez-Martin, A., Berger, R., et.al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer, N Engl J Med, 2019. 381(25): p. 2416-2428., https://pubmed.ncbi.nlm.nih.gov/31851799/

439. Gonzalez-Martin, A., Pothuri, B., Vergote, I., DePont Christensen, R., Graybill, W., Mirza, M. R., et.al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer, N Engl J Med, 2019. 381(25): p. 2391-2402., https://pubmed.ncbi.nlm.nih.gov/31562799/

440. Coleman, R. L., Fleming, G. F., Brady, M. F., Swisher, E. M., Steffensen, K. D., Friedlander, M., et.al. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer, N Engl J Med, 2019. 381(25): p. 2403-2415., https://pubmed.ncbi.nlm.nih.gov/31562800/

441. DiSilvestro, P, Banerjee, S, Colombo, N, Scambia, G, Kim, BG, Oaknin, A, et.al. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial., J Clin Oncol, 2023. 41 (3)(3): p. 609-617., https://pubmed.ncbi.nlm.nih.gov/36082969/

442. Ray-Coquard, I, Leary, A, Pignata, S, Cropet, C, González-Martín, A, Marth, C, et.al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial., Ann Oncol, 2023. 34 (8)(8): p. 681-692., https://pubmed.ncbi.nlm.nih.gov/37211045/

443. Moore, K, Colombo, N, Scambia, G, Kim, BG, Oaknin, A, Friedlander, M, et.al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer., N Engl J Med, 2018. 379 (26)(26): p. 2495-2505., https://pubmed.ncbi.nlm.nih.gov/30345884/

444. du Bois, A., Neijt, J. P., Thigpen, J. T., First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer--a new standard of care?, Ann Oncol, 1999. 10 Suppl 1: p. 35-41., https://pubmed.ncbi.nlm.nih.gov/10219451/

445. Vasey, P. A., Jayson, G. C., Gordon, A., Gabra, H., Coleman, R., Atkinson, R., et.al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma, J Natl Cancer Inst, 2004. 96(22): p. 1682-91., https://pubmed.ncbi.nlm.nih.gov/15547181/

446. du Bois, A., Lück, H.J., Meier, W., Adams, H.P., Möbus, V., Costa, S., et.al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer, Journal of the National Cancer Institute, 2003. 95(17): p. 1320-1329., https://pubmed.ncbi.nlm.nih.gov/12953086/

447. Katsumata, N, Yasuda, M, Isonishi, S, Takahashi, F, Michimae, H, Kimura, E, et.al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial., Lancet Oncol, 2013. 14 (10)(10): p. 1020-6., https://pubmed.ncbi.nlm.nih.gov/23948349/

448. Pignata, S., Scambia, G., Katsaros, D., Gallo, C., Pujade-Lauraine, E., De Placido, S., et.al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial, Lancet Oncol, 2014. 15(4): p. 396-405., https://pubmed.ncbi.nlm.nih.gov/24582486/

449. Clamp, A. R., James, E. C., McNeish, I. A., Dean, A., Kim, J. W., O'Donnell, D. M., et.al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial, Lancet, 2019. 394(10214): p. 2084-2095., https://pubmed.ncbi.nlm.nih.gov/31791688/

450. Chan, JK, Brady, MF, Penson, RT, Huang, H, Birrer, MJ, Walker, JL, et.al. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer., N Engl J Med, 2016. 374 (8)(8): p. 738-48., https://pubmed.ncbi.nlm.nih.gov/26933849/

451. Blagden, SP, Cook, AD, Poole, C, Howells, L, McNeish, IA, Dean, A, et.al. Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial., Lancet Oncol, 2020. 21 (7)(7): p. 969-977., https://pubmed.ncbi.nlm.nih.gov/32615110/

452. Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., et.al. Incorporation of bevacizumab in the primary treatment of ovarian cancer, N Engl J Med, 2011. 365(26): p. 2473-83., https://pubmed.ncbi.nlm.nih.gov/22204724/

453. Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., et.al. A phase 3 trial of bevacizumab in ovarian cancer, N Engl J Med, 2011. 365(26): p. 2484-96., https://pubmed.ncbi.nlm.nih.gov/22204725/

454. Oza, A. M., Cook, A. D., Pfisterer, J., Embleton, A., Ledermann, J. A., Pujade-Lauraine, E., et.al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial, Lancet Oncol, 2015. 16(8): p. 928-36., https://pubmed.ncbi.nlm.nih.gov/26115797/

455. Burger, R. A., Brady, M. F., Rhee, J., Sovak, M. A., Kong, G., Nguyen, H. P., et.al. Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer, Gynecol Oncol, 2013. 131(1): p. 21-6., https://pubmed.ncbi.nlm.nih.gov/23906656/

456. Stark, D., Nankivell, M., Pujade-Lauraine, E., Kristensen, G., Elit, L., Stockler, M., et.al. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial, Lancet Oncol, 2013. 14(3): p. 236-43., https://pubmed.ncbi.nlm.nih.gov/23333117/

457. Monk, BJ, Barretina-Ginesta, MP, Pothuri, B, Vergote, I, Graybill, W, Mirza, MR, et.al. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial., Ann Oncol, 2024. 35 (11)(11): p. 981-992., https://pubmed.ncbi.nlm.nih.gov/39284381/

458. Monk, BJ, Parkinson, C, Lim, MC, O'Malley, DM, Oaknin, A, Wilson, MK, et.al. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)., J Clin Oncol, 2022. 40 (34)(34): p. 3952-3964., https://pubmed.ncbi.nlm.nih.gov/35658487/

459. Li, N, Zhu, J, Yin, R, Wang, J, Pan, L, Kong, B, et.al. Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial., JAMA Oncol, 2023. 9 (9)(9): p. 1230-1237., https://pubmed.ncbi.nlm.nih.gov/37440217/

460. du Bois, A., Floquet, A., Kim, J. W., Rau, J., del Campo, J. M., Friedlander, M., et.al. Incorporation of pazopanib in maintenance therapy of ovarian cancer, J Clin Oncol, 2014. 32(30): p. 3374-82., https://pubmed.ncbi.nlm.nih.gov/25225436/

461. du Bois, A., Kristensen, G., Ray-Coquard, I., Reuss, A., Pignata, S., Colombo, N., et.al. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial, Lancet Oncol, 2016. 17(1): p. 78-89., https://pubmed.ncbi.nlm.nih.gov/26590673/

462. Floquet, A., Vergote, I., Colombo, N., Fiane, B., Monk, B. J., Reinthaller, A., et.al. Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial, Gynecol Oncol, 2015. 136(1): p. 37-42., https://pubmed.ncbi.nlm.nih.gov/25434635/

463. Vergote, I., du Bois, A., Floquet, A., Rau, J., Kim, J. W., Del Campo, J. M., et.al. Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer, Gynecol Oncol, 2019. 155(2): p. 186-191., https://pubmed.ncbi.nlm.nih.gov/31519320/

464. Ray-Coquard, I., Cibula, D., Mirza, M. R., Reuss, A., Ricci, C., Colombo, N., et.al. Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer, Int J Cancer, 2020. 146(2): p. 439-448., https://pubmed.ncbi.nlm.nih.gov/31381147/

465. Alberts, D. S., Markman, M., Armstrong, D., Rothenberg, M. L., Muggia, F., Howell, S. B., Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come!, J Clin Oncol, 2002. 20(19): p. 3944-6., https://pubmed.ncbi.nlm.nih.gov/12351590/

466. van Driel, W. J., Koole, S. N., Sikorska, K., Schagen van Leeuwen, J. H., Schreuder, H. W. R., Hermans, R. H. M., et.al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer, N Engl J Med, 2018. 378(3): p. 230-240., https://pubmed.ncbi.nlm.nih.gov/29342393/

467. Aronson, SL, Lopez-Yurda, M, Koole, SN, Schagen van Leeuwen, JH, Schreuder, HWR, Hermans, RHM, et.al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial., Lancet Oncol, 2023. 24 (10)(10): p. 1109-1118., https://pubmed.ncbi.nlm.nih.gov/37708912/

468. van Driel, W. J., Koole, S. N., Sikorska, K., Schagen van Leeuwen, J. H., Schreuder, H. W. R., Hermans, R. H. M., et.al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer, N Engl J Med, 2018. 378(3): p. 230-240., https://pubmed.ncbi.nlm.nih.gov/29342393/

469. Vergote, I., Chiva, L., du Bois, A., Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer, N Engl J Med, 2018. 378(14): p. 1362-3., https://pubmed.ncbi.nlm.nih.gov/29619815/

470. Fotopoulou, C., Sehouli, J., Mahner, S., Harter, P., Van Nieuwenhuysen, E., Gonzalez-Martin, A., et.al. HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?, Ann Oncol, 2018. 29(8): p. 1610-1613., https://pubmed.ncbi.nlm.nih.gov/29873689/

471. McGuire, W. P., 3rd, High-dose chemotherapeutic approaches to ovarian cancer management, Semin Oncol, 2000. 27(3 Suppl 7): p. 41-6., https://pubmed.ncbi.nlm.nih.gov/10952126/

472. Mobus, V., Wandt, H., Frickhofen, N., Bengala, C., Champion, K., Kimmig, R., et.al. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT, J Clin Oncol, 2007. 25(27): p. 4187-93., https://pubmed.ncbi.nlm.nih.gov/17698804/

473. Katsumata, N., Yasuda, M., Takahashi, F., Isonishi, S., Jobo, T., Aoki, D., et.al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial, Lancet, 2009. 374(9698): p. 1331-8., https://pubmed.ncbi.nlm.nih.gov/19767092/

474. Hoskins, P., Vergote, I., Cervantes, A., Tu, D., Stuart, G., Zola, P., et.al. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel, J Natl Cancer Inst, 2010. 102(20): p. 1547-56., https://pubmed.ncbi.nlm.nih.gov/20937992/

475. Jaaback, K., Johnson, N., Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer, Cochrane Database Syst Rev, 2006. p. CD005340., https://pubmed.ncbi.nlm.nih.gov/16437527/

476. Buyse, M., Burzykowski, T., Parmar, M., Torri, V., Omura, G., Colombo, N., et.al. Using the expected survival to explain differences between the results of randomized trials: a case in advanced ovarian cancer, J Clin Oncol, 2003. 21(9): p. 1682-7., https://pubmed.ncbi.nlm.nih.gov/12721242/

477. Aravantinos, G., Fountzilas, G., Kosmidis, P., Dimopoulos, M. A., Stathopoulos, G. P., Pavlidis, N., et.al. Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study, Ann Oncol, 2005. 16(7): p. 1116-22., https://pubmed.ncbi.nlm.nih.gov/15928071/

478. Dizon, D. S., Weitzen, S., Rojan, A., Schwartz, J., Miller, J., Disilvestro, P., et.al. Two for good measure: six versus eight cycles of carboplatin and paclitaxel as adjuvant treatment for epithelial ovarian cancer, Gynecol Oncol, 2006. 100(2): p. 417-21., https://pubmed.ncbi.nlm.nih.gov/16336992/

479. Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., et.al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer, N Engl J Med, 2006. 354(1): p. 34-43., https://pubmed.ncbi.nlm.nih.gov/16394300/

480. Grenman, S., Wiklund, T., Jalkanen, J., Kuoppala, T., Maenpaa, J., Kuronen, A., et.al. A randomised phase III study comparing high-dose chemotherapy to conventionally dosed chemotherapy for stage III ovarian cancer: the Finnish Ovarian Cancer (FINOVA) study, Eur J Cancer, 2006. 42(14): p. 2196-9., https://pubmed.ncbi.nlm.nih.gov/16893642/

481. Spriggs, D. R., Brady, M. F., Vaccarello, L., Clarke-Pearson, D. L., Burger, R. A., Mannel, R., et.al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study, J Clin Oncol, 2007. 25(28): p. 4466-71., https://pubmed.ncbi.nlm.nih.gov/17906207/

482. Lhomme, C., Joly, F., Walker, J. L., Lissoni, A. A., Nicoletto, M. O., Manikhas, G. M., et.al. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer, J Clin Oncol, 2008. 26(16): p. 2674-82., https://pubmed.ncbi.nlm.nih.gov/18509179/

483. Safra, T., Menczer, J., Bernstein, R. M., Shpigel, S., Matcejevsky, D., Inbar, M. J., et.al. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma, Gynecol Oncol, 2009. 114(2): p. 215-8., https://pubmed.ncbi.nlm.nih.gov/19446318/

484. McGuire, W. P., 3rd, High-dose chemotherapeutic approaches to ovarian cancer management, Semin Oncol, 2000. 27(3 Suppl 7): p. 41-6., https://pubmed.ncbi.nlm.nih.gov/10952126/

485. Mobus, V., Wandt, H., Frickhofen, N., Bengala, C., Champion, K., Kimmig, R., et.al. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT, J Clin Oncol, 2007. 25(27): p. 4187-93., https://pubmed.ncbi.nlm.nih.gov/17698804/

486. Katsumata, N., Yasuda, M., Takahashi, F., Isonishi, S., Jobo, T., Aoki, D., et.al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial, Lancet, 2009. 374(9698): p. 1331-8., https://pubmed.ncbi.nlm.nih.gov/19767092/

487. Hoskins, P., Vergote, I., Cervantes, A., Tu, D., Stuart, G., Zola, P., et.al. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel, J Natl Cancer Inst, 2010. 102(20): p. 1547-56., https://pubmed.ncbi.nlm.nih.gov/20937992/

488. Jaaback, K., Johnson, N., Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer, Cochrane Database Syst Rev, 2006. p. CD005340., https://pubmed.ncbi.nlm.nih.gov/16437527/

489. Buyse, M., Burzykowski, T., Parmar, M., Torri, V., Omura, G., Colombo, N., et.al. Using the expected survival to explain differences between the results of randomized trials: a case in advanced ovarian cancer, J Clin Oncol, 2003. 21(9): p. 1682-7., https://pubmed.ncbi.nlm.nih.gov/12721242/

490. Aravantinos, G., Fountzilas, G., Kosmidis, P., Dimopoulos, M. A., Stathopoulos, G. P., Pavlidis, N., et.al. Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study, Ann Oncol, 2005. 16(7): p. 1116-22., https://pubmed.ncbi.nlm.nih.gov/15928071/

491. Dizon, D. S., Weitzen, S., Rojan, A., Schwartz, J., Miller, J., Disilvestro, P., et.al. Two for good measure: six versus eight cycles of carboplatin and paclitaxel as adjuvant treatment for epithelial ovarian cancer, Gynecol Oncol, 2006. 100(2): p. 417-21., https://pubmed.ncbi.nlm.nih.gov/16336992/

492. Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., et.al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer, N Engl J Med, 2006. 354(1): p. 34-43., https://pubmed.ncbi.nlm.nih.gov/16394300/

493. Grenman, S., Wiklund, T., Jalkanen, J., Kuoppala, T., Maenpaa, J., Kuronen, A., et.al. A randomised phase III study comparing high-dose chemotherapy to conventionally dosed chemotherapy for stage III ovarian cancer: the Finnish Ovarian Cancer (FINOVA) study, Eur J Cancer, 2006. 42(14): p. 2196-9., https://pubmed.ncbi.nlm.nih.gov/16893642/

494. Spriggs, D. R., Brady, M. F., Vaccarello, L., Clarke-Pearson, D. L., Burger, R. A., Mannel, R., et.al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study, J Clin Oncol, 2007. 25(28): p. 4466-71., https://pubmed.ncbi.nlm.nih.gov/17906207/

495. Lhomme, C., Joly, F., Walker, J. L., Lissoni, A. A., Nicoletto, M. O., Manikhas, G. M., et.al. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer, J Clin Oncol, 2008. 26(16): p. 2674-82., https://pubmed.ncbi.nlm.nih.gov/18509179/

496. Safra, T., Menczer, J., Bernstein, R. M., Shpigel, S., Matcejevsky, D., Inbar, M. J., et.al. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma, Gynecol Oncol, 2009. 114(2): p. 215-8., https://pubmed.ncbi.nlm.nih.gov/19446318/

497. van der Burg, M. E., Onstenk, W., Boere, I. A., Look, M., Ottevanger, P. B., de Gooyer, D., et.al. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer, Eur J Cancer, 2014. 50(15): p. 2592-601., https://pubmed.ncbi.nlm.nih.gov/25096168/

498. Harano, K., Terauchi, F., Katsumata, N., Takahashi, F., Yasuda, M., Takakura, S., et.al. Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016), Ann Oncol, 2014. 25(1): p. 251-7., https://pubmed.ncbi.nlm.nih.gov/24356636/

499. Lambert, H. E., Rustin, G. J., Gregory, W. M., Nelstrop, A. E., A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study, Ann Oncol, 1997. 8(4): p. 327-33., https://pubmed.ncbi.nlm.nih.gov/9209661/

500. Sorbe, B., Trope, C., Nordal, Himmelmann, Simonsen, E., Hogberg, et.al. Chemotherapy vs radiotherapy as consolidation treatment of ovarian carcinoma stage III at surgical complete remission from induction chemotherapy, ASCO, 1996.

501. Mei, L., Chen, H., Wei, D. M., Fang, F., Liu, G. J., Xie, H. Y., et.al. Maintenance chemotherapy for ovarian cancer, Cochrane Database Syst Rev, 2010. p. CD007414., https://pubmed.ncbi.nlm.nih.gov/20824860/

502. Berek, J., Taylor, P., McGuire, W., Smith, L. M., Schultes, B., Nicodemus, C. F., Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer, J Clin Oncol, 2009. 27(3): p. 418-25., https://pubmed.ncbi.nlm.nih.gov/19075271/

503. Pecorelli, S., Favalli, G., Gadducci, A., Katsaros, D., Panici, P. B., Carpi, A., et.al. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1, J Clin Oncol, 2009. 27(28): p. 4642-8., https://pubmed.ncbi.nlm.nih.gov/19704064/

504. Penson, R. T., Dizon, D. S., Cannistra, S. A., Roche, M. R., Krasner, C. N., Berlin, S. T., et.al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors, J Clin Oncol, 2010. 28(1): p. 154-9., https://pubmed.ncbi.nlm.nih.gov/19917843/

505. Pomel, C., Ferron, G., Lorimier, G., Rey, A., Lhomme, C., Classe, J. M., et.al. Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study, Eur J Surg Oncol, 2010. 36(6): p. 589-93., https://pubmed.ncbi.nlm.nih.gov/20466507/

506. Hess, L. M., Rong, N., Monahan, P. O., Gupta, P., Thomaskutty, C., Matei, D., Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysis, Cancer, 2010. 116(22): p. 5251-60., https://pubmed.ncbi.nlm.nih.gov/20665885/

507. Lambert, H. E., Rustin, G. J., Gregory, W. M., Nelstrop, A. E., A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study, Ann Oncol, 1997. 8(4): p. 327-33., https://pubmed.ncbi.nlm.nih.gov/9209661/

508. Sorbe, B., Trope, C., Nordal, Himmelmann, Simonsen, E., Hogberg, et.al. Chemotherapy vs radiotherapy as consolidation treatment of ovarian carcinoma stage III at surgical complete remission from induction chemotherapy, ASCO, 1996.

509. Mei, L., Chen, H., Wei, D. M., Fang, F., Liu, G. J., Xie, H. Y., et.al. Maintenance chemotherapy for ovarian cancer, Cochrane Database Syst Rev, 2010. p. CD007414., https://pubmed.ncbi.nlm.nih.gov/20824860/

510. Berek, J., Taylor, P., McGuire, W., Smith, L. M., Schultes, B., Nicodemus, C. F., Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer, J Clin Oncol, 2009. 27(3): p. 418-25., https://pubmed.ncbi.nlm.nih.gov/19075271/

511. Pecorelli, S., Favalli, G., Gadducci, A., Katsaros, D., Panici, P. B., Carpi, A., et.al. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1, J Clin Oncol, 2009. 27(28): p. 4642-8., https://pubmed.ncbi.nlm.nih.gov/19704064/

512. Penson, R. T., Dizon, D. S., Cannistra, S. A., Roche, M. R., Krasner, C. N., Berlin, S. T., et.al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors, J Clin Oncol, 2010. 28(1): p. 154-9., https://pubmed.ncbi.nlm.nih.gov/19917843/

513. Pomel, C., Ferron, G., Lorimier, G., Rey, A., Lhomme, C., Classe, J. M., et.al. Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study, Eur J Surg Oncol, 2010. 36(6): p. 589-93., https://pubmed.ncbi.nlm.nih.gov/20466507/

514. Hess, L. M., Rong, N., Monahan, P. O., Gupta, P., Thomaskutty, C., Matei, D., Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysis, Cancer, 2010. 116(22): p. 5251-60., https://pubmed.ncbi.nlm.nih.gov/20665885/

515. du Bois, A., Reuss, A., Pujade-Lauraine, E., Harter, P., Ray-Coquard, I., Pfisterer, J., Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO), Cancer, 2009. 115(6): p. 1234-44., https://pubmed.ncbi.nlm.nih.gov/19189349/

516. Wimberger, P., Lehmann, N., Kimmig, R., Burges, A., Meier, W., Du Bois, A., Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR), Gynecol Oncol, 2007. 106(1): p. 69-74., https://pubmed.ncbi.nlm.nih.gov/17397910/

517. Aletti, G. D., Eisenhauer, E. L., Santillan, A., Axtell, A., Aletti, G., Holschneider, C., et.al. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment, Gynecol Oncol, 2011. 120(1): p. 23-8., https://pubmed.ncbi.nlm.nih.gov/20933255/

518. Voest, E. E., van Houwelingen, J. C., Neijt, J. P., A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives, Eur J Cancer Clin Oncol, 1989. 25(4): p. 711-20., https://pubmed.ncbi.nlm.nih.gov/2714347/

519. van Houwelingen, J. C., ten Bokkel Huinink, W. W., van der Burg, M. E., van Oosterom, A. T., Neijt, J. P., Predictability of the survival of patients with advanced ovarian cancer, J Clin Oncol, 1989. 7(6): p. 769-73., https://pubmed.ncbi.nlm.nih.gov/2654332/

520. Silvestrini, R., Daidone, M. G., Bolis, G., Fontanelli, R., Landoni, F., Andreola, S., et.al. Cell kinetics: a prognostic marker in epithelial ovarian cancer, Gynecol Oncol, 1989. 35(1): p. 15-9., https://pubmed.ncbi.nlm.nih.gov/2676750/

521. Schneider, J., Edler, L., Kleine, W., Volm, M., DNA analysis, chemoresistance testing and hormone receptor levels as prognostic factors in advanced ovarian carcinoma, Arch Gynecol Obstet, 1990. 248(1): p. 45-52., https://pubmed.ncbi.nlm.nih.gov/2256719/

522. Lund, B., Williamson, P., Prognostic factors for overall survival in patients with advanced ovarian carcinoma, Ann Oncol, 1991. 2(4): p. 281-7., https://pubmed.ncbi.nlm.nih.gov/1868024/

523. Omura, G. A., Brady, M. F., Homesley, H. D., Yordan, E., Major, F. J., Buchsbaum, H. J., et.al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience, J Clin Oncol, 1991. 9(7): p. 1138-50., https://pubmed.ncbi.nlm.nih.gov/1904477/

524. Gadducci, A., Zola, P., Landoni, F., Maggino, T., Sartori, E., Bergamino, T., et.al. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study, Gynecol Oncol, 1995. 58(1): p. 42-7., https://pubmed.ncbi.nlm.nih.gov/7789889/

525. Baekelandt, M. M., Holm, R., Nesland, J. M., Trope, C. G., Kristensen, G. B., P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer, Anticancer Res, 2000. 20(2B): p. 1061-7., https://pubmed.ncbi.nlm.nih.gov/10810398/

526. Sugiyama, T., Kamura, T., Kigawa, J., Terakawa, N., Kikuchi, Y., Kita, T., et.al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy, Cancer, 2000. 88(11): p. 2584-9., https://pubmed.ncbi.nlm.nih.gov/10861437/

527. van Dalen, A., Favier, J., Burges, A., Hasholzner, U., de Bruijn, H. W., Dobler-Girdziunaite, D., et.al. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients, Gynecol Oncol, 2000. 79(3): p. 444-50., https://pubmed.ncbi.nlm.nih.gov/11104617/

528. Camilleri-Broet, S., Hardy-Bessard, A. C., Le Tourneau, A., Paraiso, D., Levrel, O., Leduc, B., et.al. HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group, Ann Oncol, 2004. 15(1): p. 104-12., https://pubmed.ncbi.nlm.nih.gov/14679128/

529. Riener, E. K., Arnold, N., Kommoss, F., Lauinger, S., Pfisterer, J., The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study, Gynecol Oncol, 2004. 95(1): p. 89-94., https://pubmed.ncbi.nlm.nih.gov/15385115/

530. Green, J. A., Berns, E. M., Coens, C., van Luijk, I., Thompson-Hehir, J., van Diest, P., et.al. Alterations in the p53 pathway and prognosis in advanced ovarian cancer: a multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865), Eur J Cancer, 2006. 42(15): p. 2539-48., https://pubmed.ncbi.nlm.nih.gov/16965910/

531. Secord, A. A., Darcy, K. M., Hutson, A., Lee, P. S., Havrilesky, L. J., Grace, L. A., et.al. Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study, Gynecol Oncol, 2007. 106(1): p. 221-32., https://pubmed.ncbi.nlm.nih.gov/17481705/

532. Kommoss, S., Schmidt, D., Kommoss, F., Hedderich, J., Harter, P., Pfisterer, J., et.al. Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol), Virchows Arch, 2009. 454(3): p. 249-56., https://pubmed.ncbi.nlm.nih.gov/19172293/

533. Ferron, J. G., Uzan, C., Rey, A., Gouy, S., Pautier, P., Lhomme, C., et.al. Histological response is not a prognostic factor after neoadjuvant chemotherapy in advanced-stage ovarian cancer with no residual disease, Eur J Obstet Gynecol Reprod Biol, 2009. 147(1): p. 101-5., https://pubmed.ncbi.nlm.nih.gov/19740592/

534. Mackay, H. J., Brady, M. F., Oza, A. M., Reuss, A., Pujade-Lauraine, E., Swart, A. M., et.al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer, Int J Gynecol Cancer, 2010. 20(6): p. 945-52., https://pubmed.ncbi.nlm.nih.gov/20683400/

535. Sugiyama, T., Okamoto, A., Enomoto, T., Hamano, T., Aotani, E., Terao, Y., et.al. Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial, J Clin Oncol, 2016. 34(24): p. 2881-7., https://pubmed.ncbi.nlm.nih.gov/27400948/

536. Colombo, N, Gadducci, A, Landoni, F, Lorusso, D, Sabbatini, R, Artioli, G, et.al. Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study., Gynecol Oncol, 2023. 175 (): p. 182-189., https://pubmed.ncbi.nlm.nih.gov/37355448/

537. Perez-Fidalgo, A, Schmalfeldt, B, George, A, Gourley, C, Pignata, S, Lorusso, D, et.al. Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer., Int J Gynecol Cancer, 2025. 35 (7)(7): p. 101863., https://pubmed.ncbi.nlm.nih.gov/39448084/

538. Charkhchi, P, Cybulski, C, Gronwald, J, Wong, FO, Narod, SA, Akbari, MR, CA125 and Ovarian Cancer: A Comprehensive Review., Cancers (Basel), 2020. 12 (12)(12):, https://pubmed.ncbi.nlm.nih.gov/33322519/

539. Rustin, G. J., Vergote, I., Eisenhauer, E., Pujade-Lauraine, E., Quinn, M., Thigpen, T., et.al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG), Int J Gynecol Cancer, 2011. 21(2): p. 419-23., https://pubmed.ncbi.nlm.nih.gov/21270624/

540. You, B, Purdy, C, Copeland, LJ, Swisher, EM, Bookman, MA, Fleming, G, et.al. Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study., J Clin Oncol, 2022. 40 (34)(34): p. 3965-3974., https://pubmed.ncbi.nlm.nih.gov/36252167/

541. Colomban, O, Tod, M, Peron, J, Perren, TJ, Leary, A, Cook, AD, et.al. Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7)., JNCI Cancer Spectr, 2020. 4 (3)(3): p. pkaa026., https://pubmed.ncbi.nlm.nih.gov/32596636/

542. Zouzoulas, D, Tsolakidis, D, Tzitzis, P, Chatzistamatiou, K, Theodoulidis, V, Sofianou, I, et.al. CA-125 KELIM as an Alternative Predictive Tool to Identify Which Patients Can Benefit from PARPi in High-Grade Serous Advanced Ovarian Cancer: A Retrospective Pilot Diagnostic Accuracy Study., Int J Mol Sci, 2024. 25 (10)(10):, https://pubmed.ncbi.nlm.nih.gov/38791269/

543. Marchetti, C, Ergasti, R, Capomacchia, FM, Giannarelli, D, Mastrantoni, L, Pepe, F, et.al. Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery., Gynecol Oncol, 2025. 195 (): p. 16-25., https://pubmed.ncbi.nlm.nih.gov/40048982/

544. Williams, C., Simera, I., Bryant, A., Tamoxifen for relapse of ovarian cancer, Cochrane Database Syst Rev, 2010. p. CD001034., https://pubmed.ncbi.nlm.nih.gov/20238312/

545. ten Bokkel Huinink, W., Gore, M., Carmichael, J., Gordon, A., Malfetano, J., Hudson, I., et.al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer, J Clin Oncol, 1997. 15(6): p. 2183-93., https://pubmed.ncbi.nlm.nih.gov/9196130/

546. Parmar, M. K., Ledermann, J. A., Colombo, N., du Bois, A., Delaloye, J. F., Kristensen, G. B., et.al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial, Lancet, 2003. 361(9375): p. 2099-106., https://pubmed.ncbi.nlm.nih.gov/12826431/

547. Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., Lacave, A. J., Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan, J Clin Oncol, 2001. 19(14): p. 3312-22., https://pubmed.ncbi.nlm.nih.gov/11454878/

548. Cantu, M. G., Buda, A., Parma, G., Rossi, R., Floriani, I., Bonazzi, C., et.al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens, J Clin Oncol, 2002. 20(5): p. 1232-7., https://pubmed.ncbi.nlm.nih.gov/11870165/

549. Blackledge, G., Lawton, F., Redman, C., Kelly, K., Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials, Br J Cancer, 1989. 59(4): p. 650-3., https://pubmed.ncbi.nlm.nih.gov/2713253/

550. Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., et.al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), 2009., https://pubmed.ncbi.nlm.nih.gov/19097774/

551. Rustin, G. J., Vergote, I., Eisenhauer, E., Pujade-Lauraine, E., Quinn, M., Thigpen, T., et.al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG), Int J Gynecol Cancer, 2011. 21(2): p. 419-23., https://pubmed.ncbi.nlm.nih.gov/21270624/

552. Friedlander, M., Trimble, E., Tinker, A., Alberts, D., Avall-Lundqvist, E., Brady, M., et.al. Clinical trials in recurrent ovarian cancer, 2011., https://pubmed.ncbi.nlm.nih.gov/21543939/

553. Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., et.al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 2009. 45(2): p. 228-47., https://pubmed.ncbi.nlm.nih.gov/19097774/

554. NHS National Institute for Health and Clinical Excellence, Technology Appraisal Guidance 91 Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer, 2005. 2012:, http://www.nice.org.uk/TA091

555. Meier, W., du Bois, A., Reuss, A., Kuhn, W., Olbricht, S., Gropp, M., et.al. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR), Gynecol Oncol, 2009. 114(2): p. 199-205., https://pubmed.ncbi.nlm.nih.gov/19446314/

556. ten Bokkel Huinink, W., Lane, S. R., Ross, G. A., Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma, Ann Oncol, 2004. 15(1): p. 100-3., https://pubmed.ncbi.nlm.nih.gov/14679127/

557. Vergote, I., Finkler, N., del Campo, J., Lohr, A., Hunter, J., Matei, D., et.al. Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer, 2009., https://pubmed.ncbi.nlm.nih.gov/19515553/

558. Ferrandina, G., Ludovisi, M., Lorusso, D., Pignata, S., Breda, E., Savarese, A., et.al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer, J Clin Oncol, 2008. 26(6): p. 890-6., https://pubmed.ncbi.nlm.nih.gov/18281662/

559. Mutch, D. G., Orlando, M., Goss, T., Teneriello, M. G., Gordon, A. N., McMeekin, S. D., et.al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer, 2007., https://pubmed.ncbi.nlm.nih.gov/17602086/

560. du Bois, A., Meier, W., Luck, H. J., Emons, G., Moebus, V., Schroeder, W., et.al. Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer, 2002., https://pubmed.ncbi.nlm.nih.gov/11886002/

561. Sehouli, J., Stengel, D., Oskay-Oezcelik, G., Zeimet, A. G., Sommer, H., Klare, P., et.al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group, J Clin Oncol, 2008. 26(19): p. 3176-82., https://pubmed.ncbi.nlm.nih.gov/18591555/

562. Peng, L. H., Chen, X. Y., Wu, T. X., Topotecan for ovarian cancer, 2008., https://pubmed.ncbi.nlm.nih.gov/18425923/

563. Pujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., et.al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial, J Clin Oncol, 2014. 32(13): p. 1302-8., https://pubmed.ncbi.nlm.nih.gov/24637997/

564. Moore, KN, Angelergues, A, Konecny, GE, García, Y, Banerjee, S, Lorusso, D, et.al. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer., N Engl J Med, 2023. 389 (23)(23): p. 2162-2174., https://pubmed.ncbi.nlm.nih.gov/38055253/

565. Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., Lacave, A. J., Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan, J Clin Oncol, 2001. 19(14): p. 3312-22., https://pubmed.ncbi.nlm.nih.gov/11454878/

566. ten Bokkel Huinink, W., Gore, M., Carmichael, J., Gordon, A., Malfetano, J., Hudson, I., et.al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer, J Clin Oncol, 1997. 15(6): p. 2183-93., https://pubmed.ncbi.nlm.nih.gov/9196130/

567. ten Bokkel Huinink, W., Lane, S. R., Ross, G. A., Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma, Ann Oncol, 2004. 15(1): p. 100-3., https://pubmed.ncbi.nlm.nih.gov/14679127/

568. Ferrandina, G., Ludovisi, M., Lorusso, D., Pignata, S., Breda, E., Savarese, A., et.al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer, J Clin Oncol, 2008. 26(6): p. 890-6., https://pubmed.ncbi.nlm.nih.gov/18281662/

569. Mutch, D. G., Orlando, M., Goss, T., Teneriello, M. G., Gordon, A. N., McMeekin, S. D., et.al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer, 2007., https://pubmed.ncbi.nlm.nih.gov/17602086/

570. Meier, W., du Bois, A., Reuss, A., Kuhn, W., Olbricht, S., Gropp, M., et.al. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR), Gynecol Oncol, 2009. 114(2): p. 199-205., https://pubmed.ncbi.nlm.nih.gov/19446314/

571. Vergote, I., Finkler, N., del Campo, J., Lohr, A., Hunter, J., Matei, D., et.al. Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer, Eur J Cancer, 2009. 45(13): p. 2324-32., https://pubmed.ncbi.nlm.nih.gov/19515553/

572. Sehouli, J., Stengel, D., Oskay-Oezcelik, G., Zeimet, A. G., Sommer, H., Klare, P., et.al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group, J Clin Oncol, 2008. 26(19): p. 3176-82., https://pubmed.ncbi.nlm.nih.gov/18591555/

573. Williams, C., Simera, I., Bryant, A., Tamoxifen for relapse of ovarian cancer, Cochrane Database Syst Rev, 2010. p. CD001034., https://pubmed.ncbi.nlm.nih.gov/20238312/

574. Vergote, I., Finkler, N., del Campo, J., Lohr, A., Hunter, J., Matei, D., et.al. Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer, 2009., https://pubmed.ncbi.nlm.nih.gov/19515553/

575. du Bois, A., Meier, W., Luck, H. J., Emons, G., Moebus, V., Schroeder, W., et.al. Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer, 2002., https://pubmed.ncbi.nlm.nih.gov/11886002/

576. Kristensen, G, Kaern, J, Baekelandt, M, Skeie-Jensensen, T, dePont Christensen, R, Åvall-Lundqvist, E, et.al. Chemotherapy versus hormonal treatment in patients with platinum and taxane resistant ovarian cancer.: A NSGO study, J Clin Oncol, 2008. 26(15S): p. 5508., https://ascopubs.org/doi/abs/10.1200/jco.2008.26.15_suppl.5508

577. Lindemann, K., Gibbs, E., Avall-Lundqvist, E., dePont Christensen, R., Woie, K., Kalling, M., et.al. Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist), Br J Cancer, 2017. 116(4): p. 455-463., https://pubmed.ncbi.nlm.nih.gov/28118323/

578. Pujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., et.al. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC), J Clin Oncol, 2012. 30(suppl; abstr LBA5002^):, https://ascopubs.org/doi/abs/10.1200/jco.2012.30.18_suppl.lba5002

579. Friedlander, M., Butow, P., Stockler, M., Gainford, C., Martyn, J., Oza, A., et.al. Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer, Int J Gynecol Cancer, 2009. 19 Suppl 2: p. S44-8., https://pubmed.ncbi.nlm.nih.gov/19955914/

580. Chekerov, R, Hilpert, F, Mahner, S, El-Balat, A, Harter, P, De Gregorio, N, et.al. Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial., Lancet Oncol, 2018. 19 (9)(9): p. 1247-1258., https://pubmed.ncbi.nlm.nih.gov/30100379/

581. Moore, KN, Oza, AM, Colombo, N, Oaknin, A, Scambia, G, Lorusso, D, et.al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I., Ann Oncol, 2021. 32 (6)(6): p. 757-765., https://pubmed.ncbi.nlm.nih.gov/33667670/

582. Monk, B. J., Herzog, T. J., Kaye, S. B., Krasner, C. N., Vermorken, J. B., Muggia, F. M., et.al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer, J Clin Oncol, 2010. 28(19): p. 3107-14., https://pubmed.ncbi.nlm.nih.gov/20516432/

583. Pignata, S., Scambia, G., Bologna, A., Signoriello, S., Vergote, I. B., Wagner, U., et.al. Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study, J Clin Oncol, 2017. p. JCO2017734293., https://pubmed.ncbi.nlm.nih.gov/28825853/

584. Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., et.al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer, N Engl J Med, 2012. 366(15): p. 1382-92., https://pubmed.ncbi.nlm.nih.gov/22452356/

585. Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., et.al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial, Lancet Oncol, 2014. 15(8): p. 852-61., https://pubmed.ncbi.nlm.nih.gov/24882434/

586. Ledermann, J. A., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., et.al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial, Lancet Oncol, 2016. 17(11): p. 1579-1589., https://pubmed.ncbi.nlm.nih.gov/27617661/

587. Oza, A. M., Cibula, D., Benzaquen, A. O., Poole, C., Mathijssen, R. H., Sonke, G. S., et.al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial, Lancet Oncol, 2015. 16(1): p. 87-97., https://pubmed.ncbi.nlm.nih.gov/25481791/

588. Swisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., et.al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial, Lancet Oncol, 2017. 18(1): p. 75-87., https://pubmed.ncbi.nlm.nih.gov/27908594/

589. Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., et.al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer, N Engl J Med, 2016. 375(22): p. 2154-2164., https://pubmed.ncbi.nlm.nih.gov/27717299/

590. Pujade-Lauraine, E., Ledermann, J. A., Selle, F., Gebski, V., Penson, R. T., Oza, A. M., et.al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial, Lancet Oncol, 2017. 18(9): p. 1274-1284., https://pubmed.ncbi.nlm.nih.gov/28754483/

591. Coleman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A., et.al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 2017. 390(10106): p. 1949-1961., https://pubmed.ncbi.nlm.nih.gov/28916367/

592. Pujade-Lauraine, E., Selle, F., Scambia, G., Asselain, B., Marmé, F., Lindemann, K., et.al. LBA33 Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial, Abstract Book of the ESMO Congress 2021, 16 – 21 September 2021, 2021. 32: p. S1308 - S1309., https://www.sciencedirect.com/science/article/pii/S0923753421044148

593. Aghajanian, C., Blank, S. V., Goff, B. A., Judson, P. L., Teneriello, M. G., Husain, A., et.al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer, J Clin Oncol, 2012. 30(17): p. 2039-45., https://pubmed.ncbi.nlm.nih.gov/22529265/

594. Aghajanian, C., Goff, B., Nycum, L. R., Wang, Y. V., Husain, A., Blank, S. V., Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer, Gynecol Oncol, 2015. 139(1): p. 10-6., https://pubmed.ncbi.nlm.nih.gov/26271155/

595. Parmar, M. K., Ledermann, J. A., Colombo, N., du Bois, A., Delaloye, J. F., Kristensen, G. B., et.al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial, Lancet, 2003. 361(9375): p. 2099-106., https://pubmed.ncbi.nlm.nih.gov/12826431/

596. Pfisterer, J., Plante, M., Vergote, I., du Bois, A., Hirte, H., Lacave, A. J., et.al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG, J Clin Oncol, 2006. 24(29): p. 4699-707., https://pubmed.ncbi.nlm.nih.gov/16966687/

597. Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P. A., et.al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse, J Clin Oncol, 2010. 28(20): p. 3323-9., https://pubmed.ncbi.nlm.nih.gov/20498395/

598. Coleman, RL, Brady, MF, Herzog, TJ, Sabbatini, P, Armstrong, DK, Walker, JL, et.al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial., Lancet Oncol, 2017. 18 (6)(6): p. 779-791., https://pubmed.ncbi.nlm.nih.gov/28438473/

599. Sehouli, J., Chekerov, R., Reinthaller, A., Richter, R., Gonzalez-Martin, A., Harter, P., et.al. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR), Ann Oncol, 2016. 27(12): p. 2236-2241., https://pubmed.ncbi.nlm.nih.gov/27789470/

600. Fabbro, M, Moore, KN, Dørum, A, Tinker, AV, Mahner, S, Bover, I, et.al. Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial., Gynecol Oncol, 2019. 152 (3)(3): p. 560-567., https://pubmed.ncbi.nlm.nih.gov/30638768/

601. Oza, AM, Matulonis, UA, Malander, S, Hudgens, S, Sehouli, J, Del Campo, JM, et.al. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial., Lancet Oncol, 2018. 19 (8)(8): p. 1117-1125., https://pubmed.ncbi.nlm.nih.gov/30026000/

602. Friedlander, M, Matulonis, U, Gourley, C, du Bois, A, Vergote, I, Rustin, G, et.al. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy., Br J Cancer, 2018. 119 (9)(9): p. 1075-1085., https://pubmed.ncbi.nlm.nih.gov/30353045/

603. Friedlander, M, Gebski, V, Gibbs, E, Davies, L, Bloomfield, R, Hilpert, F, et.al. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial., Lancet Oncol, 2018. 19 (8)(8): p. 1126-1134., https://pubmed.ncbi.nlm.nih.gov/30026002/

604. Eisenkop, S. M., Friedman, R. L., Spirtos, N. M., The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma, 2000., https://pubmed.ncbi.nlm.nih.gov/10618617/

605. Harter, P., du Bois, A., Hahmann, M., Hasenburg, A., Burges, A., Loibl, S., et.al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial, 2006., https://pubmed.ncbi.nlm.nih.gov/17009163/

606. Sehouli, J., Richter, R., Braicu, E. I., Buhling, K. J., Bahra, M., Neuhaus, P., et.al. Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients, J Surg Oncol, 2010. 102(6): p. 656-62., https://pubmed.ncbi.nlm.nih.gov/20734422/

607. Galaal, K., Naik, R., Bristow, R. E., Patel, A., Bryant, A., Dickinson, H. O., Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer, Cochrane Database Syst Rev, 2010. p. CD007822., https://pubmed.ncbi.nlm.nih.gov/20556785/

608. Bristow, R. E., Puri, I., Chi, D. S., Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis, Gynecol Oncol, 2009. 112(1): p. 265-74., https://pubmed.ncbi.nlm.nih.gov/18937969/

609. Harter, P., Sehouli, J., Reuss, A., Hasenburg, A., Scambia, G., Cibula, D., et.al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO, Int J Gynecol Cancer, 2011. 21(2): p. 289-95., https://pubmed.ncbi.nlm.nih.gov/21270612/

610. Scottish Intercollegiate Guidelines Network, SIGN #75: Epithelial ovarian cancer. A national clinical guideline.Scottish Intercollegiate Guidelines Network,, 2003., https://www.sign.ac.uk/media/1073/sign135_oct2018.pdf

611. Shi, T, Zhu, J, Feng, Y, Tu, D, Zhang, Y, Zhang, P, et.al. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial., Lancet Oncol, 2021. 22 (4)(4): p. 439-449., https://pubmed.ncbi.nlm.nih.gov/33705695/

612. Oskay-Ozcelik, G., Alavi, S., Richter, R., Keller, M., Chekerov, R., Cecere, S. C., et.al. Expression III: patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries, Ann Oncol, 2018. 29(4): p. 910-916., https://pubmed.ncbi.nlm.nih.gov/29415128/

613. Cramp, F., Byron-Daniel, J., Exercise for the management of cancer-related fatigue in adults, Cochrane Database Syst Rev, 2012. 11: p. Cd006145., https://pubmed.ncbi.nlm.nih.gov/23152233/

614. Beesley, V., Janda, M., Eakin, E., Obermair, A., Battistutta, D., Lymphedema after gynecological cancer treatment : prevalence, correlates, and supportive care needs, Cancer, 2007. 109(12): p. 2607-14., https://pubmed.ncbi.nlm.nih.gov/17474128/

615. Devoogdt, N., Christiaens, M. R., Geraerts, I., Truijen, S., Smeets, A., Leunen, K., et.al. Effect of manual lymph drainage in addition to guidelines and exercise therapy on arm lymphoedema related to breast cancer: randomised controlled trial, Bmj, 2011. 343: p. d5326., https://pubmed.ncbi.nlm.nih.gov/21885537/

616. Streckmann, F., Zopf, E. M., Lehmann, H. C., May, K., Rizza, J., Zimmer, P., et.al. Exercise intervention studies in patients with peripheral neuropathy: a systematic review, Sports Med, 2014. 44(9): p. 1289-304., https://pubmed.ncbi.nlm.nih.gov/24927670/

617. Roth, A.J., Carter, J., Nelson, C.J., Sexuality after cancer, Psycho-oncology. 2nd ed. New York, NY: Oxford University Press, Inc, 2010. p. 245-50.

618. Kew, F., Galaal, K., Bryant, A., Naik, R., Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment, Cochrane Database Syst Rev, 2011. p. CD006119., https://pubmed.ncbi.nlm.nih.gov/21678351/

619. Gadducci, A., Cosio, S., Zola, P., Landoni, F., Maggino, T., Sartori, E., Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature, Int J Gynecol Cancer, 2007. 17(1): p. 21-31., https://pubmed.ncbi.nlm.nih.gov/17291227/

620. Kew, F., Galaal, K., Bryant, A., Naik, R., Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment, Cochrane Database Syst Rev, 2011. p. CD006119., https://pubmed.ncbi.nlm.nih.gov/21678351/

621. Gadducci, A., Cosio, S., Zola, P., Landoni, F., Maggino, T., Sartori, E., Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature, Int J Gynecol Cancer, 2007. 17(1): p. 21-31., https://pubmed.ncbi.nlm.nih.gov/17291227/

622. Woopen, H, Sehouli, J, Davis, A, Lee, YC, Cohen, PA, Ferrero, A, et.al. GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: A position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee., Cancer Treat Rev, 2022. 107 (): p. 102396., https://pubmed.ncbi.nlm.nih.gov/35525106/

623. Guidozzi, F., Daponte, A., Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial, Cancer, 1999. 86(6): p. 1013-8., https://pubmed.ncbi.nlm.nih.gov/10491528/

624. Eeles, R. A., Tan, S., Wiltshaw, E., Fryatt, I., A'Hern, R. P., Shepherd, J. H., et.al. Hormone replacement therapy and survival after surgery for ovarian cancer, BMJ, 1991. 302(6771): p. 259-62., https://pubmed.ncbi.nlm.nih.gov/1998789/

625. Ursic-Vrscaj, M., Bebar, S., Zakelj, M. P., Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival, Menopause, 2001. 8(1): p. 70-5., https://pubmed.ncbi.nlm.nih.gov/11201519/

626. Mascarenhas, C., Lambe, M., Bellocco, R., Bergfeldt, K., Riman, T., Persson, I., et.al. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival, Int J Cancer, 2006. 119(12): p. 2907-15., https://pubmed.ncbi.nlm.nih.gov/16998830/

627. Eeles, R. A., Morden, J. P., Gore, M., Mansi, J., Glees, J., Wenczl, M., et.al. Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial, J Clin Oncol, 2015. 33(35): p. 4138-44., https://pubmed.ncbi.nlm.nih.gov/26417001/

628. Guidozzi, F., Daponte, A., Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial, Cancer, 1999. 86(6): p. 1013-8., https://pubmed.ncbi.nlm.nih.gov/10491528/

629. Mascarenhas, C., Lambe, M., Bellocco, R., Bergfeldt, K., Riman, T., Persson, I., et.al. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival, Int J Cancer, 2006. 119(12): p. 2907-15., https://pubmed.ncbi.nlm.nih.gov/16998830/

630. Eeles, R. A., Tan, S., Wiltshaw, E., Fryatt, I., A'Hern, R. P., Shepherd, J. H., et.al. Hormone replacement therapy and survival after surgery for ovarian cancer, BMJ, 1991. 302(6771): p. 259-62., https://pubmed.ncbi.nlm.nih.gov/1998789/

631. Ursic-Vrscaj, M., Bebar, S., Zakelj, M. P., Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival, Menopause, 2001. 8(1): p. 70-5., https://pubmed.ncbi.nlm.nih.gov/11201519/

632. Eeles, R. A., Morden, J. P., Gore, M., Mansi, J., Glees, J., Wenczl, M., et.al. Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial, J Clin Oncol, 2015. 33(35): p. 4138-44., https://pubmed.ncbi.nlm.nih.gov/26417001/

633. Gershenson, D. M., Bodurka, D. C., Coleman, R. L., Lu, K. H., Malpica, A., Sun, C. C., Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum, J Clin Oncol, 2017. 35(10): p. 1103-1111., https://pubmed.ncbi.nlm.nih.gov/28221866/

634. Pergialiotis, V., Pitsouni, E., Prodromidou, A., Frountzas, M., Perrea, D. N., Vlachos, G. D., Hormone therapy for ovarian cancer survivors: systematic review and meta-analysis, Menopause, 2016. 23(3): p. 335-42., https://pubmed.ncbi.nlm.nih.gov/26308232/

635. Brown, L. F., Kroenke, K., Cancer-related fatigue and its associations with depression and anxiety: a systematic review, Psychosomatics, 2009. 50(5): p. 440-7., https://pubmed.ncbi.nlm.nih.gov/19855028/

636. Steele, R., Fitch, M. I., Supportive care needs of women with gynecologic cancer, Cancer Nurs, 2008. 31(4): p. 284-91., https://pubmed.ncbi.nlm.nih.gov/18600115/

637. Hodgkinson, K., Butow, P., Fuchs, A., Hunt, G. E., Stenlake, A., Hobbs, K. M., et.al. Long-term survival from gynecologic cancer: psychosocial outcomes, supportive care needs and positive outcomes, Gynecol Oncol, 2007. 104(2): p. 381-9., https://pubmed.ncbi.nlm.nih.gov/17027072/

638. Reuter, K., Raugust, S., Marschner, N., Harter, M., Differences in prevalence rates of psychological distress and mental disorders in inpatients and outpatients with breast and gynaecological cancer, Eur J Cancer Care (Engl), 2007. 16(3): p. 222-30., https://pubmed.ncbi.nlm.nih.gov/17508941/

639. Norton, T. R., Manne, S. L., Rubin, S., Carlson, J., Hernandez, E., Edelson, M. I., et.al. Prevalence and predictors of psychological distress among women with ovarian cancer, J Clin Oncol, 2004. 22(5): p. 919-26., https://pubmed.ncbi.nlm.nih.gov/21542447/

640. Bodurka-Bevers, D., Basen-Engquist, K., Carmack, C. L., Fitzgerald, M. A., Wolf, J. K., de Moor, C., et.al. Depression, anxiety, and quality of life in patients with epithelial ovarian cancer, Gynecol Oncol, 2000. 78(3 Pt 1): p. 302-8., https://pubmed.ncbi.nlm.nih.gov/10985884/

641. O'Sullivan, C. K., Bowles, K. H., Jeon, S., Ercolano, E., McCorkle, R., Psychological Distress during Ovarian Cancer Treatment: Improving Quality by Examining Patient Problems and Advanced Practice Nursing Interventions, Nurs Res Pract, 2011. 2011: p. 351642., https://pubmed.ncbi.nlm.nih.gov/21994822/

642. Carmack Taylor, C. L., Basen-Engquist, K., Shinn, E. H., Bodurka, D. C., Predictors of sexual functioning in ovarian cancer patients, J Clin Oncol, 2004. 22(5): p. 881-9., https://pubmed.ncbi.nlm.nih.gov/14990644/

643. Gershenson, D. M., Miller, A. M., Champion, V. L., Monahan, P. O., Zhao, Q., Cella, D., et.al. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study, J Clin Oncol, 2007. 25(19): p. 2792-7., https://pubmed.ncbi.nlm.nih.gov/17602084/

644. Fitch, M. I., Steele, R., Identifying supportive care needs of women with ovarian cancer, Can Oncol Nurs J, 2010. 20(2): p. 66-74., https://pubmed.ncbi.nlm.nih.gov/20572429/

645. Kaufmann, M., Ernst, B., Was Frauen mit Krebs erfahren, empfinden, wissen und vermissen, Deutsches Ärzteblatt, 2000. 97(47): p. 3191 - 3196., https://www.aerzteblatt.de/archiv/25201/CAWAC-Umfrage-in-Deutschland-Was-Frauen-mit-Krebs-erfahren-empfinden-wissen-und-vermissen

646. Devine, E. C., Westlake, S. K., The effects of psychoeducational care provided to adults with cancer: meta-analysis of 116 studies, Oncol Nurs Forum, 1995. 22(9): p. 1369-81., https://pubmed.ncbi.nlm.nih.gov/8539178/

647. Stead, M. L., Brown, J. M., Fallowfield, L., Selby, P., Lack of communication between healthcare professionals and women with ovarian cancer about sexual issues, Br J Cancer, 2003. 88(5): p. 666-71., https://pubmed.ncbi.nlm.nih.gov/12618871/

648. Chan, Y. M., Lee, P. W., Fong, D. Y., Fung, A. S., Wu, L. Y., Choi, A. Y., et.al. Effect of individual psychological intervention in Chinese women with gynecologic malignancy: a randomized controlled trial, J Clin Oncol, 2005. 23(22): p. 4913-24., https://pubmed.ncbi.nlm.nih.gov/15939927/

649. Beesley, V., Eakin, E., Steginga, S., Aitken, J., Dunn, J., Battistutta, D., Unmet needs of gynaecological cancer survivors: implications for developing community support services, Psychooncology, 2008. 17(4): p. 392-400., https://pubmed.ncbi.nlm.nih.gov/17680554/

650. Herschbach, P., Weis, J., Screeningverfahren in der Psychoonkologie: Testinstrumente zur Identifikation betreuungsbedürftiger Krebspatienten, 2. Auflage, Deutsche Krebsgesellschaft, 2010., https://www.dapo-ev.de/wp-content/uploads/2017/04/pso_broschuere2.pdf

651. Velikova, G., Booth, L., Smith, A. B., Brown, P. M., Lynch, P., Brown, J. M., et.al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial, J Clin Oncol, 2004. 22(4): p. 714-24., https://pubmed.ncbi.nlm.nih.gov/14966096/

652. Watts, S., Prescott, P., Mason, J., McLeod, N., Lewith, G., Depression and anxiety in ovarian cancer: a systematic review and meta-analysis of prevalence rates, BMJ Open, 2015. 5(11): p. e007618., https://pubmed.ncbi.nlm.nih.gov/26621509/

653. Mehnert, A., Brahler, E., Faller, H., Harter, M., Keller, M., Schulz, H., et.al. Four-week prevalence of mental disorders in patients with cancer across major tumor entities, J Clin Oncol, 2014. 32(31): p. 3540-6., https://pubmed.ncbi.nlm.nih.gov/25287821/

654. Radbruch, Payne, Standards und Richtlinien für Hospiz- und Palliativversorgung in Europa, Weißbuch zu Empfehlungen der Europäischen Gesellschaft für Palliative Care (EAPC): Teil 2, Z Palliativmed, 2011. 12: p. 260 - 270.

655. Radbruch, Payne, Standards und Richtlinien für Hospiz- und Palliativversorgung in Europa, Weißbuch zu Empfehlungen der Europäischen Gesellschaft für Palliative Care (EAPC): Teil 1, Z Palliativmed, 2011. 12: p. 216 - 227., https://www.dgpalliativmedizin.de/images/Radbruch_2010_Standards_Norms_DeutschTeil1_ZPallMed.pdf

656. Kucukmetin, A., Naik, R., Galaal, K., Bryant, A., Dickinson, H. O., Palliative surgery versus medical management for bowel obstruction in ovarian cancer, Cochrane Database Syst Rev, 2010. p. CD007792., https://pubmed.ncbi.nlm.nih.gov/20614464/

657. Shaw, P., Agarwal, R., Pleurodesis for malignant pleural effusions, Cochrane Database Syst Rev, 2004. p. CD002916., https://pubmed.ncbi.nlm.nih.gov/14973997/

658. Terra, R. M., Kim, S. Y., Pego-Fernandes, P. M., Teixeira, L. R., Vargas, F. S., Jatene, F. B., Is silver nitrate pleurodesis for patients with malignant pleural effusion feasible and safe when performed in an outpatient setting?, Ann Surg Oncol, 2011. 18(4): p. 1145-50., https://pubmed.ncbi.nlm.nih.gov/21161728/

659. Neto, J. D., de Oliveira, S. F., Vianna, S. P., Terra, R. M., Efficacy and safety of iodopovidone pleurodesis in malignant pleural effusions, Respirology, 2010. 15(1): p. 115-8., https://pubmed.ncbi.nlm.nih.gov/19947987/

660. Sioris, T., Sihvo, E., Salo, J., Rasanen, J., Knuuttila, A., Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis, Eur J Surg Oncol, 2009. 35(5): p. 546-51., https://pubmed.ncbi.nlm.nih.gov/18644696/

661. Sioris, T., Sihvo, E., Salo, J., Rasanen, J., Knuuttila, A., Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis, Eur J Surg Oncol, 2009. 35(5): p. 546-51., https://pubmed.ncbi.nlm.nih.gov/18644696/

662. WHO, Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs, 2003.

663. Kaern, J., Trope, C. G., Abeler, V. M., A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities, Cancer, 1993. 71(5): p. 1810-20., https://pubmed.ncbi.nlm.nih.gov/8383580/

664. Leake, J. F., Currie, J. L., Rosenshein, N. B., Woodruff, J. D., Long-term follow-up of serous ovarian tumors of low malignant potential, Gynecol Oncol, 1992. 47(2): p. 150-8., https://pubmed.ncbi.nlm.nih.gov/1468692/

665. Odegaard, E., Staff, A. C., Langebrekke, A., Engh, V., Onsrud, M., Surgery of borderline tumors of the ovary: retrospective comparison of short-term outcome after laparoscopy or laparotomy, Acta Obstet Gynecol Scand, 2007. 86(5): p. 620-6., https://pubmed.ncbi.nlm.nih.gov/17464594/

666. Camatte, S., Morice, P., Thoury, A., Fourchotte, V., Pautier, P., Lhomme, C., et.al. Impact of surgical staging in patients with macroscopic "stage I" ovarian borderline tumours: analysis of a continuous series of 101 cases, Eur J Cancer, 2004. 40(12): p. 1842-9., https://pubmed.ncbi.nlm.nih.gov/15288285/

667. Menczer, J., Chetrit, A., Sadetzki, S., The effect of hysterectomy on survival of patients with borderline ovarian tumors, Gynecol Oncol, 2012. 125(2): p. 372-5., https://pubmed.ncbi.nlm.nih.gov/22366596/

668. Trillsch, F., Mahner, S., Woelber, L., Vettorazzi, E., Reuss, A., Ewald-Riegler, N., et.al. Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study, Ann Oncol, 2014. 25(7): p. 1320-7., https://pubmed.ncbi.nlm.nih.gov/24618151/

669. du Bois, A., Ewald-Riegler, N., de Gregorio, N., Reuss, A., Mahner, S., Fotopoulou, C., et.al. Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynakologische Onkologie (AGO) Study Group, Eur J Cancer, 2013. 49(8): p. 1905-14., https://pubmed.ncbi.nlm.nih.gov/23490647/

670. Kaern, J., Trope, C. G., Abeler, V. M., A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities, Cancer, 1993. 71(5): p. 1810-20., https://pubmed.ncbi.nlm.nih.gov/8383580/

671. Leake, J. F., Currie, J. L., Rosenshein, N. B., Woodruff, J. D., Long-term follow-up of serous ovarian tumors of low malignant potential, Gynecol Oncol, 1992. 47(2): p. 150-8., https://pubmed.ncbi.nlm.nih.gov/1468692/

672. Menczer, J., Chetrit, A., Sadetzki, S., The effect of hysterectomy on survival of patients with borderline ovarian tumors, Gynecol Oncol, 2012. 125(2): p. 372-5., https://pubmed.ncbi.nlm.nih.gov/22366596/

673. Odegaard, E., Staff, A. C., Langebrekke, A., Engh, V., Onsrud, M., Surgery of borderline tumors of the ovary: retrospective comparison of short-term outcome after laparoscopy or laparotomy, Acta Obstet Gynecol Scand, 2007. 86(5): p. 620-6., https://pubmed.ncbi.nlm.nih.gov/17464594/

674. Camatte, S., Morice, P., Thoury, A., Fourchotte, V., Pautier, P., Lhomme, C., et.al. Impact of surgical staging in patients with macroscopic "stage I" ovarian borderline tumours: analysis of a continuous series of 101 cases, Eur J Cancer, 2004. 40(12): p. 1842-9., https://pubmed.ncbi.nlm.nih.gov/15288285/

675. Trillsch, F., Mahner, S., Woelber, L., Vettorazzi, E., Reuss, A., Ewald-Riegler, N., et.al. Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study, Ann Oncol, 2014. 25(7): p. 1320-7., https://pubmed.ncbi.nlm.nih.gov/24618151/

676. du Bois, A., Ewald-Riegler, N., de Gregorio, N., Reuss, A., Mahner, S., Fotopoulou, C., et.al. Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynakologische Onkologie (AGO) Study Group, Eur J Cancer, 2013. 49(8): p. 1905-14., https://pubmed.ncbi.nlm.nih.gov/23490647/

677. du Bois, A., Ewald-Riegler, N., Borderline-Tumoren des Ovars – eine systematische Übersicht, Geburtsh Frauenheilk, 2009. p. 807 - 833.

678. du Bois, A., Ewald-Riegler, N., Borderline-Tumoren des Ovars – eine systematische Übersicht, Geburtsh Frauenheilk, 2009. p. 807 - 833.

679. Morice, P., Denschlag, D., Rodolakis, A., Reed, N., Schneider, A., Kesic, V., et.al. Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology about the conservative management of ovarian malignant tumors, Int J Gynecol Cancer, 2011. 21(5): p. 951-63., https://pubmed.ncbi.nlm.nih.gov/21697684/

680. Plett, H, Harter, P, Ataseven, B, Heitz, F, Prader, S, Schneider, S, et.al. Fertility-sparing surgery and reproductive-outcomes in patients with borderline ovarian tumors., Gynecol Oncol, 2020. 157 (2)(2): p. 411-417., https://pubmed.ncbi.nlm.nih.gov/32115229/

681. Faluyi, O., Mackean, M., Gourley, C., Bryant, A., Dickinson, H. O., Interventions for the treatment of borderline ovarian tumours, Cochrane Database Syst Rev, 2010. p. CD007696., https://pubmed.ncbi.nlm.nih.gov/20824864/

682. Faluyi, O., Mackean, M., Gourley, C., Bryant, A., Dickinson, H. O., Interventions for the treatment of borderline ovarian tumours, Cochrane Database Syst Rev, 2010. p. CD007696., https://pubmed.ncbi.nlm.nih.gov/20824864/

683. Miller, B. E., Barron, B. A., Wan, J. Y., Delmore, J. E., Silva, E. G., Gershenson, D. M., Prognostic factors in adult granulosa cell tumor of the ovary, Cancer, 1997. 79(10): p. 1951-5., https://pubmed.ncbi.nlm.nih.gov/9149022/

684. Nosov, V., Silva, I., Tavassoli, F., Adamyan, L., Farias-Eisner, R., Schwartz, P. E., Predictors of recurrence of ovarian granulosa cell tumors, Int J Gynecol Cancer, 2009. 19(4): p. 628-33., https://pubmed.ncbi.nlm.nih.gov/19509561/

685. Colombo, N., Parma, G., Zanagnolo, V., Insinga, A., Management of ovarian stromal cell tumors, J Clin Oncol, 2007. 25(20): p. 2944-51., https://pubmed.ncbi.nlm.nih.gov/17617526/

686. Sehouli, J., Drescher, F. S., Mustea, A., Elling, D., Friedmann, W., Kuhn, W., et.al. Granulosa cell tumor of the ovary: 10 years follow-up data of 65 patients, Anticancer Res, 2004. 24(2C): p. 1223-9., https://pubmed.ncbi.nlm.nih.gov/15154651/

687. Seagle, B. L., Ann, P., Butler, S., Shahabi, S., Ovarian granulosa cell tumor: A National Cancer Database study, Gynecol Oncol, 2017. 146(2): p. 285-291., https://pubmed.ncbi.nlm.nih.gov/28532858/

688. Gershenson, D. M., Fertility-sparing surgery for malignancies in women, J Natl Cancer Inst Monogr, 2005. p. 43-7., https://pubmed.ncbi.nlm.nih.gov/15784822/

689. Miller, B. E., Barron, B. A., Wan, J. Y., Delmore, J. E., Silva, E. G., Gershenson, D. M., Prognostic factors in adult granulosa cell tumor of the ovary, Cancer, 1997. 79(10): p. 1951-5., https://pubmed.ncbi.nlm.nih.gov/9149022/

690. Nosov, V., Silva, I., Tavassoli, F., Adamyan, L., Farias-Eisner, R., Schwartz, P. E., Predictors of recurrence of ovarian granulosa cell tumors, Int J Gynecol Cancer, 2009. 19(4): p. 628-33., https://pubmed.ncbi.nlm.nih.gov/19509561/

691. Colombo, N., Parma, G., Zanagnolo, V., Insinga, A., Management of ovarian stromal cell tumors, J Clin Oncol, 2007. 25(20): p. 2944-51., https://pubmed.ncbi.nlm.nih.gov/17617526/

692. Sehouli, J., Drescher, F. S., Mustea, A., Elling, D., Friedmann, W., Kuhn, W., et.al. Granulosa cell tumor of the ovary: 10 years follow-up data of 65 patients, Anticancer Res, 2004. 24(2C): p. 1223-9., https://pubmed.ncbi.nlm.nih.gov/15154651/

693. Zanagnolo, V., Pasinetti, B., Sartori, E., Clinical review of 63 cases of sex cord stromal tumors, Eur J Gynaecol Oncol, 2004. 25(4): p. 431-8., https://pubmed.ncbi.nlm.nih.gov/15285297/

694. Evans, A. T., 3rd, Gaffey, T. A., Malkasian, G. D., Jr., Annegers, J. F., Clinicopathologic review of 118 granulosa and 82 theca cell tumors, Obstet Gynecol, 1980. 55(2): p. 231-8., https://pubmed.ncbi.nlm.nih.gov/6243409/

695. Zhang, M., Cheung, M. K., Shin, J. Y., Kapp, D. S., Husain, A., Teng, N. N., et.al. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--an analysis of 376 women, Gynecol Oncol, 2007. 104(2): p. 396-400., https://pubmed.ncbi.nlm.nih.gov/17030354/

696. Fotopoulou, C., Savvatis, K., Braicu, E. I., Brink-Spalink, V., Darb-Esfahani, S., Lichtenegger, W., et.al. Adult granulosa cell tumors of the ovary: tumor dissemination pattern at primary and recurrent situation, surgical outcome, Gynecol Oncol, 2010. 119(2): p. 285-90., https://pubmed.ncbi.nlm.nih.gov/20637497/

697. Zambetti, M., Escobedo, A., Pilotti, S., De Palo, G., cis-platinum/vinblastine/bleomycin combination chemotherapy in advanced or recurrent granulosa cell tumors of the ovary, Gynecol Oncol, 1990. 36(3): p. 317-20., https://pubmed.ncbi.nlm.nih.gov/1690679/

698. Colombo, N., Sessa, C., Landoni, F., Sartori, E., Pecorelli, S., Mangioni, C., Cisplatin, vinblastine, and bleomycin combination chemotherapy in metastatic granulosa cell tumor of the ovary, Obstet Gynecol, 1986. 67(2): p. 265-8., https://pubmed.ncbi.nlm.nih.gov/2418394/

699. Seagle, B. L., Ann, P., Butler, S., Shahabi, S., Ovarian granulosa cell tumor: A National Cancer Database study, Gynecol Oncol, 2017. 146(2): p. 285-291., https://pubmed.ncbi.nlm.nih.gov/28532858/

700. Zhang, M., Cheung, M. K., Shin, J. Y., Kapp, D. S., Husain, A., Teng, N. N., et.al. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--an analysis of 376 women, Gynecol Oncol, 2007. 104(2): p. 396-400., https://pubmed.ncbi.nlm.nih.gov/17030354/

701. Fotopoulou, C., Savvatis, K., Braicu, E. I., Brink-Spalink, V., Darb-Esfahani, S., Lichtenegger, W., et.al. Adult granulosa cell tumors of the ovary: tumor dissemination pattern at primary and recurrent situation, surgical outcome, Gynecol Oncol, 2010. 119(2): p. 285-90., https://pubmed.ncbi.nlm.nih.gov/20637497/

702. Zambetti, M., Escobedo, A., Pilotti, S., De Palo, G., cis-platinum/vinblastine/bleomycin combination chemotherapy in advanced or recurrent granulosa cell tumors of the ovary, Gynecol Oncol, 1990. 36(3): p. 317-20., https://pubmed.ncbi.nlm.nih.gov/1690679/

703. Colombo, N., Sessa, C., Landoni, F., Sartori, E., Pecorelli, S., Mangioni, C., Cisplatin, vinblastine, and bleomycin combination chemotherapy in metastatic granulosa cell tumor of the ovary, Obstet Gynecol, 1986. 67(2): p. 265-8., https://pubmed.ncbi.nlm.nih.gov/2418394/

704. Meisel, J. L., Hyman, D. M., Jotwani, A., Zhou, Q., Abu-Rustum, N. R., Iasonos, A., et.al. The role of systemic chemotherapy in the management of granulosa cell tumors, Gynecol Oncol, 2015. 136(3): p. 505-11., https://pubmed.ncbi.nlm.nih.gov/25546114/

705. Wilson, M. K., Fong, P., Mesnage, S., Chrystal, K., Shelling, A., Payne, K., et.al. Stage I granulosa cell tumours: A management conundrum? Results of long-term follow up, Gynecol Oncol, 2015. 138(2): p. 285-91., https://pubmed.ncbi.nlm.nih.gov/26003143/

706. Gurumurthy, M., Bryant, A., Shanbhag, S., Effectiveness of different treatment modalities for the management of adult-onset granulosa cell tumours of the ovary (primary and recurrent), Cochrane Database Syst Rev, 2014. p. CD006912., https://pubmed.ncbi.nlm.nih.gov/24753008/

707. Mangili, G., Sigismondi, C., Frigerio, L., Candiani, M., Savarese, A., Giorda, G., et.al. Recurrent granulosa cell tumors (GCTs) of the ovary: a MITO-9 retrospective study, Gynecol Oncol, 2013. 130(1): p. 38-42., https://pubmed.ncbi.nlm.nih.gov/23623833/

708. Ottolina, J., Ferrandina, G., Gadducci, A., Scollo, P., Lorusso, D., Giorda, G., et.al. Is the endometrial evaluation routinely required in patients with adult granulosa cell tumors of the ovary?, Gynecol Oncol, 2015. 136(2): p. 230-4., https://pubmed.ncbi.nlm.nih.gov/25527364/

709. Mancari, R., Portuesi, R., Colombo, N., Adult granulosa cell tumours of the ovary, Curr Opin Oncol, 2014. 26(5): p. 536-41., https://pubmed.ncbi.nlm.nih.gov/25024052/

710. van Meurs, H. S., van Lonkhuijzen, L. R., Limpens, J., van der Velden, J., Buist, M. R., Hormone therapy in ovarian granulosa cell tumors: a systematic review, Gynecol Oncol, 2014. 134(1): p. 196-205., https://pubmed.ncbi.nlm.nih.gov/24713548/

711. van Meurs, H. S., Buist, M. R., Westermann, A. M., Sonke, G. S., Kenter, G. G., van der Velden, J., Effectiveness of chemotherapy in measurable granulosa cell tumors: a retrospective study and review of literature, Int J Gynecol Cancer, 2014. 24(3): p. 496-505., https://pubmed.ncbi.nlm.nih.gov/24469325/

712. van Meurs, H. S., van der Velden, J., Buist, M. R., van Driel, W. J., Kenter, G. G., van Lonkhuijzen, L. R., Evaluation of response to hormone therapy in patients with measurable adult granulosa cell tumors of the ovary, Acta Obstet Gynecol Scand, 2015. 94(11): p. 1269-75., https://pubmed.ncbi.nlm.nih.gov/26230362/

713. van Meurs, H. S., Bleeker, M. C., van der Velden, J., Overbeek, L. I., Kenter, G. G., Buist, M. R., The incidence of endometrial hyperplasia and cancer in 1031 patients with a granulosa cell tumor of the ovary: long-term follow-up in a population-based cohort study, Int J Gynecol Cancer, 2013. 23(8): p. 1417-22., https://pubmed.ncbi.nlm.nih.gov/24257556/

714. Brown, J., Brady, W. E., Schink, J., Van Le, L., Leitao, M., Yamada, S. D., et.al. Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group, Cancer, 2014. 120(3): p. 344-51., https://pubmed.ncbi.nlm.nih.gov/24166194/

715. Sigismondi, C., Gadducci, A., Lorusso, D., Candiani, M., Breda, E., Raspagliesi, F., et.al. Ovarian Sertoli-Leydig cell tumors. a retrospective MITO study, Gynecol Oncol, 2012. 125(3): p. 673-6., https://pubmed.ncbi.nlm.nih.gov/22446621/

716. Guerriero, S., Testa, A. C., Timmerman, D., Van Holsbeke, C., Ajossa, S., Fischerova, D., et.al. Imaging of gynecological disease (6): clinical and ultrasound characteristics of ovarian dysgerminoma, Ultrasound Obstet Gynecol, 2011. 37(5): p. 596-602., https://pubmed.ncbi.nlm.nih.gov/21305635/

717. Heifetz, S. A., Cushing, B., Giller, R., Shuster, J. J., Stolar, C. J., Vinocur, C. D., et.al. Immature teratomas in children: pathologic considerations: a report from the combined Pediatric Oncology Group/Children's Cancer Group, Am J Surg Pathol, 1998. 22(9): p. 1115-24., https://pubmed.ncbi.nlm.nih.gov/9737245/

718. Emoto, M., Obama, H., Horiuchi, S., Miyakawa, T., Kawarabayashi, T., Transvaginal color Doppler ultrasonic characterization of benign and malignant ovarian cystic teratomas and comparison with serum squamous cell carcinoma antigen, Cancer, 2000. 88(10): p. 2298-304., https://pubmed.ncbi.nlm.nih.gov/10820352/

719. Kapp, D. S., Kohorn, E. I., Merino, M. J., LiVolsi, V. A., Pure dysgerminoma of the ovary with elevated serum human chorionic gonadotropin: diagnostic and therapeutic considerations, Gynecol Oncol, 1985. 20(2): p. 234-44., https://pubmed.ncbi.nlm.nih.gov/2579008/

720. Roberts, D. K., Wells, M. M., Horbelt, D. V., Dysgerminoma in the differential diagnosis of hydatidiform mole, Obstet Gynecol, 1986. 67(3 Suppl): p. 92S-94S., https://pubmed.ncbi.nlm.nih.gov/3945470/

721. Lazebnik, N., Balog, A., Bennett, S., Redline, R., Liu, J., Ovarian dysgerminoma: a challenging clinical and sonographic diagnosis, J Ultrasound Med, 2009. 28(10): p. 1409-15., https://pubmed.ncbi.nlm.nih.gov/19778893/

722. Gershenson, D. M., Management of ovarian germ cell tumors, J Clin Oncol, 2007. 25(20): p. 2938-43., https://pubmed.ncbi.nlm.nih.gov/17617525/

723. Gershenson, D. M., Management of ovarian germ cell tumors, J Clin Oncol, 2007. 25(20): p. 2938-43., https://pubmed.ncbi.nlm.nih.gov/17617525/

724. Mahdi, H., Swensen, R. E., Hanna, R., Kumar, S., Ali-Fehmi, R., Semaan, A., et.al. Prognostic impact of lymphadenectomy in clinically early stage malignant germ cell tumour of the ovary, Br J Cancer, 2011. 105(4): p. 493-7., https://pubmed.ncbi.nlm.nih.gov/21772335/

725. Pectasides, D., Pectasides, E., Kassanos, D., Germ cell tumors of the ovary, Cancer Treat Rev, 2008. 34(5): p. 427-41., https://pubmed.ncbi.nlm.nih.gov/18378402/

726. Kumar, S., Shah, J. P., Bryant, C. S., Imudia, A. N., Cote, M. L., Ali-Fehmi, R., et.al. The prevalence and prognostic impact of lymph node metastasis in malignant germ cell tumors of the ovary, Gynecol Oncol, 2008. 110(2): p. 125-32., https://pubmed.ncbi.nlm.nih.gov/18571705/

727. Oltmann, S. C., Garcia, N. M., Barber, R., Hicks, B., Fischer, A. C., Pediatric ovarian malignancies: how efficacious are current staging practices?, J Pediatr Surg, 2010. 45(6): p. 1096-102., https://pubmed.ncbi.nlm.nih.gov/20620302/

728. Gobel, U., Haas, R. J., Calaminus, G., Bamberg, M., Bokkerink, E. B., Engert, J., et.al. Treatment of germ cell tumors in children: results of European trials for testicular and non-testicular primary sites, Crit Rev Oncol Hematol, 1990. 10(2): p. 89-98., https://pubmed.ncbi.nlm.nih.gov/1694438/

729. Marina, N. M., Cushing, B., Giller, R., Cohen, L., Lauer, S. J., Ablin, A., et.al. Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study, J Clin Oncol, 1999. 17(7): p. 2137-43., https://pubmed.ncbi.nlm.nih.gov/10561269/

730. Gershenson, D. M., Copeland, L. J., del Junco, G., Edwards, C. L., Wharton, J. T., Rutledge, F. N., Second-look laparotomy in the management of malignant germ cell tumors of the ovary, Obstet Gynecol, 1986. 67(6): p. 789-93., https://pubmed.ncbi.nlm.nih.gov/3010204/

731. Billmire, D., Vinocur, C., Rescorla, F., Cushing, B., London, W., Schlatter, M., et.al. Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study, J Pediatr Surg, 2004. 39(3): p. 424-9; discussion 424-9., https://pubmed.ncbi.nlm.nih.gov/15017564/

732. Beiner, M. E., Gotlieb, W. H., Korach, Y., Shrim, A., Stockheim, D., Segal, Y., et.al. Cystectomy for immature teratoma of the ovary, Gynecol Oncol, 2004. 93(2): p. 381-4., https://pubmed.ncbi.nlm.nih.gov/15099949/

733. Mahdi, H., Swensen, R. E., Hanna, R., Kumar, S., Ali-Fehmi, R., Semaan, A., et.al. Prognostic impact of lymphadenectomy in clinically early stage malignant germ cell tumour of the ovary, Br J Cancer, 2011. 105(4): p. 493-7., https://pubmed.ncbi.nlm.nih.gov/21772335/

734. Kumar, S., Shah, J. P., Bryant, C. S., Imudia, A. N., Cote, M. L., Ali-Fehmi, R., et.al. The prevalence and prognostic impact of lymph node metastasis in malignant germ cell tumors of the ovary, Gynecol Oncol, 2008. 110(2): p. 125-32., https://pubmed.ncbi.nlm.nih.gov/18571705/

735. Marina, N. M., Cushing, B., Giller, R., Cohen, L., Lauer, S. J., Ablin, A., et.al. Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study, J Clin Oncol, 1999. 17(7): p. 2137-43., https://pubmed.ncbi.nlm.nih.gov/10561269/

736. Billmire, D., Vinocur, C., Rescorla, F., Cushing, B., London, W., Schlatter, M., et.al. Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study, J Pediatr Surg, 2004. 39(3): p. 424-9; discussion 424-9., https://pubmed.ncbi.nlm.nih.gov/15017564/

737. Gershenson, D. M., del Junco, G., Silva, E. G., Copeland, L. J., Wharton, J. T., Rutledge, F. N., Immature teratoma of the ovary, Obstet Gynecol, 1986. 68(5): p. 624-9., https://pubmed.ncbi.nlm.nih.gov/3763073/

738. Pectasides, D., Pectasides, E., Kassanos, D., Germ cell tumors of the ovary, Cancer Treat Rev, 2008. 34(5): p. 427-41., https://pubmed.ncbi.nlm.nih.gov/18378402/

739. Gobel, U., Haas, R. J., Calaminus, G., Bamberg, M., Bokkerink, E. B., Engert, J., et.al. Treatment of germ cell tumors in children: results of European trials for testicular and non-testicular primary sites, Crit Rev Oncol Hematol, 1990. 10(2): p. 89-98., https://pubmed.ncbi.nlm.nih.gov/1694438/

740. Cushing, B., Giller, R., Ablin, A., Cohen, L., Cullen, J., Hawkins, E., et.al. Surgical resection alone is effective treatment for ovarian immature teratoma in children and adolescents: a report of the pediatric oncology group and the children's cancer group, Am J Obstet Gynecol, 1999. 181(2): p. 353-8., https://pubmed.ncbi.nlm.nih.gov/10454682/

741. Kang, H., Kim, T. J., Kim, W. Y., Choi, C. H., Lee, J. W., Kim, B. G., et.al. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor, Gynecol Oncol, 2008. 111(1): p. 106-10., https://pubmed.ncbi.nlm.nih.gov/18656249/

742. Cushing, B., Giller, R., Ablin, A., Cohen, L., Cullen, J., Hawkins, E., et.al. Surgical resection alone is effective treatment for ovarian immature teratoma in children and adolescents: a report of the pediatric oncology group and the children's cancer group, Am J Obstet Gynecol, 1999. 181(2): p. 353-8., https://pubmed.ncbi.nlm.nih.gov/10454682/

743. Kang, H., Kim, T. J., Kim, W. Y., Choi, C. H., Lee, J. W., Kim, B. G., et.al. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor, Gynecol Oncol, 2008. 111(1): p. 106-10., https://pubmed.ncbi.nlm.nih.gov/18656249/

744. Raveendran, A., Gupta, S., Bagga, R., Saha, S. C., Gainder, S., Dhaliwal, L. K., et.al. Advanced germ cell malignancies of the ovary: should neo-adjuvant chemotherapy be the first line of treatment?, J Obstet Gynaecol, 2010. 30(1): p. 53-5., https://pubmed.ncbi.nlm.nih.gov/20121506/

745. Abdul Razak, A. R., Li, L., Bryant, A., Diaz-Padilla, I., Chemotherapy for malignant germ cell ovarian cancer in adult patients with early stage, advanced and recurrent disease, Cochrane Database Syst Rev, 2011. p. CD007584., https://pubmed.ncbi.nlm.nih.gov/21412906/

746. Ray-Coquard, I, Morice, P, Lorusso, D, Prat, J, Oaknin, A, Pautier, P, et.al. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up., Ann Oncol, 2018. 29 (Suppl 4)(Suppl 4): p. iv1-iv18., https://pubmed.ncbi.nlm.nih.gov/29697741/

747. Sumi, T., Ishiko, O., Yoshida, H., Ogita, S., Bleomycin, actinomycin-D, and cisplatin treatment of ovarian germ-cell malignancies contributes to reducing adverse drug reactions, Oncol Rep, 2000. 7(6): p. 1235-8., https://pubmed.ncbi.nlm.nih.gov/11032921/

748. Germa, J. R., Izquierdo, M. A., Segui, M. A., Climent, M. A., Ojeda, B., Alonso, C., Malignant ovarian germ cell tumors: the experience at the Hospital de la Santa Creu i Sant Pau, Gynecol Oncol, 1992. 45(2): p. 153-9., https://pubmed.ncbi.nlm.nih.gov/1375576/

749. Lin, K. Y., Bryant, S., Miller, D. S., Kehoe, S. M., Richardson, D. L., Lea, J. S., Malignant ovarian germ cell tumor - role of surgical staging and gonadal dysgenesis, Gynecol Oncol, 2014. 134(1): p. 84-9., https://pubmed.ncbi.nlm.nih.gov/24836278/

750. Sigismondi, C., Scollo, P., Ferrandina, G., Candiani, M., Angioli, R., Vigano, R., et.al. Management of bilateral malignant ovarian germ cell tumors: a MITO-9 retrospective study, Int J Gynecol Cancer, 2015. 25(2): p. 203-7., https://pubmed.ncbi.nlm.nih.gov/25569816/

751. Kleppe, M., Amkreutz, L. C., Van Gorp, T., Slangen, B. F., Kruse, A. J., Kruitwagen, R. F., Lymph-node metastasis in stage I and II sex cord stromal and malignant germ cell tumours of the ovary: a systematic review, Gynecol Oncol, 2014. 133(1): p. 124-7., https://pubmed.ncbi.nlm.nih.gov/24440833/

752. Liu, Q., Ding, X., Yang, J., Cao, D., Shen, K., Lang, J., et.al. The significance of comprehensive staging surgery in malignant ovarian germ cell tumors, Gynecol Oncol, 2013. 131(3): p. 551-4., https://pubmed.ncbi.nlm.nih.gov/24007946/

753. Talukdar, S., Kumar, S., Bhatla, N., Mathur, S., Thulkar, S., Kumar, L., Neo-adjuvant chemotherapy in the treatment of advanced malignant germ cell tumors of ovary, Gynecol Oncol, 2014. 132(1): p. 28-32., https://pubmed.ncbi.nlm.nih.gov/24145115/

754. Solheim, O., Trope, C. G., Rokkones, E., Kaern, J., Paulsen, T., Salvesen, H. B., et.al. Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era", Gynecol Oncol, 2015. 136(2): p. 224-9., https://pubmed.ncbi.nlm.nih.gov/25511159/

755. Solheim, O., Gershenson, D. M., Trope, C. G., Rokkones, E., Sun, C. C., Weedon-Fekjaer, H., et.al. Prognostic factors in malignant ovarian germ cell tumours (The Surveillance, Epidemiology and End Results experience 1978-2010), Eur J Cancer, 2014. 50(11): p. 1942-50., https://pubmed.ncbi.nlm.nih.gov/24857045/

756. Solheim, O., Kaern, J., Trope, C. G., Rokkones, E., Dahl, A. A., Nesland, J. M., et.al. Malignant ovarian germ cell tumors: presentation, survival and second cancer in a population based Norwegian cohort (1953-2009), Gynecol Oncol, 2013. 131(2): p. 330-5., https://pubmed.ncbi.nlm.nih.gov/24001518/

757. Low, J. J., Ilancheran, A., Ng, J. S., Malignant ovarian germ-cell tumours, Best Pract Res Clin Obstet Gynaecol, 2012. 26(3): p. 347-55., https://pubmed.ncbi.nlm.nih.gov/22301054/

758. Weinberg, L. E., Lurain, J. R., Singh, D. K., Schink, J. C., Survival and reproductive outcomes in women treated for malignant ovarian germ cell tumors, Gynecol Oncol, 2011. 121(2): p. 285-9., https://pubmed.ncbi.nlm.nih.gov/21256579/

759. De Backer, A., Madern, G. C., Pieters, R., Haentjens, P., Hakvoort-Cammel, F. G., Oosterhuis, J. W., et.al. Influence of tumor site and histology on long-term survival in 193 children with extracranial germ cell tumors, Eur J Pediatr Surg, 2008. 18(1): p. 1-6., https://pubmed.ncbi.nlm.nih.gov/18302061/

760. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Entwicklung von leitlinienbasierten Qualitätsindikatoren. Methodenpapier für das Leitlinienprogramm Onkologie, Version 3.0, 2021., http://www.leitlinienprogramm-onkologie.de/methodik/informationen-zur-methodik/